Journal Menu
► ▼ Journal Menu-
- Pharmaceutics Home
- Aims & Scope
- Editorial Board
- Reviewer Board
- Topical Advisory Panel
- Instructions for Authors
- Special Issues
- Topics
- Sections & Collections
- Article Processing Charge
- Indexing & Archiving
- Editor’s Choice Articles
- Most Cited & Viewed
- Journal Statistics
- Journal History
- Journal Awards
- Society Collaborations
- Conferences
- Editorial Office
Journal Browser
► ▼ Journal BrowserNeed Help?
Announcements
15 November 2024
Prof. Dr. A. Douglas Kinghorn Appointed Chair of the 2024 Tu Youyou Award Committee
We are honored to announce that Prof. Dr. A. Douglas Kinghorn will serve as the Chair of the 2024 Tu Youyou Award Committee.
Name: Prof. Dr. A. Douglas Kinghorn
Affiliation: College of Pharmacy, The Ohio State University, USA
Prof. Dr. Kinghorn is a leading expert in pharmacognosy and natural products research. He is recognized for his key contributions to discovering bioactive compounds from plants, especially in anticancer, cancer chemopreventive, and substances with a sweet taste and taste-modifying agents. His prolific contributions include over 590 peer-reviewed works and edited or co-edited 40 scientific volumes.
The 2024 Tu Youyou Award Committee, under Prof. Dr. Kinghorn's guidance, will focus on identifying innovative research in the fields of natural products chemistry and medicinal chemistry. The committee will aim to identify groundbreaking work with the potential to lead to significant advancements in these areas.
We are confident that, with Prof. Dr. Kinghorn at the helm, the 2024 Tu Youyou Award will continue to inspire excellence and innovation in the related fields.
About the Tu Youyou Award
Established in 2016, the Tu Youyou Award seeks to honor those who excel in the fields of natural products chemistry and medicinal chemistry. This award offers a total prize of CHF 100,000, which will be equally divided among the winners if there is more than one, with each recipient receiving an award medal.
The 2024 Tu Youyou Award remains open for nominations until 31 December 2024. We encourage all eligible candidates to participate in this prestigious recognition, as this award not only honors individual achievement but also encourages further scientific exchange, exploration and discovery in critical areas of medicine.
If you are interested in participating, please visit the Tu Youyou Award website for more information on the nomination requirements.
5 November 2024
MDPI INSIGHTS: The CEO's Letter #17 - OA Week, Basel Open Day, Beijing Graphene Forum
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
Open Access Week: Forging the Future of Open Access through Global Reach and Collaboration
From 21 to 27 October, we celebrated International Open Access Week (OAW), highlighting the importance of making research accessible to everyone. This campaign reinforced our commitment to advancing open access (OA) and showcased how we are helping research communities worldwide adopt OA as their standard.
“OA publishing is now a cornerstone of global research”
Throughout the week, we featured MDPI’s efforts to support quality open research through blog posts on topics such as how Research Integrity Promotes OA Practices, our Preprints.org platform, and supporting societies with different OA models. These initiatives capture our commitment to making research more inclusive and accessible to all.
OA publishing is now a cornerstone of global research, with more researchers choosing OA over traditional paywalled models, and embracing new, community-driven models.
Benefits of Open Access and Open Research
- Accelerated Discoveries: OA speeds up scientific progress by allowing immediate access to findings, enabling researchers to build on each other’s work faster.
- Community-Led Innovation: Open research empowers communities to manage their own platforms, creating collaboration and shared knowledge.
- Increased Visibility: OA broadens the reach of your research, leading to greater recognition, collaboration, and impact.
- Cross-Disciplinary Connections: By removing financial and geographical barriers, OA unites diverse fields, sparking innovation across disciplines.
MDPI Singapore Celebrates Open Access Week
MDPI Singapore also hosted its first-ever OAW event at the Marina Bay Sands Convention Centre, bringing together academics, researchers, and students to discuss the future of open scholarship. Conversations focused on the potential of new publishing models, alternative funding strategies, and the importance of communicating research to wider audiences.
As OA evolves, MDPI remains a committed partner in advancing open science and creating a transparent, inclusive research environment. For a full recap of the week’s highlights and resources, visit our campaign page.
Impactful Research
MDPI Connection to Nobel-Winning Protein Research
David Baker, an American biochemist, and Demis Hassabis and John M. Jumper, two scientists from Google DeepMind, have been awarded the 2024 Nobel Prize in Chemistry for their groundbreaking advancements in better understanding the structure of proteins, the molecular engines of life’s processes.
One half of the prize was awarded to Professor David Baker from the University of Washington for his development of revolutionary protein design software enabling the creation of novel proteins for vaccines, nanomaterials, and sensors. Prof. Baker co-authored a 2016 paper in MDPI’s Toxins journal on protein-based therapeutics.
Meanwhile, DeepMind’s Demis Hassabis and John M. Jumper received recognition for AlphaFold, the AI model that predicts protein structures from amino acid sequences, fulfilling a long-held scientific dream.
“We congratulate this year’s Nobel laureates for their groundbreaking contributions to the study of life”
Nobel Prize Laureates Entrust MDPI with Their Research
As at October 2024, 45 Nobel laureates had contributed to more than 115 articles across
35 MDPI journals. The privilege of hosting the research of such contributors, who significantly influence the open access movement, resonates deeply with our editorial teams.
We are proud to list the names of Pierre Agostini, Hiroshi Amano, Werner Arber, Aaron Ciechanover, Robert H. Grubbs, Oliver Hart, Gerard ‘t Hooft, Michael Houghton, Harald zur Hausen, Katalin Karikó, Jean-Marie Lehn, Gérard Mourou, Ferid Murad, Shuji Nakamura, William Nordhaus, Kostya S. Novoselov, Giorgio Parisi, Charles M. Rice, Alvin E. Roth, Donna Strickland, K. Barry Sharpless, George F. Smoot, Anne L’Huillier, Drew Weissman, Kurt Wüthrich, Ada Yonath, Tomas Lindahl, Thomas C. Südhof, Stanley B. Prusiner, Roger Kornberg, Robert F. Engle, Richard J. Roberts, Ōmura Satoshi, Kenneth J. Arrow, John B. Goodenough, Jennifer Doudna, Hamilton Othanel Smith, Eric R. Kandel, Carlo Rubbia, Bernard Feringa, Barry J. Marshall, Anthony J. Leggett, Andrew Victor Schally, and David Baker.
Notable MRNA Published in Cells
On 7 October 2024, the 2024 Nobel Prize in Physiology or Medicine was jointly awarded to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in post-transcriptional gene regulation.
MicroRNAs are proving to be fundamentally important for how organisms develop and function. Some interesting papers about microRNA research are published in the MDPI journal Cells. I invite you browse through the notable papers related to microRNA research in Cells.
Inside MDPI
Basel Open Day
On 21 October, we held the Basel Open Day at our headquarters, welcoming a group of journal Editors-in-Chief (EiC) and Editorial Board Members (EBMs) for a full-day workshop. The event featured presentations and discussions on MDPI’s latest editorial updates, data integrity policies, society collaborations, and local market insights.
The following MDPI journals were represented during the visit: Physics, Journal of Personalized Medicine (JPM), Sci, Remote Sensing, Animals, Cells, Buildings, Histories, Sensors, and International Journal of Environmental Research and Public Health (IJERPH).
This was a great opportunity to showcase our new office space while gathering feedback from leading journal stakeholders. To get everyone on the same page, we took 60 minutes for round-table introductions, which helped set a collaborative tone and ground us in MDPI’s mission of disseminating open science.
“This was a great opportunity to gather feedback from leading journal stakeholders”
The general feedback from the day highlighted positive developments around our editorial and ethics policies, as well as areas for improvement, including flexibility regarding reviewer deadlines. There was a genuine appreciation and push for our ongoing efforts to share more about MDPI, including company updates and promoting high-quality research through our blog, announcements, and social media channels, which we have been growing and expanding.
Our Basel Open Day was a positive experience, bringing together key journal stakeholders and gathering insights to guide MDPI’s continued engagement with the academic community. We look forward to hosting future events of this kind and welcoming more scholars to our headquarters in Basel, Switzerland.
Coming Together for Science
ncRNA 2024 Conference in Basel
I am pleased to share that we held Non-coding RNA World 2024: Exploring Mechanisms, Designing Medicines (ICM 2024) in Basel, Switzerland this past 7–9 October.
The three-day event attracted just over 100 attendees, including two Chairs, 10 invited speakers and two keynotes from Prof. Mauro Giacca and Prof. Ling-Ling Chen. Of the presentations on site, there were 35 posters and 44 oral presentations.
The overall feedback was positive, with people enjoying the intimate event and the unique activities offered, including a guided tour around Basel’s Old Town (a must-see for anyone visiting the city) and a memorable conference dinner.
It was cool to see the winners of the 2024 Nobel Prize in Physiology or Medicine announced during the conference days. This was exciting for attendees, as the winners discovered a new class of RNA molecules (miRNAs). As one invited speaker put it, “It's exciting to be among fellows when something that important for the field is announced.”
“It's exciting to be among fellows when something that important for the field is announced”
Every attendee receives a conference survey, and I’m always pleased to see a high percentage of ‘Very Satisfied’ responses when asked about ‘treatment from conference personnel’. Kudos to our conference team for meeting our attendees’ needs. These events are a great opportunity for us to reach new audiences, as 92% of the respondents had never been to an MDPI conference, so I am thrilled to see us connecting with a new demographic of your researchers in the RNA field.
A special thank-you to our partnering societies The Epigenetics Society, The French Society of Genetics, LS2 / USGEB (Union of Swiss Societies for Experimental Biology), and The RNA Biology Group, as well as to our sponsors New England Biolabs and Arraystar for their support of the ncRNA 2024 conference. I am also pleased to report that we presented two awards, including the Best Presentation Award and two Best Poster Award, recognizing the contributions of our participants.
Upcoming In-Person Event
27–29 November 2024
Pharmaceuticals 2024 – Recent Advances in Pharmaceutical Sciences Towards a Healthy Life
Location: Barcelona, Spain
The discovery of new molecules, their properties, and actions to enhance human health and quality of life.
Find more upcoming MDPI events here.
Closing Thoughts
Beijing Graphene Forum 2024
I am pleased to share that we had a successful time at the Beijing Graphene Forum 2024, which drew around 1,000 attendees, including Konstantin Novoselov (2015 Nobel Prize in Physics) and other high-profile scholars in materials science and chemistry. It was a great opportunity to present MDPI on the big stage, with university presidents from institutions such as Peking University also in attendance.
I had the honour of awarding Prof. Zhongfan Liu, Chairman of the Chemical Science Committee, with a medal and presenting certificates to the members of the Chemical Science Committee; this is an important initiative to help expand MDPI’s journals and influence in China. These are highly respected scholars, and we enjoyed connecting with them over lunch as well.
“This is an important initiative to help expand MDPI’s journals and influence in China”
I also had the chance to speak about MDPI and open access, giving a five-minute speech during the opening ceremony and a 20-minute presentation at the close. MDPI hosted a sub-forum where both academic scholars and MDPI members shared insights, and we engaged with attendees at our MDPI booth.
This was a great opportunity to spotlight MDPI as the main publishing partner for the event, and I was proud to represent us on stage. We also met with scholars to discuss topics such as their publishing needs and institutional policies, open access, impact journals, and IOAP.
Chief Executive Officer
MDPI AG
16 October 2024
MDPI's Newly Launched Journals in September 2024
Five new journals covering a diverse range of subjects launched their inaugural issue in September 2024. Like other journals in MDPI’s portfolio, these journals are dedicated to sharing the latest research through open access, reflecting our commitment to making knowledge accessible to all.
We extend our sincere gratitude to the Editorial Board Members for their dedication to the launch and development of our new journals. Each journal will ensure its high-quality output via excellent editorial and rigorous peer-review processes so that the published articles achieve significant impact and broad visibility.
We invite you to explore and learn more about these new journals below.
Journal | Founding Editor-in-Chief | Journal Topics (Selected) |
Prof. Dr. Nejat Düzgüneş, University of the Pacific, USA | Editorial | view inaugural issue | biological therapy and stem-cell therapy; drug therapy; chemotherapy; radiation and other nonsurgical therapeutic strategies | view journal scope | submit an article | |
Prof. Dr. Magda Tsolaki, Greek Federation of Alzheimer’s Disease, Greece; Aristotle University of Thessaloniki, Greece | Editorial | view inaugural issue | surgical/procedural complications; complications; perioperative adverse events; postoperative adverse events | view journal scope | submit an article | |
Prof. Dr. Steven R. Fassnacht, Colorado State University, USA; Cooperative Institute for Research in the Atmosphere, USA | Editorial | view inaugural issue | ice as a mineral; atmospheric ice; sea ice; freshwater ice; ice sheets; ice caps and ice shelves | view journal scope | submit an article | |
Dr. Francisco Epelde, Hospital Universitari Parc Tauli, Spain; University Autonoma of Barcelona, Spain | Editorial | view inaugural issue | hospital management; hospital facilities; hospital services; hospital risk management; health law | view journal scope | submit an article | |
Prof. Dr. Nicola Ferri, University of Padova, Italy | Editorial | view inaugural issue | lipids in cells and whole organisms; lipid structure and function; lipid products and processes; dietary lipids and nutrition | view journal scope | submit an article |
We wish to thank everyone who has supported the development of open access publishing. You are welcome to send an application here or contact the New Journal Committee ([email protected]) if you would like to create more new journals.
4 October 2024
MDPI INSIGHTS: The CEO's Letter #16 - UNGA79 Science Summit, OASPA, Peer Review Week
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
MDPI Joins the Science Summit at UNGA79 (23–27 September 2024, New York)
On Friday 27 September, I had the privilege of giving the opening talk at the “Youth at the Science Summit” panel during the Science Summit conference, held in New York at the 79th session of the United Nations General Assembly (UNGA). Together, we discussed the future of science, publishing, innovation, and sustainable development.
It was a great opportunity to learn from our young leaders, whose voices must be included in the conversation as science shapes the future of artificial intelligence, climate mitigation, healthcare, technology, and more. This was also a powerful reminder of how essential global collaboration is in solving the major challenges we face. I left inspired by the dedication of these young researchers to making the world a better place!
Today’s youth are not just the leaders of tomorrow – they are already leading the change today.
Stefan Tochev (second from left) at the UNGA Science Summit 2024: “A great opportunity to learn from our young leaders.”
MDPI Supports the Future Generation of Scientists
This aligns with MDPI’s mission to support the next generation of scientists and early-career researchers by recognizing their achievements through our various MDPI awards, including the Young Investigator Awards, Best PhD Thesis Awards, Travel Awards, and more.
Our presence at this global event showed our commitment to advancing Open Science as a key driver for sustainable development. As a leading Open Access (OA) publisher, MDPI’s role at the summit was to emphasize the critical importance of democratizing scientific knowledge, making it accessible to all, and promoting global collaboration.
Through OA publishing, we aim to address pressing global challenges such as climate change, public health, and inequality, in line with the United Nations Sustainable Development Goals (SDGs).
“We aim to address pressing global challenges”
MDPI and the SDGs
In 2020, the SDG Publishers Compact was launched to accelerate implementation of the SDGs by promoting content that informs, develops, and inspires action. MDPI joined this initiative in 2021 and subsequently launched the MDPI SDG Hub in 2022, offering free access to recent research within the scope of each of the 17 SDGs.
During the summit, we highlighted the connection between Open Science and the SDG Publishers Compact, supporting the core objective to “Leave No One Behind” (LNOB). The transformative promise of the SDGs relies heavily on the Open Access model, which serves as a fundamental enabler of Open Science. We advocate for the wider adoption of Open Science practices in order to achieve the SDGs by 2030.
Impactful Research
Presenting at the 1st International Conference of Environmental Medicine
In September, MDPI and our journals IJERPH and Diseases sponsored and participated in the 1st International Conference of Environmental Medicine: Environmental Threats to Human Health: From Genetics to Epigenetics, held in Chieti, Italy.
The conference was organized in collaboration with various societies, including the Italian Society of Environmental Medicine (SIMA), one of more than 160 societies partnering MDPI journals.
The conference brought together influential figures from the Italian scholarly community, such as Antonio Felice Uricchio (President of the National Agency for University Research Assessment [ANVUR]), Alessandro Miani (President of SIMA), and Liborio Stuppia (Director of ‘Gabriele d’Annunzio’ University of Chieti-Pescara), among others.
MDPI was the sole publishing sponsor of the conference, at which I had the opportunity to present on behalf of the company. I provided an overview of MDPI, covering key facts and figures, the peer-review process, our strong collaboration with the Italian market, and insights into Nobel Prize winners who have published with MDPI, ahead of Sir Richard Roberts’ Nobel lecture.
“As at September 2024, 44 Nobel laureates have contributed to over 115 articles across 35 MDPI journals”
The keynote speaker at the event was Sir Richard Roberts, Nobel Laureate and 1993 Nobel Prize winner in Medicine, recognized for his discovery of split genes.
Nobel Laureates’ Contributions to MDPI
As at September 2024, 44 Nobel laureates have contributed to over 115 articles across 35 MDPI journals. I’ll share more details on this in the October newsletter.
Hosting such prominent figures in their respective fields, who play a significant role in advancing the OA movement, of which we are leaders in, resonates deeply with our editorial teams.
Sponsoring and supporting academic conferences is something we do on a large scale, and it continues to grow. Attending and speaking about MDPI shows our commitment by taking the time to connect with the scholarly community in person.
MDPI’s Presence in Italy
Italy ranks third globally in total MDPI publications, with nearly 130,000 contributions. We collaborate with about 12,000 Editorial Board Members in Italy, over 6,100 of whom have an H-index of more than 25.
We have 83 Editors-in-Chief and 209 Section Editors-in-Chief from Italy. We also support 20 Italian universities through our Institutional Open Access Program (IOAP) agreements with major institutions such as Sapienza University of Rome, the University of Milan, and the University of Pisa, among others.
Inside MDPI
Celebrating Peer Review Week, 23–27 September 2024
As we conclude another productive month at MDPI, I am pleased to highlight our participation in this year’s Peer Review Week (PRW), which took place from 23–27 September 2024. This global, community-driven celebration underscores the vital importance of peer review in maintaining the integrity and reliability of academic work. PRW provide a platform for institutions, publishers, and scholars to come together and reflect on the processes that uphold the quality of scholarly communication.
“We remain committed to enhancing the peer review process”
The theme for PRW 2024 was ‘Innovation and Technology in Peer Review.’ At MDPI, we were proud to contribute through various online and in-person events, including webinars from Europe, Asia-Pacific, and a roundtable discussion on innovation and technology in peer review. These events offer an opportunity to explore new tools and technologies that are shaping the future of peer review, particularly the integration of AI. As a company, we remain committed to enhancing the peer review process with innovative solutions while preserving the essential human expertise that makes it effective.
Peer Review Innovation and Technology at MDPI
Our efforts to improve peer review extend beyond the activities of this week. We also released a blog article discussing New Tools for Advancing Research Integrity and Peer Review, where we highlight two tools that MDPI has developed to support research integrity: Eureka – Reviewer Recommender and Online Proofreader. We are continually refining SuSy, our in-house submission system, to provide a seamless experience for authors and reviewers alike.
Listening to MDPI’s Authors and Reviewers
We highly value the time of our reviewers, and so do the authors who contribute to our journals. Our editorial process is bolstered by a network of dedicated reviewers, a team of over 6,000 diligent, well-trained staff members, and an in-house article submission platform designed to ensure efficient processes.
We make it a point to continually improve the experiences of both our authors and our reviewers throughout the entire editorial process, from submission to publication. This is why we regularly ask for feedback by conducting surveys. Here is what some of our respondents recently had to say about working with MDPI:
Coming Together for Science
ICM 2024 – Advances in Material Innovation
I am pleased to share that we held The 5th International Conference on Materials: Advances in Material Innovation (ICM 2024) in Basel, Switzerland this past 25–27 September.
This intimate event brought together leading scientists, researchers, and industry experts to exchange insights on recent advancements in materials characterization, processing, and manufacturing. Key focus areas included nanotechnology in material sciences and engineering, optical, electrical, and magnetic materials, soft, biological, and biomaterials, fibres, membranes, thin films, sensing materials, as well as materials and devices for energy and solar fuels. In addition, discussions featured the integration of AI and machine learning in materials research.
We received 90 abstract submissions. Over the course of the three-day event, 18 posters were displayed, and 34 talks were delivered, including three plenary speeches, seven invited talks, and 24 selected oral presentations.
A special thank-you to our partnering societies The Polish Membrane Society and The North American Thermal Analysis Society, as well as our sponsor, Nanomegas, for their support of the ICM conference. I am also pleased to share that we presented three awards, including the Best Presentation Award and two Best Poster Awards, recognizing the outstanding contributions of our participants.
Upcoming In-Person Event
7–9 October 2024
Non-coding RNA World 2024: Exploring Mechanisms, Designing Medicines
Location: Basel, Switzerland
ncRNA 2024 will explore the latest advances in the field, covering topics from basic biology to medical and technological applications.
Find more upcoming MDPI events here.
Closing Thoughts
Reflections from OASPA 2024 Conference in Lisbon (16–18 September)
Amidst my September travels, I also had pleasure of attending the OASPA 2024 Conference in Lisbon from 16–18 September. It’s the first in-person Open Access Scholarly Publishing Association (OASPA) event in five years, and being in the sunny city of Lisbon made it even better! MDPI has long been a member of OASPA, and attending this conference gave us an opportunity to connect with other key members of the organization to see the latest developments in the OA movement.
“I believe that publishers have a lot to offer in terms of data and insights”
Main Themes from OASPA 2024
The main themes covered were equity and inclusivity, diamond OA, AI and openness, OA books, research integrity, and how OA can address broader societal challenges such as climate change. While it was great to see the latest developments in these areas, it was also clear that certain voices were missing, particularly those of major publishers. Although it’s not easy to incorporate every perspective, I believe that publishers, including MDPI, have a lot to offer in terms of data and insights. During the membership meeting, a few of us raised the point that large-scale publisher input could add value to these discussions.
It’s important to participate in industry conferences such as OASPA in order to be part of the discussions and remain at the forefront of the OA movement.
It’s an opportunity to build meaningful relationships with organizations that share our commitment to OA.
While sponsorship is one way to show our support, it’s clear that being part of the conversation through participating in the OASPA groups and committee is what really makes a difference.
It took the last 20 years for more than 50% of the world's research to be published via open access. This provides a sobering reminder that flipping the remaining 50% will be a big challenge.
An important takeaway for me was that there is no "one-size-fits-all" solution for OA challenges: different regions and different stakeholders need different forms of support, whether it is infrastructure, funding, education, or policy, for example. I also enjoyed Rebecca Ross' presentation on how OA can drive action on climate. A few panellists shared the need for transparency in the peer-review process, advocating for open review reports, which is something we have been offering since 2014.
Speaking of openness, we are excited to celebrate Open Access Week 2024 with the scholarly community from 21–27 October. I look forward to sharing a recap of our activities in the next newsletter.
Chief Executive Officer
MDPI AG
29 September 2024
MDPI New Journal Proposal—Invitation to Shape the Future of Open Science Together
As a leader in open access publishing, MDPI is eager to explore new collaboration opportunities, including the launch of new journals and the transfer of existing ones. At present, MDPI publishes over 400 journals, more than 160 of which have established partnerships with academic organizations. Additionally, we publish 19 association journals.
In order to enhance exchange and cooperation with scientific researchers and share the results of open science, MDPI invites experts and scholars from various fields to submit proposals for new journal collaboration opportunities. If your proposal is approved, you could take on the role of Editor-in-Chief, Deputy Editor-in-Chief, or Editorial Board Member of the journal. This position allows you to manage the manuscript review process alongside our editorial department, participate in calls for papers, strengthen your network with scholars in the field, expand scientific research cooperation, enhance your personal and academic influence internationally, and play a leading role in academia.
Once the new journal is online, MDPI will provide a variety of promotional channels to market the journal internationally.
MDPI will offer various promotional channels to enhance its visibility and promote it internationally.
How can you determine the theme of a new journal?
- Assess research hotspots/academic frontiers;
- Assess pioneers in the field/key research directions of universities;
- Determine whether MDPI has already established a journal in the field.
You can browse MDPI’s existing journals at the following link: https://www.mdpi.com/about/journals.
Advantages of collaborating with MDPI:
- MDPI is a global leader in open-access publishing with extensive academic resources.
- MDPI offers a professional publishing team that provides comprehensive support throughout the publishing process.
- MDPI’s diverse promotional platforms and channels help journals quickly increase their international visibility and influence.
We invite you to submit new journal proposal here, and contribute to academic development! In addition, if your institution (university, institute, college, national key laboratory, society, etc.) intends to establish a journal, you can also submit a draft to MDPI on its behalf.
27 September 2024
MDPI’s 2023 Travel Awards—Winners Announced
MDPI journals frequently grant travel awards to empower junior researchers to showcase their latest research at academic conferences, thereby amplifying their impact within their research fields.
We extend our heartfelt congratulations to the 103 recipients of MDPI's 2023 Travel Awards from different countries and territories for their exceptional presentations. These outstanding individuals were selected by the journal editors based on the strength of their research proposals and the anticipated impact of their presentations at academic conferences. We commend their exceptional contributions and wish them continued success in their academic endeavors.
MDPI will continue to provide support and recognition to the academic community. To learn more about the list of awardees, please visit the following pages:
- Biology and Life Sciences;
- Chemistry and Materials Sciences;
- Engineering;
- Environmental and Earth Sciences;
- Medicine and Pharmacology;
- Public Health and Healthcare;
- Others.
About MDPI Awards:
To reward the academic community, especially young researchers, and enhance communication among scientists, MDPI journals regularly offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and recognition, help raise the influence of talented individuals who have been credited with outstanding achievements and are making a significant contribution to the advancement of their fields.
To explore more MDPI awards, please click here.
27 September 2024
Companionship Established Between the Journal of Pharmaceutical and BioTech Industry and Pharmaceutics
We are pleased to announce that the Journal of Pharmaceutical and BioTech Industry (JPBI, ISSN: 2813-9380) has established a companionship with its sister journal, Pharmaceutics (ISSN: 1999-4923).
The Journal of Pharmaceutical and BioTech Industry is an international, peer-reviewed, and open access journal committed to publishing research and development studies on all aspects of science, engineering, and technology applicable to the pharmaceutical and biotech industry sectors, published quarterly online by MDPI. The founding Editor-in-Chief is Prof. Dr. Ecevit Bilgili from the New Jersey Institute of Technology, USA.
The Journal of Pharmaceutical and BioTech Industry aims to create a platform on which scientists and engineers from academia, industry, and regulatory as well as other governmental agencies share and complement each other’s discoveries and advance science, engineering, and technology with the goal of enhancing patient wellbeing. All aspects of the discovery, development, delivery, and manufacturing of drugs (drug substances and drug products, including biodrugs, delivery devices, diagnostic agents, etc.) are covered. We accept original research articles, critical and timely reviews, short communications, opinions, technical notes, reports, and expert perspectives. For details on the background and scope of this journal, please click on the following link: https://www.mdpi.com/journal/jpbi/about.
We offer a full waiver on article processing charges for papers submitted before 1 January 2025. Manuscripts are peer-reviewed and a first decision is provided to authors approximately 16 days after submission; acceptance to publication is undertaken in 5.8 days (median values for MDPI journals in the first half of 2024). If accepted after peer review, your paper will be published in an open access format.
Manuscripts can be submitted via the journal’s online submission system at the following link: https://susy.mdpi.com/user/manuscripts/upload?journal=jpbi.
You can read the Opening Editorial by the Editor-in-Chief at the following link: https://www.mdpi.com/2813-9380/1/1/3.
You can read the short interview with Prof. Dr. Ecevit Bilgili, the Editor-in-Chief, who shared his vision for the journal with us, as well as his views of the area and open access publishing: https://www.mdpi.com/journal/jpbi/announcements/9313.
We cordially invite you to consider the Journal of Pharmaceutical and BioTech Industry as the platform for publishing your work.
JPBI Editorial Office
11 September 2024
MDPI’s 2023 Best PhD Thesis Awards—Winners Announced
MDPI’s Best PhD Thesis Awards are granted to promising young scholars whose PhD theses are deemed exceptional within their respective research fields. These awards aim to encourage young scholars to continue their outstanding accomplishments and further contribute to their field.
We extend our heartfelt congratulations to the 54 winners of the 2023 Best PhD Thesis Awards and wish them success with their future research endeavors.
MDPI will continue to provide support and recognition to the academic community. To learn more about all the awardees and their research projects in your field of study, please visit the following pages:
About MDPI Awards:
To reward the academic community, especially young researchers, and enhance communication among scientists, MDPI journals regularly offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and recognition, help raise the influence of talented individuals who have been credited with outstanding achievements and are making a significant contribution to the advancement of their fields.
To explore more MDPI awards, please click here.
3 September 2024
MDPI INSIGHTS: The CEO's Letter #15 - CHORUS, Best Paper Award, August Events
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
I am pleased to share that MDPI is now an Affiliate Member of CHORUS, a not-for-profit organization dedicated to ensuring public access to articles reporting on U.S. government-funded research. This partnership highlights our long-standing commitment to advancing Open Access (OA) publishing and meeting funders’ open research requirements.
Read the full announcement here.
With the White House Office of Science and Technology Policy (OSTP) 2022 memorandum calling for immediate public access to all federally funded research by 2026, this partnership positions MDPI to further support academic institutions in adhering to national mandates while providing authors with fully compliant (CC-BY) OA journals.
The CHORUS platform went live in July 2014 and includes NASA, the U.S. Department of Energy, the U.S. Department of Defense, the U.S. Geological Survey, and the National Science Foundation.
“This partnership positions MDPI to further support academic institutions in adhering to national mandates”
Joining CHORUS perfectly aligns our mission as the leading OA publisher, which is to drive transparency and innovation in scholarly publishing, with that of CHORUS itself, which is to advance Open Access research. It will also support MDPI publications from organizations such as NASA, with 1,200 research papers published by NASA-affiliated authors as at 31 August 2024.
Impactful Research
MDPI’s Best Paper Awards—Award-Winning Papers in 2023 Announced
MDPI is committed to supporting and recognizing the academic community and is proud to announce the recipients of the 2023 Best Paper Awards, which recognize high-quality papers of significant scientific merit and impact. Each year, the editors of our journals carefully select papers that showcase outstanding scientific achievement.
This year, 115 Best Paper Awards were presented, chosen from 346 exceptional papers in a highly competitive selection process. Congratulations to the authors for their remarkable contributions!
To learn more about all the awardees and their research projects, visit the following pages:
- Biology and Life Sciences
- Business and Economics
- Chemistry and Materials Sciences
- Computer Sciences and Mathematics
- Engineering
- Environmental and Earth Sciences
- Medicine and Pharmacology
- Public Health and Healthcare
- Social Sciences, Arts and Humanities
- Physical Sciences
About MDPI Awards
MDPI regularly offers various awards to recognize researchers, particularly young scientists, and to promote communication within the scientific community. These awards exist to inspire and acknowledge talented scientists who have made significant contributions to advancing their fields.
To find out more MDPI awards, please click here.
“Our awards exist to inspire and acknowledge talented scientists”
Inside MDPI
MDPI AI Team Presented at EuroSciPy 2024 in Poland
As part of the CEO Letter, I hold dear this ‘Inside MDPI’ section, where I have an opportunity to highlight various projects, teams and updates within our organization. As such, I’m happy to showcase the following presentations from members of MDPI’s Artificial Intelligence (AI) team, which were recently presented at the EuroSciPy 2024 (16th European Conference on Python in Science). This conference took place in Szczecin, Poland from 26–30 August.
“This event was a great opportunity to reinforce our commitment to innovation and excellence in publishing”
MDPI colleagues Frank Sauerburger (AI Tech Leader) and Daniele Raimondi (Senior Data Scientist) both presented at the conference. Frank discussed MDPI’s AI infrastructure, while Daniele showcased a new methodological approach we have been developing to track the journey of rejected academic manuscripts. This approach combines AI, data science and analytics to improve the identification of manuscripts and authors, enhancing our understanding of publishing dynamics.
This event was a great opportunity to reinforce our commitment to innovation and excellence in publishing. It also allowed us to contribute to the academic discussion on integrating AI and data science into scholarly communication.
From data analysis in Jupyter Notebooks to production applications: AI infrastructure at reasonable scale – Frank Sauerburger
Frank’s presentation on MDPI’s AI infrastructure provided a chance to showcase the advanced technological frameworks that power our operations. Given the technical and academic focus of EuroSciPy, this talk demonstrated how MDPI’s AI capabilities are not only cutting-edge but also central to driving efficiency and innovation in scholarly publishing. Engaging with the EuroSciPy community helps position MDPI as a leader in applying AI within the publishing industry, fostering potential collaborations and attracting interest from top researchers.
A Qdrant and Specter2 framework for tracking resubmissions of rejected manuscripts in academia – Daniele Raimondi
Daniele’s talk on the novel methodological approach that combines AI, Data Science, and Analytics was crucial in highlighting how MDPI is advancing the precision and effectiveness of manuscript and author identification. This approach is pivotal in enhancing our understanding of publishing dynamics and ensuring the quality and integrity of the academic content we manage. By presenting at EuroSciPy, we had the opportunity to engage with an audience deeply involved in scientific computing, gaining feedback and insights that could further refine our methodologies.
Thank you, Frank and Daniele, for representing MDPI so well!
I will share more about MDPI’s AI team and projects in upcoming CEO Letters, as we have a well-rounded AI and Data Team working on an exciting suite of AI products for MDPI and the scholarly community at large.
Coming Together for Science
The 1st International Conference on AI Sensors & The 10th International Symposium on Sensor Science
I am pleased to share the success of our MDPI conference The 1st International Conference on Artificial Intelligence (AI) Sensors and the 10th International Symposium on Sensor Science in Singapore this past 1–4 August.
With nearly 400 attendees, the event brought together researchers and industry experts from China, Singapore, Japan, Korea, Taiwan, India and other countries to share their findings on the latest developments in sensors, sensing technology, artificial intelligence for sensing applications and AI-enhanced sensing systems.
We accepted a total of 355 abstracts, featuring 772 authors from 28 countries. Over the course of the four-day event, 66 posters were displayed and 296 talks were delivered, including 4 plenary talks, 46 keynote speeches, 122 invited talks, and 124 selected oral presentations. View the event gallery here.
I am pleased to announce the winners of the four awards, including Best Presentation and Best Poster, recognizing the contributions of our participants during the conference.
Looking ahead, the 2nd International Conference on AI Sensors and Transducers is scheduled to take place from 29 July to 5 August, 2025, in Bangkok, Thailand.
Thank you to our Conference team, including Ionut Spatar, Teodora Nicoleta Cremene, Ang Kai Lin, Benjamin Tay, Leong Jin Yue Esther, Wong Jolin, Judith Wu, Alethea Liu and Flora Li, who were involved in making this event a success. A big thank-you also goes to our local MDPI colleagues for their support: Yu Nwe Soe, Hen Chu Yang, Kwah Zhi En Watcharapong, Zephan Yang, Daphne Neo, Huimin Cheng, Nathan Li and Ting Yin.
Upcoming In-Person Event
25–27 September, 2024
The 5th International Conference on Materials: Advances in Material Innovation
Location: Basel, Switzerland
ICM 2024 will unite experts to share insights on recent advancements in Materials Characterization, Processing and Manufacturing.
7–9 October, 2024
Non-coding RNA World 2024: Exploring Mechanisms, Designing Medicines
Location: Basel, Switzerland
ncRNA 2024 will explore the latest advances in the field, covering topics from basic biology to medical and technological applications.
Find more upcoming MDPI events here.
Closing Thoughts
The 2nd Sustainable Publishing Forum
In 2022, the International Association of Scientific, Technical and Medical Publishers (STM) outlined three goals to reflect the academic community’s shared aspirations: promoting Open Science, maintaining research integrity and fulfilling social responsibility. Open Science has evolved from the Open Access movement of the early 2000s to become a preferred model in academic publishing. Publishers and academic journals play a crucial role in ensuring research integrity, with efforts to prevent misconduct markedly on the increase now.
As the world faces sustainability challenges, the academic publishing industry is increasingly committed to contributing the achievement of the United Nations Sustainable Development Goals (SDGs). Many publishers are implementing strategies to support these objectives, including ours, which you can view here.
The 2nd MDPI Sustainable Publishing Forum provided a platform for global editors and publishers to discuss these themes, aiming to strengthen collaboration and advance the contributions that scientific publishing can make to academia and society.
“Open Science has evolved to become a preferred model in academic publishing”
The 2nd Sustainable Publishing Forum
We hosted MDPI’s 2nd Sustainable Publishing Forum in Beijing, China, on 15–16 August, attracting nearly 120 attendees from local and international publishers, university presses, scientific and technical journal associations, libraries and the Chinese Academy of Sciences. The event focused on promoting Open Science, maintaining research integrity, and fulfilling social responsibility.
This was an excellent opportunity for us to share more with conference attendees about the approach of our research integrity team. Our Head of Publishing, Peter Roth, also participated, speaking on how to identify and avoid predatory publishers and about the principles that underpin ethical academic publishing.
I extend my thanks to all of our conference speakers, including Hylke Koers (STM Solutions), who presented on STM Trends 2028 and shared insights on the STM Integrity Hub, of which MDPI is a member.
Chief Executive Officer
MDPI AG
3 September 2024
Meet Us at the 33rd Annual Conference Biomaterials in Medicine and Veterinary Medicine, 10–13 October 2024, Rytro, Poland
Conference: The 33rd Annual Conference Biomaterials in Medicine and Veterinary Medicine
Date: 10–13 October 2024
Location: Rytro, Poland
Conference homepage: https://www.biomat.agh.edu.pl/
The annual conferences on Biomaterials in Medicine and Veterinary Medicine organized by the Polish Society for Biomaterials address both the fundamentals and clinical applications of carbon, metals, polymers, ceramics and composite biomaterials. Their aim is to present the latest results of scientific research and to provide a platform for the exchanging of ideas, knowledge and experiences with scientists, researchers and clinicians in the field of biomaterials.
This year, the conference will be held from 10 to 13 October 2024 in Rytro, Poland. Excellent plenary speakers have been invited, such as Prof. Małgorzata Włodarczyk-Biegun, Prof. Sachiro Kakinoki, and Prof. Miguel Oliveira, to share their passion and knowledge with conference participants. Podium and poster presentations will allow our presenters to showcase their latest research. Also, Best Poster and Rapid-Fire Presentation Competitions are planned for early career scientists. Finally, in addition to the high-quality scientific elements, a rich cultural and social program is offered for attendees to enjoy throughout the conference (all included in the fee).
Abstracts for late posters can be still submitted from 26–31 August 2024.
26 August 2024
Meet Us at the 15th APS PharmSci International Conference, 4–6 September 2024, Huddersfield, UK
Conference: The 15th APS PharmSci International Conference
Date: 4–6 September 2024
Location: Huddersfield, UK
Conference homepage: https://apspharmsci.com/
The Academy of Pharmaceutical Sciences (APS) is a UK-based professional membership body for pharmaceutical scientists. We represent individuals and organizations from around the globe, helping them throughout their development, ensuring consistently excellent delivery in the Pharmaceutical Science sector. Pharmaceutical scientists are experts in the research, development and manufacturing of medicines. They have a major role in the regulation of medicines and understanding their use in patients.
The aim of the 2024 APS conference is to provide a forum for the presentation and exchange of ideas relating to the latest high-quality developments in the design and manufacturing of new medicines from discovery to commercialization. The conference will provide a dynamic forum for members of industry, both large and small, to come together with academic colleagues to explore new technologies and processes. Collaboration and cooperation is the key to modern pharmaceutical development, and the University of Huddersfield will provide an ideal setting to bring together groups from across Ireland, the UK and beyond to showcase internationally leading work and to set the stage for a new era of pharmaceutically driven healthcare.
19 August 2024
MDPI’s 2023 Young Investigator Awards—Winners Announced
MDPI’s Young Investigator Awards recognize promising early career scientists, acknowledge their contributions, and foster collaboration within the scientific community. We are proud to announce the recipients for 2023, who were carefully selected by the journals’ esteemed Award Evaluation Committee.
We extend our heartfelt congratulations to the 79 winners of MDPI’s 2023 Young Investigator Awards for their excellent contributions in their research field. We look forward to seeing these rising stars continue to contribute to the advancement of science.
MDPI will continue to support and recognize the academic community. To explore details about the awardees by field, please visit the individual pages listed below:
Congratulations to all the winners for their exceptional contributions and dedication to advancing scientific research.
About MDPI Awards:
To support the academic community, particularly young researchers, and to enhance communication among scientists, MDPI journals regularly offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and recognition, help to elevate the profiles of talented individuals who have made outstanding achievements and are making significant contributions to advancements in their respective fields.
To find out more about MDPI awards, please click here.
16 August 2024
MDPI at the 22nd International Nanomedicine and Drug Delivery Symposium (NanoDDS 2024), 13–15 September 2024, Orlando, USA
Conference name: 22nd International Nanomedicine and Drug Delivery Symposium (NanoDDS 2024)
Date: 13–15 September 2024
Location: Orlando, FL, USA
Conference homepage: https://pharmacy.ufl.edu/nanodds/
Pharmaceutics (ISSN: 1999-4923) is now collaborating with the 22nd International Nanomedicine and Drug Delivery Symposium, or nanoDDS, which will be held in Orlando, FL, USA from 13 to 15 September 2024. The annual event serves as an important gathering for researchers developing next-generation delivery vehicles—targeted, responsive, biodegradable nanomaterials to make diagnostics more sensitive and drugs more effective. Established in 2003 by Dr. Alexander Kabanov and Dr. Kazunori Kataoka, the symposium has attracted more than 3,000 participants from 30 different countries over the years and has become one of the most authoritative forums in its field.
We invite you to join this excellent event and communicate with the top experts in the community.
7 August 2024
MDPI Insights: The CEO's Letter #14 - New Headquarters, Marketing, Poland
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
MDPI Moves to New Headquarters in Basel, Switzerland
I am excited to share that MDPI has moved to a new state-of-the-art office space in Basel, Switzerland. This move consolidates our operations by bringing together our two previously separated Basel offices into one central location.
We are always growing our talent pool and encourage you to view our Careers Page for the positions available in Basel and across our offices.
New Address: Grosspeteranlage 5, CH-4052 Basel, Switzerland
Effective Date: 1 July 2024
This new chapter in our company’s journey is designed to continue our mission of positioning MDPI as a leader in Open Access (OA) publishing, highlighting our commitment to making scholarly research accessible to everyone.
Boasting modern amenities, improved meeting and event spaces designed to support our growing needs, the new location provides a more collaborative and efficient working environment for our employees. The location offers convenient accessibility to public transportation and is situated near the Basel SBB railway station, with a variety of nearby services and amenities.
In fact, I can see the trains right outside of my window as I write these lines!
This move marks an exciting milestone in MDPI’s development, and I am confident that the new headquarters will serve as an inspiring and productive space for everyone. We also very much look forward to welcoming visitors here. You can read more about MDPI's history here.
“This new chapter continues our mission of positioning MDPI as a leader in OA publishing”
For Those New to MDPI
A pioneer in scholarly, Open Access publishing, MDPI has supported academic communities since 1996. MDPI is leading the transition to Open Science by making a greater proportion of the research conducted worldwide free and accessible to everyone. To date, over 3.5 million researchers have entrusted MDPI with publishing their scientific discoveries. MDPI’s editorial process is bolstered by a network of dedicated reviewers, a team of 6,000 professional, well-trained staff members, and an in-house article submission platform designed to ensure efficient processes within its 440 fully Open Access titles. MDPI supports more than 800 academic institutions worldwide, helping them adhere to national mandates while facilitating authors’ publication in fully compliant (CC BY) Open Access journals.
Impactful Research
New and Emerging MDPI Journals Making an Immediate Impact
Unpacking some of the Impact Factor updates from the June CEO Letter, I wanted to dive a little deeper into the 137 MDPI journals which received Impact Factor for the first time.
Academic authors highly value efficient publishing processes, robust editorial support, and the opportunity to publish in high-impact journals. We are proud that our newly launched journals typically achieve coverage in the Emerging Sources Citation Index (ESCI) of the Web of Science within just a few years, with a median time of only three years from release to inclusion.
As part of our commitment to advancing academic research and providing high-quality OA publishing, we actively seek new research areas to expand our portfolio of journals. We have a proven track record of successfully establishing new journals.
Our dedicated teams excel in fostering dynamic editorial boards and working closely with Editors-in-Chief (EiC) to define the precise scope and focus of each new journal. Our expertise extends to collaborating with indexing services, ensuring that our journals comply with best practices and are indexed promptly in all relevant databases.
Emerging Titles Ranked for the First Time
Our commitment to excellence is reflected in the annual impact metrics released this past June. The latest edition of the Journal Citation Reports (JCR) showcases the integration of journals from the ESCI in the new unified category rankings, providing a simplified and more complete view of all journals within each subject category, including newly established titles.
Out of 137 new and developing MDPI journals ranked in the 2024 release, 79 are in the top half (Q1 or Q2) of their categories. Here is a breakdown of the number of MDPI’s ESCI-indexed journals by quartile in the JCR:
Quartile | No. of journals |
Q1 | 17 (12.4%) |
Q2 | 62 (45.3%) |
Q3 | 43 (31.4%) |
Q4 | 15 (10.9%) |
Not ranked (humanities-related journals) | 2 |
These rankings highlight our success in rapidly establishing high-impact new journals. Among those that made it directly into the top 25% of their category are the International Journal of Neonatal Screening, Journal of Xenobiotics, Polysaccharides, Smart Cities, and thirteen other journals.
You can browse MDPI journals by Indexing. Simply visit our Journals page and select from the list of Indexing bodies in the top left-hand corner.
Inside MDPI
MDPI Corporate Marketing Strategy and Team Meeting 2024
In July, I hosted the annual Corporate Marketing strategy and team-building activity with 15 of our team members.
The aim was to align the Corporate Marketing strategy with MDPI's goal of becoming the world's most trusted OA publisher. While we provide a high-level publishing experience for our authors, as seen from our surveys, we need to keep building on our transparent and open communication to foster trust within the scholarly community and continue enhancing our reputation.
The Corporate Marketing team plays an important role as the mouthpiece for all our major activities within MDPI, especially those that model what it means to be a trusted partner. The purpose of the strategy meeting was to develop a feeling of trust in one another and an understanding of how to inspire trust in the stakeholders with whom we interact.
“We need to keep building on our transparent and open communication to foster trust within the scholarly community”
We conducted a set of activities to facilitate that sense of mutual trust and trustworthiness. Examples of some activities we worked on during this strategy-building event include:
- Exploring what trust means
- ‘Letter to self’
- ‘The brand I most trust’
- Most Trusted Academic Publisher
- ‘The brand I would like MDPI to become’
- ‘The 2029 MDPI Annual Report’
- Voice of Customer and Share of Voice – survey/data update on MDPI Brand Experience and Brand Perception
- Integrate Trust-Based Objective into Marketing Plan
- ‘Becoming the MDPI experience’
- ‘Trusting the next steps’
While two days is not enough to finalize a marketing strategy, it is sufficient to get everyone who attended into the mindset of the direction in which we are working. From here, we will develop a program with next steps on main projects, update communications, and collaborate with team leads to incorporate this approach into our work going forward.
As a marketing team, we can communicate our messages, but trust has to be built at every touchpoint in the stakeholder journey. Just talking about it isn’t enough. We need to be about it. That’s a role each of us plays, from editorial to IT, from marketing to HR. We must build trust from the inside out. It starts with each manager and resonates out via every team member.
As a company, our goal is to give all stakeholders with whom we interact – whether internal or external – the experience of working with an organization it can trust.
Coming Together for Science
MDPI in Poland: Krakow Office
In July, I had the pleasure of visiting our Krakow office, following my recent trip to Warsaw to meet with the Polish Ministry of Science and Higher Education.
During these visits, I prioritized meeting with our Office Manager, Editorial Director, Group Leads, and members from various teams, including editorial, production, marketing, and journal relationship specialists, to understand their roles and current challenges. Instead of a formal presentation, I opted for an open discussion, sharing updates from headquarters to engage with colleagues in a more personal way.
Our Krakow office has many things to be proud of, including a large number of PhD colleagues (over a third of its staff holds a PhD degree). Krakow provides an opportunity for expanding beyond the 100 colleagues we currently have, by adding new hires in departments including editorial, production and marketing, among others.
About our Krakow office
- Opened in 2020
- 99 staff members as at 1 August 2024
- Main Departments include Editorial, Production, English Department, JRS, PR
Our Krakow office participates in international conferences, conducts author trainings and scholar visits, and engages in local market outreach. The office is also a member of the Polish Chamber of Commerce for High Technology (IZTECH) and is working on expanding its local engagement.
Krakow is the second-largest city in Poland, with a population of about 800,000. It also has a large student population of around 128,000, with seven universities. This means that roughly one in every eight residents is a student.
Poland and MDPI
Poland is a crucial market for MDPI. From 2020 to June 2024, Poland ranked 7th in submissions and 5th in publications for MDPI research articles. As at 31 July 2024, Poland ranks 7th in total MDPI publications, with approximately 70,000 research papers.
Between 2020 and June 2024, 61,500 authors from Poland published with MDPI. As at 30 June 2024, there are 1,205 active Editorial Board Members (EBMs) from Poland, with 661 EBMs (55% of the total) having an H-index over 25.
We also have four Editors-in-Chief (EiC) from Poland leading our journals: Coatings, Venereology, Advances in Respiratory Medicine, and Limnological Review, along with six Section EiC.
In 2023, we received approximately 21,000 submissions from Polish-affiliated authors, of which 12,032 were published.
“Poland is a crucial market for MDPI”
Meeting with Ministry of Education
On 22 July, we visited Warsaw to meet with the Polish Ministry of Science and Higher Education.
We were pleased to learn that they are strong supporters of the OA publishing model and value MDPI’s approach to the peer-review process, including our high ethical standards for quality control.
In 2023 Polish authors predominantly published their papers in OA, with MDPI holding the largest market share in OA publications within the country.
Our commitment to collaborating with Polish institutions is evident through our 33 Institutional Open Access Program (IOAP) agreements with prestigious institutions such as the University of Warsaw, the University of Wroclaw, the Jagiellonian University, and Gdańsk University of Technology. Through IOAP discounts, a healthy waiver rate, and our peer-review voucher system, we provide the Polish scholarly community with significant savings in OA publishing. The Minister greatly appreciated these efforts and our commitment to offsetting some of the APC costs.
We discussed industry concerns about the threat of papermills and presented the preventive measures MDPI has in place to mitigate this risk and uphold high ethical standards. We informed them of our commitment to combating papermills, including our involvement with United2Act and the STM Research Integrity Hub, as well as our efforts to expand our research integrity team and explore proactive measures.
Closing Thoughts
MDPI Thought Leadership Op-ed on Open Access is Now Live on Politico
I am pleased to share that our thought leadership Op-ed piece on Open Access (OA) is now live on Politico. This is a nice push for continued influence and support of OA among policymakers and industry leaders.
Why Politico?
Politico's reputation as a highly credible and influential news platform makes it an important venue to reach key opinion leaders (KOL) from academia, policymakers, and thought leaders from many industries. This visibility helps promote the OA philosophy.
Open Access: A Moral Imperative for Progress
In this piece, I discuss the necessity of making scientific research freely available to all. I argue that publicly funded research should be publicly accessible, highlighting how OA democratizes scientific knowledge, accelerates research availability, and fosters collaboration.
“Open Access is a fundamental right for all citizens”
Democratizing scientific communication
The impulse to democratize scientific communication is nothing new. OA may seem like a recent innovation, but its principles have historical roots traceable to Europe in the 15th century. Just as the printing revolution accelerated the dissemination of new ideas, OA publishing unlocks new scientific insights that would otherwise only be accessible to a few.
Benefits for scholars: amplifying impact through Open Access
Authors publishing in an OA journal can expect more citations of their work, increasing its potential impact. Research findings that are freely available are more likely to be cited than those hidden behind a paywall. Freedom of access greatly increases the potential audience for each paper, fostering a sense of community among researchers worldwide. Heightened visibility can attract prospective collaborators and employers for young scientists. At MDPI, we believe that all these factors can only accelerate the advance of science. Additionally, authors retain copyright in their work instead of signing it away, permitting broader dissemination under Creative Commons licenses and increasing its capacity for impact.
The moral imperative
OA is not just a matter of scientific policy; it is a fundamental right for all citizens and a prerequisite for a brighter, more informed future. Publicly funded research should be a top priority, and I am pleased to see policy moving in this direction. Our capacity to generate transformative scientific insights has to be democratized. The question today is no longer whether we can afford to embrace OA; rather, it is whether we can afford not to.
Chief Executive Officer
MDPI AG
2 August 2024
MDPI Romania Author Training Sessions in May
In May, MDPI Romania held three author training sessions – one endorsing an external event and two stand-alone sessions.
The National Session of Scientific Student Communications took place at Technical University Cluj on 17 and 18 May 2024. MDPI Romania sponsored this event and contributed an author training session on the production of research papers and case study analyses. JRS Norbert Kiss gave a presentation called The World of Open Access to explain different open access publishing models and the benefits of open access publishing. His presentation highlighted the impact of open access publishing on scientific progress and innovation.
On 29 May 2024, MDPI Romania hosted an author training session for Ph.D. students, early career researchers, and professors at the Carol Davila University of Medicine and Pharmacy. In collaboration with Prof. Andreea Arsene, JRS Ioana Paunescu prepared two presentations: The Steps of the Publishing Process and Elaboration of a Peer Review Report. In her first presentation, she delved into MDPI’s history and mission, MDPI’s editorial process, and MDPI journals of various scopes that are accepting submissions. Her second presentation outlined the types of peer review, the contents of a peer review report by an MDPI reviewer, and the responsibilities of an MDPI reviewer.
MDPI Romania also hosted an author training session at the Iasi University of Life Sciences on 29 May 2024. JRSs Laurentiu Preda and Cosmin Artan gave four presentations: Efficient Writing of an ISI-Indexed Scientific Article, Benefits of Publishing in the Open Access Model, Various Methods of Open Access Publishing, and MDPI Guide for the Article Review Process. The first three presentations offered guidance on how to improve academic writing, the fourth focused on how to write peer review reports. A highly interactive discussion followed the presentations, during which the JRSs provided extensive answers to attendees’ questions.
MDPI is grateful for all the attendees, speakers, and organizers involved in these events. Through their enthusiasm and dedication, these events were great successes.
31 July 2024
Pharmaceutics Reaches Further Cooperation with the Korean Society of Pharmaceutical Sciences and Technology (KSPST)
We are pleased to announce that Pharmaceutics (ISSN: 1999-4923) has entered into a collaboration with the Korean Society of Pharmaceutical Sciences and Technology (KSPST) for two significant upcoming events:
2024 International Conference of the Korean Society of Pharmaceutical Sciences and Technology
Date: 26–28 November 2024
Location: Seoul, Republic of Korea
The above conference aims to highlight recent breakthroughs and innovative achievements in pharmaceutical sciences and technology, with a particular emphasis on critical advancements and the application of diverse technologies to bridge the gap between basic research and clinical application. The scientific sessions will cover a wide range of topics, including formulation development, regulatory science, drug delivery, and pharmaceutical manufacturing technology. Additionally, the conference will feature oral sessions for young scientists and poster oral presentations, offering valuable opportunities for them to present their work and engage with experts in the field. The above conference also provides a great chance for multi-disciplinary researchers from academia, research institutes, the pharmaceutical industry, and government sectors to engage in fruitful scientific discussions, fostering global collaborations and networking.
2024 Formulation Technology Workshop
Date: 20 September 2024
Location: Seoul, Republic of Korea
Since its establishment in 1971, the Korean Society of Pharmaceutical Sciences and Technology (KSPST) has been at the forefront of advancing pharmaceutical sciences. The KSPST has dedicated itself to facilitating the prompt dissemination of academic research outcomes and the industrial application of innovative science by organizing regular scientific events.
If you plan to attend either or both of these events, we would appreciate it if you could let us know your availability. The journal looks forward to the opportunity to meet with you and explore new avenues for mutual growth and development.
24 July 2024
Meet Us at the 8th China-Europe Symposium on Biomaterials in Regenerative Medicine, 15–18 September 2024, Nuremberg, Germany
The 8th China-Europe Symposium on Biomaterials in Regenerative Medicine will be held from 15 to 18 September 2024, in Nuremberg, Germany. The conference is organized by Chinese Society for Biomaterials (CSBM) and European Society for Biomaterials (ESB).
Topics include the following:
- Advanced metallic biomaterials;
- Natural and synthetic polymers;
- Bioceramics in regenerative medicine;
- Advanced biocomposites;
- Multi-functional hydrogels;
- Nanomaterials and nanomedicine;
- Biomaterials for bone regeneration;
- Biomaterials for cartilage regeneration;
- Biomaterials for nerve regeneration;
- Vascular regeneration biomaterials;
- Biomaterials in cancer microenvironment;
- Marine biomaterials;
- Biomaterials surfaces and interfaces;
- Characterization and assessment of biomaterials;
- Bio-imaging and molecular probe;
- Cardiovascular biomaterials;
- Dental biomaterials;
- Biomaterials for drug delivery systems;
- Biomaterials for in vitro disgnostics.
The following MDPI journals will be represented in the conference:
- Journal of Functional Biomaterials;
- Gels;
- Bioengineering;
- Fibers;
- Journal of Composites Science;
- Materials;
- Macromol;
- Coatings;
- Pharmaceutics.
If you are attending this conference, please feel free to start a conversation with us by contacting us online. Our delegates look forward to meeting you in person at a booth and answering any questions that you may have. For more information about the conference, please visit the following link: https://www.cesb2024.org/.
10 July 2024
MDPI's Newly Launched Journals in June 2024
Five new journals covering multiple subjects have launched their inaugural issue in June 2024. We are excited to be able to share with you the newest research rooted in the value of open access.
We would like to express our deepest appreciation to all the Editorial Board Members and each journal will ensure its high-quality output using excellent editorial and rigorous peer review processes, to ensure that the articles achieve high impact and visibility.
Please feel free to browse and discover more about the new journals below.
Journal |
Founding Editor-in-Chief |
Journal Topics (Selected) |
Prof. Dr. Marco Ranucci, IRCCS Policlinico San Donato, Italy |
anaesthetic medications; blood and fluid management; pain management; critical care; critical illness | view journal scope | submit an article |
|
Dr. Giovanni E. Cacciamani, University of Southern California, USA |
surgical/procedural complications; complications; perioperative adverse events; postoperative adverse events | view journal scope | submit an article |
|
Prof. Dr. Gassan Hodaifa, Universidad Pablo de Olavide, Spain |
laboratory management; laboratory safety; protective equipment; laboratory problems and challenges; laboratory Innovation | view journal scope | submit an article |
|
Prof. Dr. Jan S. Suchodolski, Texas A&M University, USA |
companion animals health and disease; veterinary care and nutrition; genetics and genomics; behavior and welfare; human-animal relations | view journal scope | submit an article |
|
Prof. Dr. Pierfrancesco De Paola, University of Naples Federico II, Italy |
real estate appraisal; economic and financial valuation of real estate projects; sustainable real estate; housing and urban economics | view journal scope | submit an article |
We wish to thank everyone who has supported the development of open access publishing. You are welcome to send an application here, or contact the New Journal Committee ([email protected]) if you would like to create more new journals.
25 June 2024
Meet Us at the CRS 2024 Annual Meeting and Expo (CRS 2024), 8–12 July 2024, Bologna, Italy
Conference: the CRS 2024 Annual Meeting and Expo (CRS 2024)
Date: 8–12 July 2024
Location: Bologna, Italy
This conference will be the 51st annual conference of the Controlled Release Society. The annual CRS conference is the most important one in the pharmaceutics field. The main topics of the conference include Nanomedicine and Nanoscale Delivery, Immuno Delivery, Oral Delivery, Skin and Mucosal Delivery, Ocular Delivery, Bioengineering, Gene Delivery and Gene Editing, Alternative Methods to Animal Testing, Long-Acting Drug Delivery Formulations, Delivery to the Nervous System, Artificial Intelligence, and Predictive Models in Pharmaceutical Technologies.
MDPI will be attending the CRS 2024 Annual Meeting and Expo (CRS 2024). We welcome researchers from different backgrounds to visit and share their latest ideas with us.
The following MDPI journals will be represented:
- Pharmaceutics;
- Molecules;
- Pharmaceuticals;
- Future Pharmacology;
- Applied Biosciences;
- IJMS;
- Gels;
- BioMedInformatics;
- CIMB;
- JNT;
- Life;
- Biomolecules.
If you plan to attend this conference, please contact us online. Our delegates look forward to meeting you in person at booth #29 and answering any questions you may have. For more information about the conference, please visit the following website: https://2024crsannualmeeting.eventscribe.net/.
23 June 2024
Topics Webinar | Advances in Natural Products and Their Derivatives for Metabolic and Chronic Inflammatory Disease Therapy, 28 June 2024
We are thrilled to welcome you to our upcoming webinar “Advances in Natural Products and Their Derivatives for Metabolic and Chronic Inflammatory Disease Therapy" that promises to be a pivotal event under the Special Issue “Advances in Natural Products and Their Derivatives for Metabolic and Chronic Inflammatory Disease Therapy”.
In this engaging webinar, we will shed light on the critical role of the NRF-2 transcription factor (nuclear factor erythroid 2-related factor 2) in modulating inflammatory diseases and how natural compounds offer valuable insights for research and development of effective therapies.
Join us as we delve into the latest discoveries and insights surrounding NRF-2, a pivotal protein in stress response and inflammation regulation, and explore the potential implications for therapeutic interventions.
Register now to secure your spot!
Date: 28 June 2024 at 03:00 p.m. CEST | 09:00 a.m. EDT | 09:00 p.m. CST Asia
Webinar ID: 854 8025 5074
Webinar link: https://sciforum.net/event/Topics-24
After registering, you will receive a confirmation email containing information on how to join the webinar. Registrations with academic institutional email addresses will be prioritized.
Cannot attend? Register anyway and we will let you know when the recording is available to watch.Register now for free!
Speaker/Presentation | Time in CEST | Time in EDT | Time in CST Asia |
Dr. Marisa Freitas |
3:00 p.m.–3:05 p.m. | 9:00 a.m.–9:05 a.m. | 9:00 p.m.–9:05 p.m. |
Dr. Paulo Matafome |
3:05 p.m.–3:25 p.m. | 9:05 a.m.–9:25 a.m. | 9:05 p.m.–9:25 p.m. |
Dr. Alexandre Borbely Federal University of Alagoas Zika Virus Infection and Effects on the Placental HTR-8SVneo Cell Line Are Reduced by Treatment With Passiflora edulis Extract |
3:25 p.m.–3:45 p.m. | 9:25 a.m.–9:45 a.m. | 9:25 p.m.–9:45 p.m. |
Assoc. Prof. Maria Teresa Cruz University of Coimbra The Case Study of the NRF2 Activator Isoeugenol in Alzheimer’s Disease |
3:45 p.m.–4:05 p.m. | 9:45 a.m.–10:05 a.m. | 9:45 p.m.–0:05 p.m. |
Q&A Session | 4:05 p.m.–4:20 p.m. | 10:05 a.m.–10:20 a.m. | 10:05 p.m.–10:20 p.m. |
Dr. Marisa Freitas University of Porto Closing of Webinar |
4:20 p.m.–4:30 p.m. | 10:20 a.m.–10:30 a.m. | 10:20 p.m.–10:30 p.m. |
Webinar Chair and Keynote Speakers:
- Marisa Freitas, LAQV-REQUIMTE, Associate Laboratory for Green Chemistry, Faculty of Pharmacy of University of Porto, Portugal;
- Paulo Matafome, Instituto Politécnico de Coimbra, Escola Superior de Tecnologia da Saúde de Coimbra, Portugal;
- Alexandre Borbely, Institute of Biological and Health Sciences, Federal University of Alagoas, Brazil;
- Prof. Maria Teresa Cruz, Faculty of Pharmacy, University of Coimbra, Portugal.
Relevant Special Issue:
“Advances in Natural Products and Their Derivatives for Metabolic and Chronic Inflammatory Disease Therapy, 2nd Edition”
Guest Editors: Eduarda Fernandes, Marisa Freitas and Ana Teresa Rufino
Deadline for manuscript submissions: 20 July 2024
20 June 2024
2023 Impact Factors for MDPI Journals Released
MDPI is pleased to announce the inclusion of 237 journals in the 2024 release of the Journal Citation Reports (JCR) and share the key results (see above).
This year, journals covered in the Emerging Sources Citation Index (ESCI) received category ranks together with journals in the Science Citation Index Expanded (SCIE) and Social Sciences Citation Index (SSCI). Overall, 139 MDPI journals indexed in ESCI are included in the new unified rankings for the first time.
Enhanced Comparability of Data
According to Clarivate, "the creation of unified category rankings [provides] a simpler and more complete category view for the evaluation of journal performance. [...] The category-first approach simplifies journal performance assessment with a holistic view of all journals in each subject category."
We are thrilled to announce that 72% of our ranked MDPI journals (171 of 237) are above average, in Q1 or Q2. Twenty-nine of our journals received their first Impact Factor this year, accounting for more than 5% of the journals accepted into the Web of Science last year.
MDPI Journals Ranked in JCR
The following data includes all MDPI journals indexed in SCIE, SSCI, ESCI and AHCI.
Journal |
Impact Factor |
Rank Quartile |
Category |
Q3 |
Acoustics |
||
Q2 |
Engineering, Mechanical |
||
Q2 |
Instruments & Instrumentation |
||
Q2 |
Management |
||
Q3 |
Respiratory System |
||
Q2 |
Engineering, Aerospace |
||
Q1 |
Agronomy |
||
Q2 |
Agricultural Engineering |
||
Q1 |
Agronomy |
||
Q1 |
Plant Sciences |
||
Q2 |
Computer Science, Artificial Intelligence |
||
Q2 |
Computer Science, Interdisciplinary Applications |
||
Q3 |
Computer Science, Artificial Intelligence |
||
Q2 |
Computer Science, Theory & Methods |
||
Q1 |
Agriculture, Dairy & Animal Science |
||
Q1 |
Veterinary Sciences |
||
Q1 |
Infectious Diseases |
||
Q1 |
Pharmacology & Pharmacy |
||
Q3 |
Immunology |
||
Q1 |
Biochemistry & Molecular Biology |
||
Q1 |
Chemistry, Medicinal |
||
Q1 |
Food Science & Technology |
||
Q2 |
Chemistry, Multidisciplinary |
||
Q1 |
Engineering, Multidisciplinary |
||
Q3 |
Materials Science, Multidisciplinary |
||
Q2 |
Physics, Applied |
||
Q2 |
Computer Science, Information Systems |
||
Q2 |
Engineering, Electrical & Electronic |
||
Q2 |
Telecommunications |
||
N/A |
Humanities, Multidisciplinary |
||
Q3 |
Environmental Sciences |
||
Q3 |
Meteorology & Atmospheric Sciences |
||
Q3 |
Physics, Atomic, Molecular & Chemical |
||
Q1 |
Audiology & Speech-language Pathology |
||
Q1 |
Mathematics, Applied |
||
Q2 |
Electrochemistry |
||
Q2 |
Energy & Fuels |
||
Q2 |
Materials Science, Multidisciplinary |
||
Q2 |
Psychology, Multidisciplinary |
||
Q2 |
Food Science & Technology |
||
Q2 |
Computer Science, Artificial Intelligence |
||
Q2 |
Computer Science, Information Systems |
||
Q1 |
Computer Science, Theory & Methods |
||
Q2 |
Engineering, Biomedical |
||
Q1 |
Biology |
||
Q2 |
Biochemistry & Molecular Biology |
||
Q2 |
Medicine, Research & Experimental |
||
Q1 |
Pharmacology & Pharmacy |
||
Q1 |
Engineering, Multidisciplinary |
||
Q3 |
Materials Science, Biomaterials |
||
Q1 |
Biochemistry & Molecular Biology |
||
Q1 |
Chemistry, Analytical |
||
Q1 |
Instruments & Instrumentation |
||
Q2 |
Nanoscience & Nanotechnology |
||
Q3 |
Biotechnology & Applied Microbiology |
||
Q1 |
Ornithology |
||
Q3 |
Neurosciences |
||
Q2 |
Construction & Building Technology |
||
Q2 |
Engineering, Civil |
||
Q2 |
Materials Science, Multidisciplinary |
||
Q1 |
Oncology |
||
Q4 |
Cardiac & Cardiovascular Systems |
||
Q2 |
Chemistry, Physical |
||
Q2 |
Cell Biology |
||
Q1 |
Materials Science, Ceramics |
||
Q3 |
Materials Science, Multidisciplinary |
||
Q2 |
Engineering, Chemical |
||
Q3 |
Chemistry, Multidisciplinary |
||
Q2 |
Chemistry, Analytical |
||
Q2 |
Electrochemistry |
||
Q1 |
Instruments & Instrumentation |
||
Q2 |
Pediatrics |
||
Q2 |
Engineering, Environmental |
||
Q2 |
Environmental Sciences |
||
Q3 |
Green & Sustainable Science & Technology |
||
Q2 |
Meteorology & Atmospheric Sciences |
||
Q2 |
Medicine, General & Internal |
||
Q3 |
Clinical Neurology |
||
Q3 |
Neurosciences |
||
Q2 |
Materials Science, Coatings & Films |
||
Q3 |
Materials Science, Multidisciplinary |
||
Q2 |
Physics, Applied |
||
Q3 |
Chemistry, Physical |
||
Q2 |
Mathematics, Interdisciplinary Applications |
||
Q2 |
Computer Science, Interdisciplinary Applications |
||
Q3 |
Physics, Condensed Matter |
||
Q2 |
Biochemistry & Molecular Biology |
||
Q2 |
Dermatology |
||
Q3 |
Computer Science, Information Systems |
||
Q2 |
Computer Science, Theory & Methods |
||
Q2 |
Crystallography |
||
Q3 |
Materials Science, Multidisciplinary |
||
Q3 |
Biochemistry & Molecular Biology |
||
Q2 |
Oncology |
||
Q3 |
Computer Science, Information Systems |
||
Q2 |
Multidisciplinary Sciences |
||
Q2 |
Dentistry, Oral Surgery & Medicine |
||
Q3 |
Dermatology |
||
Q3 |
Endocrinology & Metabolism |
||
Q1 |
Medicine, General & Internal |
||
Q2 |
Medicine, Research & Experimental |
||
Q2 |
Biodiversity Conservation |
||
Q3 |
Ecology |
||
Q1 |
Remote Sensing |
||
Q3 |
Environmental Sciences |
||
Q3 |
Geosciences, Multidisciplinary |
||
Q3 |
Ecology |
||
Q3 |
Economics |
||
Q2 |
Economics |
||
Q1 |
Education & Educational Research |
||
Q2 |
Computer Science, Information Systems |
||
Q2 |
Engineering, Electrical & Electronic |
||
Q2 |
Physics, Applied |
||
Q3 |
Energy & Fuels |
||
Q2 |
Physics, Multidisciplinary |
||
Q2 |
Environmental Sciences |
||
Q3 |
Genetics & Heredity |
||
Q4 |
Critical Care Medicine |
||
Q4 |
Dermatology |
||
European Journal of Investigation in Health Psychology and Education |
Q1 |
Psychology, Clinical |
|
Q2 |
Biotechnology & Applied Microbiology |
||
Q2 |
Materials Science, Multidisciplinary |
||
Q2 |
Ecology |
||
Q1 |
Forestry |
||
Q2 |
Fisheries |
||
Q2 |
Marine & Freshwater Biology |
||
Q3 |
Mechanics |
||
Q3 |
Physics, Fluids & Plasmas |
||
Q1 |
Food Science & Technology |
||
Q2 |
Multidisciplinary Sciences |
||
Q1 |
Forestry |
||
Q1 |
Mathematics, Interdisciplinary Applications |
||
Q3 |
Energy & Fuels |
||
Q3 |
Engineering, Chemical |
||
Q2 |
Computer Science, Information Systems |
||
Q2 |
Astronomy & Astrophysics |
||
Q4 |
Economics |
||
Q4 |
Mathematics, Interdisciplinary Applications |
||
Q4 |
Social Sciences, Mathematical Methods |
||
Q3 |
Gastroenterology & Hepatology |
||
Q4 |
Gastroenterology & Hepatology |
||
Q1 |
Polymer Science |
||
Q3 |
Ethnic Studies |
||
Q4 |
Family Studies |
||
Q3 |
Sociology |
||
Q2 |
Genetics & Heredity |
||
Q2 |
Geosciences, Multidisciplinary |
||
Q3 |
Geriatrics & Gerontology |
||
Q2 |
Health Care Sciences & Services |
||
Q2 |
Health Policy & Services |
||
Q4 |
Hematology |
||
Q4 |
Hematology |
||
N/A |
Humanities, Multidisciplinary |
||
Q2 |
Multidisciplinary Sciences |
||
Q1 |
Horticulture |
||
N/A |
Humanities, Multidisciplinary |
||
Q2 |
Water Resources |
||
Q4 |
Immunology |
||
Q2 |
Infectious Diseases |
||
Q2 |
Computer Science, Interdisciplinary Applications |
||
Q3 |
Computer Science, Information Systems |
||
Q2 |
Construction & Building Technology |
||
Q2 |
Engineering, Civil |
||
Q2 |
Transportation Science & Technology |
||
Q2 |
Chemistry, Inorganic & Nuclear |
||
Q1 |
Entomology |
||
Q2 |
Business, Finance |
||
Q1 |
Biochemistry & Molecular Biology |
||
Q2 |
Chemistry, Multidisciplinary |
||
Q1 |
Genetics & Heredity |
||
Q1 |
Pediatrics |
||
International Journal of Turbomachinery Propulsion and Power |
Q2 |
Engineering, Aerospace |
|
Q3 |
Engineering, Mechanical |
||
Q2 |
Engineering, Multidisciplinary |
||
Q2 |
Computer Science, Information Systems |
||
Q2 |
Geography, Physical |
||
Q2 |
Remote Sensing |
||
Q2 |
Cardiac & Cardiovascular Systems |
||
Q1 |
Medicine, General & Internal |
||
Q2 |
Materials Science, Composites |
||
Q3 |
Developmental Biology |
||
Q1 |
Engineering, Biomedical |
||
Q2 |
Materials Science, Biomaterials |
||
Q1 |
Sport Sciences |
||
Q2 |
Microbiology |
||
Q1 |
Mycology |
||
Q3 |
Imaging Science & Photographic Technology |
||
Q1 |
Psychology, Multidisciplinary |
||
Q3 |
Engineering, Electrical & Electronic |
||
Q2 |
Engineering, Manufacturing |
||
Q1 |
Engineering, Mechanical |
||
Q2 |
Materials Science, Multidisciplinary |
||
Q1 |
Engineering, Marine |
||
Q2 |
Engineering, Ocean |
||
Q2 |
Oceanography |
||
Q2 |
Health Care Sciences & Services |
||
Q1 |
Medicine, General & Internal |
||
Q2 |
Computer Science, Information Systems |
||
Q2 |
Telecommunications |
||
Journal of Theoretical and Applied Electronic Commerce Research |
Q1 |
Business |
|
Q1 |
Toxicology |
||
Q2 |
Biodiversity Conservation |
||
Q2 |
Communication |
||
Q2 |
Environmental Studies |
||
N/A |
Language & Linguistics |
||
Q2 |
Linguistics |
||
Q1 |
Law |
||
Q1 |
Biology |
||
Q2 |
Management |
||
Q2 |
Operations Research & Management Science |
||
Q2 |
Engineering, Mechanical |
||
Q2 |
Computer Science, Artificial Intelligence |
||
Q2 |
Computer Science, Interdisciplinary Applications |
||
Q2 |
Engineering, Electrical & Electronic |
||
Q3 |
Engineering, Electrical & Electronic |
||
Q2 |
Engineering, Mechanical |
||
Q2 |
Chemistry, Inorganic & Nuclear |
||
Q3 |
Chemistry, Physical |
||
Q3 |
Materials Science, Multidisciplinary |
||
Q1 |
Chemistry, Medicinal |
||
Q1 |
Pharmacology & Pharmacy |
||
Q3 |
Chemistry, Physical |
||
Q2 |
Materials Science, Multidisciplinary |
||
Q1 |
Metallurgy & Metallurgical Engineering |
||
Q2 |
Physics, Applied |
||
Q2 |
Physics, Condensed Matter |
||
Q2 |
Mathematics, Interdisciplinary Applications |
||
Q1 |
Mathematics |
||
Q1 |
Medicine, General & Internal |
||
Q2 |
Chemistry, Physical |
||
Q2 |
Engineering, Chemical |
||
Q2 |
Materials Science, Multidisciplinary |
||
Q2 |
Polymer Science |
||
Q2 |
Biochemistry & Molecular Biology |
||
Q3 |
Materials Science, Multidisciplinary |
||
Q2 |
Metallurgy & Metallurgical Engineering |
||
Q3 |
Biochemical Research Methods |
||
Q3 |
Microbiology |
||
Q2 |
Chemistry, Analytical |
||
Q2 |
Instruments & Instrumentation |
||
Q3 |
Nanoscience & Nanotechnology |
||
Q2 |
Physics, Applied |
||
Q2 |
Microbiology |
||
Q2 |
Geochemistry & Geophysics |
||
Q2 |
Mineralogy |
||
Q2 |
Mining & Mineral Processing |
||
Q3 |
Engineering, Multidisciplinary |
||
Q4 |
Chemistry, Organic |
||
Q2 |
Biochemistry & Molecular Biology |
||
Q2 |
Chemistry, Multidisciplinary |
||
Q3 |
Computer Science, Artificial Intelligence |
||
Q2 |
Computer Science, Cybernetics |
||
Q3 |
Computer Science, Information Systems |
||
Q2 |
Chemistry, Multidisciplinary |
||
Q2 |
Materials Science, Multidisciplinary |
||
Q2 |
Nanoscience & Nanotechnology |
||
Q2 |
Physics, Applied |
||
Q2 |
Clinical Neurology |
||
Q3 |
Clinical Neurology |
||
Q4 |
Neurosciences |
||
Q4 |
Environmental Sciences |
||
Q2 |
Biochemistry & Molecular Biology |
||
Q2 |
Genetics & Heredity |
||
Q1 |
Nursing |
||
Q1 |
Nutrition & Dietetics |
||
Q3 |
Marine & Freshwater Biology |
||
Q3 |
Oceanography |
||
Q4 |
Optics |
||
Q3 |
Chemistry, Organic |
||
Q3 |
Astronomy & Astrophysics |
||
Q2 |
Physics, Nuclear |
||
Q3 |
Physics, Particles & Fields |
||
Q2 |
Microbiology |
||
Q2 |
Pathology |
||
Q3 |
Pediatrics |
||
Q2 |
Chemistry, Medicinal |
||
Q1 |
Pharmacology & Pharmacy |
||
Q1 |
Pharmacology & Pharmacy |
||
Q3 |
Pharmacology & Pharmacy |
||
Q2 |
History & Philosophy of Science |
||
N/A |
Philosophy |
||
Q2 |
Optics |
||
Q2 |
Physics, Multidisciplinary |
||
Q1 |
Plant Sciences |
||
Q3 |
Physics, Fluids & Plasmas |
||
Q1 |
Polymer Science |
||
Q1 |
Polymer Science |
||
Q2 |
Engineering, Chemical |
||
Q4 |
Materials Science, Biomaterials |
||
Q2 |
Biochemistry & Molecular Biology |
||
Q4 |
Psychiatry |
||
Q1 |
Information Science & Library Science |
||
Q3 |
Instruments & Instrumentation |
||
Q3 |
Materials Science, Characterization & Testing |
||
Q4 |
Quantum Science & Technology |
||
Q2 |
Geosciences, Multidisciplinary |
||
Q3 |
Chemistry, Multidisciplinary |
||
Q2 |
Green & Sustainable Science & Technology |
||
N/A |
Religion |
||
Q2 |
Environmental Sciences |
||
Q1 |
Geosciences, Multidisciplinary |
||
Q2 |
Imaging Science & Photographic Technology |
||
Q2 |
Remote Sensing |
||
Q3 |
Medicine, General & Internal |
||
Q4 |
Obstetrics & Gynecology |
||
Q4 |
Reproductive Biology |
||
Q2 |
Environmental Sciences |
||
Q3 |
Green & Sustainable Science & Technology |
||
Q2 |
Business, Finance |
||
Q2 |
Robotics |
||
Q3 |
Public, Environmental & Occupational Health |
||
Q3 |
Pharmacology & Pharmacy |
||
Q2 |
Chemistry, Analytical |
||
Q2 |
Engineering, Electrical & Electronic |
||
Q2 |
Instruments & Instrumentation |
||
Q3 |
Chemistry, Analytical |
||
Q2 |
Medicine, General & Internal |
||
Q3 |
Psychology, Multidisciplinary |
||
Q2 |
Social Sciences, Interdisciplinary |
||
Q2 |
Womens Studies |
||
Q1 |
Engineering, Electrical & Electronic |
||
Q1 |
Urban Studies |
||
Q2 |
Social Sciences, Interdisciplinary |
||
Q2 |
Sociology |
||
Q2 |
Soil Science |
||
Q3 |
Chemistry, Physical |
||
Q3 |
Materials Science, Multidisciplinary |
||
Q2 |
Sport Sciences |
||
Q4 |
Mathematics, Interdisciplinary Applications |
||
Q3 |
Statistics & Probability |
||
Q3 |
Chemistry, Physical |
||
Q3 |
Materials Science, Multidisciplinary |
||
Q4 |
Surgery |
||
Q2 |
Environmental Sciences |
||
Q2 |
Environmental Studies |
||
Q3 |
Green & Sustainable Science & Technology |
||
Q2 |
Multidisciplinary Sciences |
||
Q1 |
Social Sciences, Interdisciplinary |
||
Q1 |
Engineering, Multidisciplinary |
||
Q3 |
Telecommunications |
||
Q4 |
Hematology |
||
Q2 |
Radiology, Nuclear Medicine & Medical Imaging |
||
Q2 |
Environmental Sciences |
||
Q1 |
Toxicology |
||
Q2 |
Food Science & Technology |
||
Q1 |
Toxicology |
||
Q2 |
Infectious Diseases |
||
Q2 |
Parasitology |
||
Q1 |
Tropical Medicine |
||
Q2 |
Astronomy & Astrophysics |
||
Q2 |
Physics, Particles & Fields |
||
Q3 |
Environmental Sciences |
||
Q3 |
Environmental Studies |
||
Q2 |
Geography |
||
Q3 |
Regional & Urban Planning |
||
Q2 |
Urban Studies |
||
Q1 |
Immunology |
||
Q1 |
Medicine, Research & Experimental |
||
Q2 |
Engineering, Mechanical |
||
Q2 |
Transportation Science & Technology |
||
Q2 |
Veterinary Sciences |
||
Q3 |
Engineering, Mechanical |
||
Q3 |
Mechanics |
||
Q2 |
Virology |
||
Q2 |
Environmental Sciences |
||
Q2 |
Water Resources |
||
Q2 |
Economics |
||
Q2 |
Political Science |
||
Q1 |
Social Sciences, Interdisciplinary |
||
Q2 |
Engineering, Electrical & Electronic |
||
Q2 |
Transportation Science & Technology |
Source: 2023 Journal Impact Factors, Journal Citation Reports TM (Clarivate, 2024)
About MDPI
A pioneer in scholarly, open access publishing, MDPI has supported academic communities since 1996. MDPI is leading the transition to open science by making more research free and accessible to everyone. Over 3.5 million researchers have entrusted MDPI with publishing their scientific discoveries. MDPI’s editorial process is bolstered by a network of dedicated reviewers, a team of 6000 professional, well-trained staff members, and an in-house article submission platform that was designed to ensure efficient processes within its 440 fully open access titles.
12 June 2024
Pharmaceutics | Selected Papers in 2023 in the Section “Physical Pharmacy and Formulation”
1. “Ionotropic Gelation and Chemical Crosslinking as Methods for Fabrication of Modified-Release Gellan Gum-Based Drug Delivery Systems”
by Piotr Gadziński, Anna Froelich, Barbara Jadach, Monika Wojtyłko, Adam Tatarek, Antoni Białek, Julia Krysztofiak, Michał Gackowski, Filip Otto and Tomasz Osmałek
Pharmaceutics 2023, 15(1), 108; https://doi.org/10.3390/pharmaceutics15010108
Available online: https://www.mdpi.com/1999-4923/15/1/108
2. “Tri-Layer Core–Shell Fibers from Coaxial Electrospinning for a Modified Release of Metronidazole”
by Ying Wang, Lin Liu, Yuanjie Zhu, Liangzhe Wang, Deng-Guang Yu, and Li-ying Liu
Pharmaceutics 2023, 15(11), 561; https://doi.org/10.3390/pharmaceutics15112561
Available online: https://www.mdpi.com/1999-4923/15/11/2561
3. “Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations”
by Frédéric Frézard, Marta M. G. Aguiar, Lucas A. M. Ferreira, Guilherme S. Ramos, Thais T. Santos, Gabriel S. M. Borges, Virgínia M. R. Vallejos and Helane L. O. De Morais
Pharmaceutics 2023, 15(1), 99; https://doi.org/10.3390/pharmaceutics15010099
Available online: https://www.mdpi.com/1999-4923/15/1/99
4. “GelMA, Click-Chemistry Gelatin and Bioprinted Polyethylene Glycol-Based Hydrogels as 3D Ex Vivo Drug Testing Platforms for Patient-Derived Breast Cancer Organoids”
by Nathalie Bock, Farzaneh Forouz, Luke Hipwood, Julien Clegg, Penny Jeffery, Madeline Gough, Tirsa van Wyngaard, Christopher Pyke, Mark N. Adams, Laura J. Bray et al.
Pharmaceutics 2023, 15(1), 261; https://doi.org/10.3390/pharmaceutics15010261
Available online: https://www.mdpi.com/1999-4923/15/1/261
5. “A Review of Protein- and Peptide-Based Chemical Conjugates: Past, Present, and Future”
by Emily Holz, Martine Darwish, Devin B. Tesar and Whitney Shatz-Binder
Pharmaceutics 2023, 15(2), 600; https://doi.org/10.3390/pharmaceutics15020600
Available online: https://www.mdpi.com/1999-4923/15/2/600
6. “Antibacterial Activity of Zinc Oxide Nanoparticles Loaded with Essential Oils”
by Ludmila Motelica, Bogdan-Stefan Vasile, Anton Ficai, Adrian-Vasile Surdu, Denisa Ficai, Ovidiu-Cristian Oprea, Ecaterina Andronescu, Gabriel Mustățea, Elena Loredana Ungureanu and Alina Alexandra Dobre
Pharmaceutics 2023, 15(10), 2470; https://doi.org/10.3390/pharmaceutics15102470
Available online: https://www.mdpi.com/1999-4923/15/10/2470
7. “Formulation and Characterisation of Carbamazepine Orodispersible 3D-Printed Mini-Tablets for Paediatric Use”
by Jiayu Hu, Rawan Fitaihi, Shorooq Abukhamees and Hend E. Abdelhakim
Pharmaceutics 2023, 15(1), 250; https://doi.org/10.3390/pharmaceutics15010250
Available online: https://www.mdpi.com/1999-4923/15/1/250
8. “Impact of Tablet Size and Shape on the Swallowability in Older Adults”
by Henriette Hummler, Cordula Stillhart, Lisa Meilicke, Michael Grimm, Elischa Krause, Marwan Mannaa, Maik Gollasch, Werner Weitschies and Susanne Page
Pharmaceutics 2023, 15(4), 1042; https://doi.org/10.3390/pharmaceutics15041042
Available online: https://www.mdpi.com/1999-4923/15/4/1042
9. “Evaluating the Skin Interactions and Permeation of Alginate/Fucoidan Hydrogels Per Se and Associated with Different Essential Oils”
by Ana Isabel Barbosa, Sofia A. Costa Lima, Ibraheem Yousef and Salette Reis
Pharmaceutics 2023, 15(1), 190; https://doi.org/10.3390/pharmaceutics15010190
Available online: https://www.mdpi.com/1999-4923/15/1/190
10. “Recent Advances in Co-Former Screening and Formation Prediction of Multicomponent Solid Forms of Low Molecular Weight Drugs”
by Yuehua Deng, Shiyuan Liu, Yanbin Jiang, Inês C. B. Martins and Thomas Rades
Pharmaceutics 2023, 15(9), 2174; https://doi.org/10.3390/pharmaceutics15092174
Available online: https://www.mdpi.com/1999-4923/15/9/2174
11 June 2024
Pharmaceutics Receives an Increased CiteScore of 7.9
We are pleased to inform you that Pharmaceutics (ISSN: 1999-4923) has received a heightened CiteScore of 7.9.
Pharmaceutics’ CiteScore ranks 32 among 183 titles (Q1) in the “Pharmaceutical Science” category.
CiteScore provides transparent metrics that enable well-informed publishing strategies, library collection development, and the benchmarking of journal performance. It is now a standard citation metric alongside SNIP and SJR that gives an up-to-date view of a journal’s impact. The 2023 CiteScore provides an assessment of the scientific influence of journals in the 2020 to 2023 period.
This result is a reflection of the excellent performance, support, and dedication of all journal editors, reviewers, authors, and readers.
For more journal statistics, please visit https://www.mdpi.com/journal/pharmaceutics/stats.
Thank you to everyone who has contributed to the journal.
Pharmaceutics Editorial Office
7 June 2024
MDPI Calls for Greater Open Access to Science for Ocean Protection
On UNESCO’s 2024 Oceans Day, MDPI encourages the scientific community to increase the accessibility of ocean research to accelerate ocean conservation.
Basel, Switzerland, June 7, 2024: MDPI, a leading open access (OA) publisher, is proud to announce its active support for World Oceans Day 2024, celebrated under UNESCO’s Ocean Decade framework. MDPI’s CEO, Stefan Tochev hopes that “the latest ocean research can be made freely accessible to help empower scientists and communities at large to save our oceans,” under UNESCO’s Ocean Decade until 2030.
Open Access: A Catalyst for Ocean Action
MDPI’s presence at the UNESCO Ocean Decade Conference 2024 highlights our unwavering commitment to using OA to advance ocean science, support research communities, and promote sustainable ocean management.
"Our involvement in the UNESCO Ocean Decade Conference underscores MDPI's commitment to the underfunded Ocean SDG. By promoting OA to scientific articles and books on SDGs, we aim to inspire critical actions," said Tochev. "Our initiatives, like the World Sustainability Award and Emerging Sustainability Award, further demonstrate our dedication to advancing sustainability.”
Showcasing MDPI’s Contributions to Ocean Research
Over the past three years, MDPI has published 30,000 papers focused on ocean research and related topics. Key MDPI journals contributing to this body of work include:
- Journal of Marine Science and Engineering (4.9k papers)
- Remote Sensing (2.6k papers)
- Sustainability (2k papers)
- International Journal of Molecular Sciences (IJMS) (1.7k papers)
- Marine Drugs (1.5k papers)
- Water (1.5k papers)
These publications highlight MDPI’s contributions to ocean science, reinforcing our role in the broader sustainability agenda by promoting blue innovation and economy.
Additionally, MDPI has launched Oceans, an international, peer-reviewed forum specifically aimed at publishing studies related to all branches of oceanography with an emphasis on the functioning of the ocean and the sustainable use of its resources and ecosystem services.
Affirming MDPI’s Commitment to Ocean Science
MDPI’s commitment to OA is pivotal in addressing critical global challenges, from climate change to ocean sustainability. Our efforts resonate with Outcome 4 of the UNESCO Ocean Decade action roadmap: an accessible ocean with open and equitable access to data, information, technology, and innovation. By aligning with UNESCO’s goals, MDPI continues to contribute to shaping a sustainable future for our oceans, reinforcing our position as a forward-thinking publisher dedicated to environmental stewardship and scientific excellence.
For more information, contact Rui Duarte at [email protected] or +41764313242.
About MDPI
A pioneer in scholarly, open access publishing, MDPI has supported academic communities since 1996. MDPI is leading the transition to open science by making more research free and accessible to everyone. Over 3.5 million researchers have entrusted MDPI with publishing their scientific discoveries. MDPI’s editorial process is bolstered by a network of dedicated reviewers, a team of over 6000 professional, well-trained staff members, and an in-house article submission platform that was designed to ensure efficient processes within its 430 fully open access titles.
5 June 2024
MDPI Sets a New Benchmark for Publishing Excellence
95% of authors rate MDPI’s publication process as excellent or good, setting a new benchmark in scientific publishing – reveals 2023 Annual Report.
Basel, Switzerland, June 4, 2024: MDPI, the leading open access (OA) publisher, proudly announces the release of its 2023 Annual Report, detailing remarkable achievements and reaffirming its leadership in advancing OA publishing. In 2023, MDPI received 655,065 submissions, of which 285,244 articles were published. The company now commands a 17% market share in gold open access articles, with a median publication time of six weeks.
Stefan Tochev, MDPI's CEO, stated, "As a pioneer in open access publishing, MDPI has long been a game-changer in the scholarly community, serving millions of authors around the world to ensure the latest research is freely available. Reflecting on our incredible journey at MDPI, 2023 has been marked by growth in paper submissions, ambitious projects and initiatives aimed at improving our internal processes and delivering top-notch services to our scientists."
MDPI's 2023 Annual Report highlights several key achievements:
- 17% market share in gold open access articles across all disciplines.
- Record satisfaction rates: 95% of authors, 82% of reviewers, and 85% of guest editors.
- Enhanced editorial standards and feedback processes.
- Increased reach and impact with 54 new MDPI journal inclusions in Scopus, 29 in Web of Science, and 77 in DOAJ.
MDPI’s unwavering commitment to advancing OA has transformed the landscape of scholarly publishing, making high-quality research freely accessible to the global scientific community. The continuous improvement in our editorial standards and feedback processes underscores MDPI’s dedication to ensuring academic integrity and excellence.
Global Reach and Collaboration
MDPI’s global footprint continues to expand, with authors from diverse regions: 37% from Asia/Pacific, 36% from Europe, 15% from the Americas, and 12% from other parts of the world. The company’s fully OA platform attracted nearly 14 million monthly visitors in 2023, reflecting its widespread influence in the scientific community.
Commitment to Partnerships
With over 800 institutional partners, MDPI continues to demonstrate its dedication to providing reliable and collaborative publishing services. The introduction of a transparent flat-fee model highlights MDPI's ongoing efforts to enhance affordability and support to the academic community. For more details read our 2023 Annual Report.
For more information, contact Rui Duarte at [email protected] or +41764313242.
About MDPI
A pioneer in scholarly, open access publishing, MDPI has supported academic communities since 1996. MDPI is leading the transition to open science by making more research free and accessible to everyone. Over 3.5 million researchers have entrusted MDPI with publishing their scientific discoveries. MDPI’s editorial process is bolstered by a network of dedicated reviewers, a team of over 6000 professional, well-trained staff members, and an in-house article submission platform that was designed to ensure efficient processes within its 430 fully open access titles.
5 June 2024
Meet Us at the ESMO Congress 2024, 13–17 September 2024, Barcelona, Spain
The ESMO Congress is a globally influential oncology platform that unites clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world. ESMO 2024 will disseminate the latest cutting-edge data, providing high-quality education and excellent networking opportunities for oncologists and other stakeholders on an international level.
The following MDPI journals will be represented:
- Cancers;
- JCM;
- Healthcare;
- Pharmaceutics;
- Applied Biosciences;
- Dermatopathology;
- Onco;
- Biomedicines;
- Cells;
- Diagnostics;
- Current Oncology;
- Immuno;
- Hemato;
- Gastrointestinal Disorders;
- Biologics;
- Biomolecules;
- Clinics and Practice;
- Medical Sciences.
If you are participating in this conference, please feel free to engage with us online prior to attendance. Our delegates look forward to meeting you in person at booth #P627 and answering any questions you may have. For more information regarding the conference, please visit the following link: https://www.esmo.org/meeting-calendar/esmo-congress-2024.
4 June 2024
Prof. Dr. Wei Wu Appointed Section Editor-in-Chief of Section “Nanomedicine and Nanotechnology” in Pharmaceutics
We are pleased to announce that Prof. Dr. Wei Wu has been appointed Section Editor-in-Chief of the “Nanomedicine and Nanotechnology” Section in Pharmaceutics (ISSN: 1999-4923). With his extensive background in scientific research and publishing, he will bring a wealth of knowledge and expertise to this prestigious role.
Prof. Dr. Wu is a professor at the Fudan University School of Pharmacy, Shanghai, China, and the director of the Fudan-Ruixing Joint Laboratories of Pharmaceutical Nanotechnology. He was the Vice Dean of his school and Deputy Director of the Institute of Pharmacy. He is currently the Vice President of Pharmaceutics and Particle Design Chapter of the China Particuology Society and the Vice President of Pharmaceutical Dosage Forms of the Traditional Chinese Medicine Committee of the World Union of TCM. His expertise is in nanomedicine, biopharmaceutics, and pharmaceutical nanotechnology. He has published more than 300 peer-reviewed publications in prestigious journals on pharmaceutics, drug delivery, and nanomedicines. A full list of his publications can be found here.
Prof. Dr. Wu and coworkers developed new types of NIR-I and NIR-II fluorophores with absolute aggregation-caused quenching (ACQ) properties for accurate bioimaging and quantification of drug nanocarriers. His group established the basic concepts and methodologies regarding nanocarrier analysis and particokinetics. He has also been among the World's Top 2% Scientists (annual and career) for several consecutive years in pharmacology and toxicology, according to the list created by researchers from Stanford University. He has also been awarded for his research and academic excellence, including New Century Excellent Talent of Ministry of Education, Shanghai Excellent Discipline Leaders, Shanghai Twilight Scholars, and Distinguished Lectureship by the Nagai Foundation Tokyo.
The following is a short Q&A with Prof. Dr. Wei Wu, who shared his vision for the journal with us, as well as his views on the research area and open access publishing:
1. What appealed to you about the journal that made you want to become its Section Editor-in-Chief?
Pharmaceutics has established a platform for communication and dissemination of knowledge within and outside of the pharmaceutics and drug delivery community. In the past, I benefited significantly from Pharmaceutics as an author, and I am satisfied for contributing to the scientific community in the role of a reviewer or an Editorial Board Member. To be a Section Editor-in-Chief, I regard it as a great opportunity to better serve the pharmaceutics and drug delivery community.
2. What are your plans and vision for the Section and the journal?
As Pharmaceutics has established its place and influence in the cross-field of pharmaceutics, drug delivery, and nanomedicines, my vision for it is steady growth, serving the scientific community with more high-quality contributions, more open access publications, and continuously increasing impact. In view of the booming research trends in nanomedicine and nanotechnology, my vision is to continuously lead the Sections and make growing contributions to the development of Pharmaceutics.
3. What does the future of this field of research look like?
Against the backdrop of the rapid development of innovative drugs and delivery systems, the field of pharmaceutics has experienced continuous growth in recent decades, and this trend will surely continue because of the demands of precision medicine for delicately orchestrated delivery strategies and delivery systems. That said, all endeavors in the discovery stages will only lead to the prosperity of pharmaceutics. Nonetheless, in the future, pharmaceutics may welcome new active ingredients spanning from small molecules to biomacromolecules and to new combinations and compounds with multiple components, which may challenge and push forward the development of theories, mindsets, and technologies in pharmaceutics and drug delivery.
4. What do you think of the development of open access in the publishing field?
Open access publication definitely benefits the scientific community by offering free access. However, excessive commercialization by compromising article quality would stymie the development of open access scientific publishing. By adhering to strict peer review standards, open access publishing may flourish, switching to a virtuous circle.
We warmly welcome Prof. Dr. Wei Wu as the new Section Editor-in-Chief and we look forward to him leading Pharmaceutics to many more milestones.
4 June 2024
Pharmaceutics | Selected Papers in 2023 in the Section “Pharmaceutical Technology, Manufacturing and Devices”
1. “3D Printing Technologies in Personalized Medicine, Nanomedicines, and Biopharmaceuticals”
by Dolores R. Serrano, Aytug Kara, Iván Yuste, Francis C. Luciano, Baris Ongoren, Brayan J. Anaya, Gracia Molina, Laura Diez, Bianca I. Ramirez, Irving O. Ramirez et al.
Pharmaceutics 2023, 15(2), 313; https://doi.org/10.3390/pharmaceutics15020313
Available online: https://www.mdpi.com/1999-4923/15/2/313
2. “Recent Advances in Intranasal Liposomes for Drug, Gene, and Vaccine Delivery”
by Van-An Duong, Thi-Thao-Linh Nguyen and Han-Joo Maeng
Pharmaceutics 2023, 15(1), 207; https://doi.org/10.3390/pharmaceutics15010207
Available online: https://www.mdpi.com/1999-4923/15/1/207
3. “Electrospinning of Potential Medical Devices (Wound Dressings, Tissue Engineering Scaffolds, Face Masks) and Their Regulatory Approach”
by Luca Éva Uhljar and Rita Ambrus
Pharmaceutics 2023, 15(2), 417; https://doi.org/10.3390/pharmaceutics15020417
Available online: https://www.mdpi.com/1999-4923/15/2/417
4. “Insights into Asymmetric Liposomes as a Potential Intervention for Drug Delivery Including Pulmonary Nanotherapeutics”
by Yaqeen Nadheer Al Badri , Cheng Shu Chaw and Amal Ali Elkordy
Pharmaceutics 2023, 15(1), 294; https://doi.org/10.3390/pharmaceutics15010294
Available online: https://www.mdpi.com/1999-4923/15/1/294
5. “Fabrication of Gastro-Floating Famotidine Tablets: Hydroxypropyl Methylcellulose-Based Semisolid Extrusion 3D Printing”
by Hyun Seok Yang and Dong Wuk Kim
Pharmaceutics 2023, 15(2), 316; https://doi.org/10.3390/pharmaceutics15020316
Available online: https://www.mdpi.com/1999-4923/15/2/316
6. “3D-Printed Fast-Dissolving Oral Dosage Forms via Fused Deposition Modeling Based on Sugar Alcohol and Poly(Vinyl Alcohol)—Preparation, Drug Release Studies and In Vivo Oral Absorption”
by Sorato Ikeda, Masanori Kobayashi, Soken Aoki, Takayuki Terukina, Takanori Kanazawa, Hiroyuki Kojima and Hiromu Kondo
Pharmaceutics 2023, 15(2), 395; https://doi.org/10.3390/pharmaceutics15020395
Available online: https://www.mdpi.com/1999-4923/15/2/395
7. “Evaluation of a Medical Grade Thermoplastic Polyurethane for the Manufacture of an Implantable Medical Device: The Impact of FDM 3D-Printing and Gamma Sterilization”
by Marie-Stella M’Bengue, Thomas Mesnard, Feng Chai, Mickaël Maton, Valérie Gaucher, Nicolas Tabary, Maria-José García-Fernandez, Jonathan Sobocinski, Bernard Martel and Nicolas Blanchemain
Pharmaceutics 2023, 15(2), 456; https://doi.org/10.3390/pharmaceutics15020456
Available online: https://www.mdpi.com/1999-4923/15/2/456
8. “Development and Optimisation of Inhalable EGCG Nano-Liposomes as a Potential Treatment for Pulmonary Arterial Hypertension by Implementation of the Design of Experiments Approach”
by Fatma Haddad, Nura Mohammed, R. C. Gopalan, Yousef Al Ayoub, Md Talat Nasim and K. H. Assi
Pharmaceutics 2023, 15(2), 539; https://doi.org/10.3390/pharmaceutics15020539
Available online: https://www.mdpi.com/1999-4923/15/2/539
4 June 2024
MDPI Insights: The CEO's Letter #12 - First Term as CEO, Tu Youyou Award, Books Report
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
Renewed Term as CEO of MDPI
I released the first CEO Letter at the end of June 2023, reflecting on my first month as CEO. Looking back at the first release, I’m pleased to see a marked consistency of content – from talking about open access (OA) and highlighting the great work being done at MDPI, to bringing together the science community with our conferences and building relations with our editorial board members and our industry as a whole.
For example, in the first letter, I highlighted our meeting with Dr. Eric O. Freed, the founding and current Editor-in-Chief (EiC) of our journal Viruses. Meeting with Eric is a pleasure, as he has a strong commitment and clear vision for the journal.
On 21 May, 2024 we met with EiC Prof. Dr. Antonino Carbone, and Section EiC Prof. Dr. Alberto Signore (pictured on the left), of our journal Hemato (tracked for Impact Factor, and indexed in Scopus), showing our continued and active collaboration with our chief editors to develop the visions for the journal. Over the course of the day, we gathered feedback and gained an understanding of the journal's expectations and focus on strategic growth.
Reflections on my first year as CEO: achievements and initiatives
During my first year as CEO, there have been many remarkable moments, including a strong focus on bringing people together, focusing on company communications and performance.
According to a recent study of 3,400 people across 10 countries, “Managers impact employees’ mental health (69%) more than doctors (51%) or therapists (41%) — and even the same as a partner (69%).” This is an important topic for me, and perhaps that’s why I place a high value on management culture due to its tangible impact on people’s lives.
When I joined MDPI, I created a weekly meet-up for the Corporate Marketing department and their team leads. On the final Thursday of every month, we hold a Global Marketing meet-up to present projects, share knowledge, and conduct training. For years, I’ve maintained the tradition of ending each of our monthly global calls with a group photo to boost morale, motivation, and productivity, and to finish on a positive note.
In keeping with this, when I stepped into the role of CEO, I launched a bi-weekly management meeting, chairing over 20 MDPI Management Team meetings in my first year. These sessions provide an opportunity for managers to present their team’s work, focusing on their achievements and the challenges they face, while at the same time creating space for sharing knowledge.
“I firmly believe that OA is the future of publishing”
I co-organized and co-led the 2023 MDPI Strategy Management meeting this past October, from which we established an Executive Task Force that meets monthly to prioritize projects aimed at building MDPI into the world’s most trusted publisher. To achieve our goals, we as managers need to maintain collaborative communication and connect to the bigger picture.
As CEO, I focused on leadership communication by publishing 12 CEO Letters, one for each month of my tenure, to share more about MDPI news and achievements. I also produced ten videos to help further communicate our message.
I was happy to attend eight publishing and conference events, including STM in Frankfurt and Washington, APE, and R2R, and facilitate critical company meetings with Elsevier, Web of Science, ResearchGate, DOAJ, and others. It was a pleasure to meet and have discussions with key organizations and governing bodies such as CAS in China and ANVUR in Italy.
The best part was the opportunity to visit seven MDPI offices across Europe and Asia-Pacific, meeting with local managers and colleagues and supporting them in person. As part of this, I conducted training sessions while continuing to lead the Corporate Marketing department.
Looking ahead
My goal for my second year as CEO is to continue building on the initiatives from the past, including leadership communications, public relations, educational marketing, and company culture, while representing MDPI to the best of my ability. Additionally, I have a few new projects I hope to launch that I believe will be valuable to MDPI and the industry at large.
I firmly believe that OA is the future of publishing, and I am grateful to be in a position to advocate for this belief as part of MDPI, the world's leading open access publisher.
Thank you to our staff and industry friends for your genuine support in this role.
Impactful Research
Nominations Open for the Prestigious Tu Youyou Award 2024
I am pleased to share that MDPI has opened nominations for the 2024 Tu Youyou Award, a prestigious recognition established in honour of Professor Tu Youyou, Nobel Laureate, whose work has significantly transformed the global fight against malaria.
The Tu Youyou Award offers CHF 100,000
In 2015, Professor Tu Youyou was awarded the Nobel Prize in Physiology or Medicine for her discovery of artemisinin, significantly reducing mortality rates from malaria and shaping global health policies. Artemisinin-based combination therapies (ACTs) are now the standard treatment endorsed by the World Health Organization (WHO), saving countless lives, especially in regions heavily burdened by malaria.
MDPI Special Issue
To mark Professor Tu’s 80th birthday in 2009, MDPI’s journal Molecules issued a Special Issue focusing on her contributions to medical research. Recognizing her continuous contribution, MDPI created the Tu Youyou Award in 2016 to honour outstanding achievements in natural products and medicinal chemistry.
The deadline for nominations is 31 December 2024
Nominations are open to scientists excelling in natural products and medicinal chemistry. Eligible nominators include academic institutes, universities, and societies. The deadline for nominations is 31 December 2024, with the winners to be announced on 30 April 2025. The Tu Youyou Award offers CHF 100,000, split equally among the winners.
MDPI encourages the academic community to nominate individuals who have demonstrated excellence and innovation in line with Professor Tu’s legacy. This award not only honours individual achievement but also encourages further scientific exploration and discovery in critical areas of medicine.
This award embodies our deep commitment to groundbreaking research that drives societal progress and celebrates the legacy of one of the greatest medical innovators of our time.
Inside MDPI
2023 MDPI Books Report
In past CEO letters, I have highlighted our publishing process and the impactful peer-reviewed articles that represent the core output of scholarly publishing. However, scholarly books are another pillar of publishing that MDPI also services, which our core audience may not be fully aware of. In this section, I highlight the 2023 MDPI Books report, released by our MDPI Books team in May 2024.
Download the 2023 MDPI Books Report
In the report, you will find a summary of MDPI Books’ 10th anniversary, the books indexed in the Web of Science Book Citation Index, our market outreach, and our outlook for 2024.
MDPI Books celebrated its 10th anniversary in 2023
MDPI Books published its first OA Reprint, “From the Renaissance to the Modern World,” in 2013. Over the past ten years, MDPI Books has seen a significant increase in both the volume and nature of published Reprints. As of December 2023, our catalogue includes a total of 7,369 Reprints, with 1,811 of them added in 2023 alone. MDPI Books includes monographs, book series, edited books and reprints of special issues and topical collections, among other book types.
We’re also celebrating the 10-year MDPI anniversary of Laura Wagner, Head of MDPI Books.
Laura Wagner (Head of Books Division)
Laura holds a Bachelor’s degree in Art History and History from the University of Basel. After her studies, she started her career at an art gallery in Basel.
Since joining MDPI in 2014, Laura has held several roles within the company. This included editorial work, development of reprint and book services, and the temporary management of the journal Arts.
Currently Laura holds the role of Head of Books Division and is in charge of the development and strategic direction of MDPI Books.
MDPI Books indexed in Web of Science Book Citation Index
Another milestone in 2023 was the indexing of four book titles in the Web of Science Book Citation Index. The indexing of our open access books is crucial for their reach and accessibility, ensuring higher visibility within the open science community.
- Self-Representation in an Expanded Field: From Self-Portraiture to Selfie, Contemporary Art in the Social Media Age by editor Ace Lehner
- Towards Socially Integrative Cities: Perspectives on Urban Sustainability in Europe and China by editors Bernhard Müller, Jian Liu, Jianming Cai, Paulina Schiappacasse, Hans-Martin Neumann, and Baojun Yang
- Transitioning to Gender Equality by editors Christa Binswanger and Andrea Zimmermann
- Under Construction: Performing Critical Identity by editor Marie-Anne Kohl
If you would like to learn more about MDPI Books, please visit: www.mdpi.com/books
If you are thinking of writing or editing a book, you can submit your proposal at www.mdpi.com/books/publish-with-us, or email us at [email protected].
Coming Together for Science
Polymers 2024 – Polymers for a Safe and Sustainable Future
Our conference team successfully managed the Polymers 2024 – Polymers for a Safe and Sustainable Future international conference which took place from 28–31 May 2024 in Athens, Greece. The conference was chaired by Prof. Dr. Dimitrios Bikiaris and Prof. Dr. Konstantinos Triantafyllidis from the Aristotle University of Thessaloniki, Greece, and Dr. Ioanna Deligkiozi from AXIA Innovation, Germany. In total, the conference had 259 accepted abstracts and over 300 attendees from 22 different countries.
The conference featured three keynote speakers and 12 invited speakers, including esteemed scholars from Europe, Asia, Africa, and Canada. It included 60 selected talks and 189 posters, chosen by the 24 members of the Scientific Committee along with the three Conference Chairs. The event explored the latest scientific advancements and innovations in polymer science, focusing on creating safe, sustainable, and environmentally friendly materials. Emphasizing green polymer chemistry and the use of bioresources, the conference promoted the synthesis of biobased and biodegradable polymers.
The conference featured esteemed scholars from Europe, Asia, Africa, and Canada
Conference awards
The conference also presented three awards: two sponsored by the journal Polymers – The Best Poster Award (€500) and the Best Oral Presentation Award (€600) – and one sponsored by Ossila, the Best Student Poster Award (€500).
Thank you to our 16 sponsors, three partnering societies (Hellenic Polymer Society, European Polymer Federation, and North American Thermal Analysis Society [NATAS]) and eight media partners.
Upcoming in-person event
1–4 August, 2024
The 1st International Conference on AI Sensors & The 10th International Symposium on Sensor Science
Location: Singapore
The AI Sensors 2024 Conference will unite innovators and experts in the realms of sensors, sensing technology, and artificial intelligence.
Find more upcoming MDPI events here.
Closing Thoughts
3rd World Forum Principles of Scientific Publications
I’m pleased to share that MDPI sponsored and attended the 3rd World Forum on Principles of Scientific Publications, which took place from 22–24 May in Malaga, Spain. The event brought together academic professionals and leading researchers to discuss critical topics in the realm of publishing and research. Presentation topics included Open Science, AI in Publishing, Predatory Journals, Fake Publications, Challenges for Non-native English Speakers, and more.
“It was great to see strong support from MDPI authors in the audience”
MDPI presentations
Stefan Tochev (CEO, MDPI) presenting at the 3rd World Forum Principles of Scientific Publications
I had the privilege of attending and presenting at the event, along with my colleague Dr. Enric Sayas (Business Analyst, MDPI) from our Barcelona office, who explored the ethical concerns and opportunities brought by AI in publishing.
I took the opportunity to present on Open Science, the benefits of Open Access, and MDPI’s performance, operations, and investment in ethics. Special thanks to Evan Escamilla (Project Manager, MDPI Books) and Facundo Santomé (Sr. Marketing Manager, MDPI) who also joined the conference.
It was great to see strong support from MDPI authors in the audience who shared their positive experiences publishing with us. Their story reflects the experience of the vast majority of authors who choose to work with MDPI.
We also encountered some conservative views on OA, which created an opportunity for open discussion aimed at addressing concerns about OA and MDPI. Engaging in such discussions is important, as scepticism sometimes arises from misinformation or from a misunderstanding of who we are and how we operate. When we engage in open and honest discussion, we tend to see people getting a better understanding of MDPI, which helps address any misconceptions they may have had.
Left to right: Dr. Enric Sayas (Business Analyst, MDPI), Stefan Tochev (CEO, MDPI), Facundo Santomé (Sr. Marketing Manager, MDPI), and Evan Escamilla (Project Manager, MDPI Books) at 3rd World Forum Principles of Scientific Publications
Chief Executive Officer
MDPI AG
28 May 2024
Pharmaceutics | Selected Papers in 2023 in the Section “Nanomedicine and Nanotechnology”
1. “Electrosprayed Core (Cellulose Acetate)–Shell (Polyvinylpyrrolidone) Nanoparticles for Smart Acetaminophen Delivery”
by Lin Xu, Hua He, Yutong Du, Shengwei Zhang, Deng-Guang Yu and Ping Liu
Pharmaceutics 2023, 15(9), 2314; https://doi.org/10.3390/pharmaceutics15092314
Available online: https://www.mdpi.com/1999-4923/15/9/2314
2. “ZnO@ZIF-8 Nanoparticles as Nanocarrier of Ciprofloxacin for Antimicrobial Activity”
by Bruno Altran Costa, Marina Paiva Abuçafy, Thúlio Wliandon Lemos Barbosa, Bruna Lallo da Silva, Rafael Bianchini Fulindi, Guilherme Isquibola, Paulo Inácio da Costa and Leila Aparecida Chiavacci
Pharmaceutics 2023, 15(1), 259; https://doi.org/10.3390/pharmaceutics15010259
Available online: https://www.mdpi.com/1999-4923/15/1/259
3. “Liposomal Iron Oxide Nanoparticles Loaded with Doxorubicin for Combined Chemo-Photothermal Cancer Therapy”
by Taehoon Park, Reeju Amatya, Kyoung Ah Min and Meong Cheol Shin
Pharmaceutics 2023, 15(1), 292; https://doi.org/10.3390/pharmaceutics15010292
Available online: https://www.mdpi.com/1999-4923/15/1/292
4. “Increasing Bioavailability of Trans-Ferulic Acid by Encapsulation in Functionalized Mesoporous Silica”
by Gabriela Petrișor, Ludmila Motelica, Denisa Ficai, Cornelia-Ioana Ilie, Roxana Doina Trușcǎ, Vasile-Adrian Surdu, Ovidiu-Cristian Oprea, Andreea-Luiza Mȋrț, Gabriel Vasilievici, Augustin Semenescu et al.
Pharmaceutics 2023, 15(2), 660; https://doi.org/10.3390/pharmaceutics15020660
Available online: https://www.mdpi.com/1999-4923/15/2/660
5. “Effect of the Size and Shape of Dendronized Iron Oxide Nanoparticles Bearing a Targeting Ligand on MRI, Magnetic Hyperthermia, and Photothermia Properties—From Suspension to In Vitro Studies”
by Barbara Freis, Maria De Los Angeles Ramirez, Céline Kiefer, Sébastien Harlepp, Cristian Iacovita, Céline Henoumont, Christine Affolter-Zbaraszczuk, Florent Meyer, Damien Mertz, Anne Boos et al.
Pharmaceutics 2023, 15(4), 1104; https://doi.org/10.3390/pharmaceutics15041104
Available online: https://www.mdpi.com/1999-4923/15/4/1104
6. “Antimicrobial Nano-Zinc Oxide Biocomposites for Wound Healing Applications: A Review”
by Paolo Pino, Francesca Bosco, Chiara Mollea and Barbara Onida
Pharmaceutics 2023, 15(3), 970; https://doi.org/10.3390/pharmaceutics15030970
Available online: https://www.mdpi.com/1999-4923/15/3/970
7. “Cationic Polymers as Transfection Reagents for Nucleic Acid Delivery”
by Xiaomeng Cai, Rui Dou, Chen Guo, Jiaruo Tang, Xiajuan Li, Jun Chen and Jiayu Zhang
Pharmaceutics 2023, 15(5), 1502; https://doi.org/10.3390/pharmaceutics15051502
Available online: https://www.mdpi.com/1999-4923/15/5/1502
8. “Superparamagnetic Iron Oxide Nanoparticles (SPION): From Fundamentals to State-of-the-Art Innovative Applications for Cancer Therapy”
by Thomas Vangijzegem, Valentin Lecomte, Indiana Ternad, Levy Van Leuven, Robert N. Muller, Dimitri Stanicki and Sophie Laurent
Pharmaceutics 2023, 15(1), 236; https://doi.org/10.3390/pharmaceutics15010236
Available online: https://www.mdpi.com/1999-4923/15/1/236
9. “Chitosan-Based Nanoparticles with Optimized Parameters for Targeted Delivery of a Specific Anticancer Drug—A Comprehensive Review”
by Joanna Kurczewska
Pharmaceutics 2023, 15(2), 503; https://doi.org/10.3390/pharmaceutics15020503
Available online: https://www.mdpi.com/1999-4923/15/2/503
10. “Carbon Dots: Opportunities and Challenges in Cancer Therapy”
by Tanima Bhattacharya, Gye Hwa Shin and Jun Tae Kim
Pharmaceutics 2023, 15(3), 1981; https://doi.org/10.3390/pharmaceutics13111981
Available online: https://www.mdpi.com/1999-4923/13/11/1981
28 May 2024
Pharmaceutics | Selected Papers in 2023 in the Section “Drug Delivery and Controlled Release”
1. “Advances in Oral Drug Delivery Systems: Challenges and Opportunities”
by Jie Lou, Hongli Duan, Qin Qin, Zhipeng Teng, Fengxu Gan, Xiaofang Zhou and Xing Zhou
Pharmaceutics 2023, 15(2), 484; https://doi.org/10.3390/pharmaceutics15020484
Available online: https://www.mdpi.com/1999-4923/15/2/484
2. “Drug Delivery Systems in Regenerative Medicine: An Updated Review”
by Alaa Mansour, Maya Romani, Anirudh Balakrishna Acharya, Betul Rahman, Elise Verron and Zahi Badran
Pharmaceutics 2023, 15(2), 695; https://doi.org/10.3390/pharmaceutics15020695
Available online: https://www.mdpi.com/1999-4923/15/2/695
3. “Lipid Nanoparticles Functionalized with Antibodies for Anticancer Drug Therapy”
by Ana Camila Marques, Paulo C. Costa, Sérgia Velho and Maria Helena Amaral
Pharmaceutics 2023, 15(1), 216; https://doi.org/10.3390/pharmaceutics15010216
Available online: https://www.mdpi.com/1999-4923/15/1/216
4. “Current Trends in Gelatin-Based Drug Delivery Systems”
by Francesca Milano, Annalia Masi, Marta Madaghiele, Alessandro Sannino, Luca Salvatore and Nunzia Gallo
Pharmaceutics 2023, 15(5), 1499; https://doi.org/10.3390/pharmaceutics15051499
Available online: https://www.mdpi.com/1999-4923/15/5/1499
5. “Rapidly Dissolving Microneedles for the Delivery of Steroid-Loaded Nanoparticles Intended for the Treatment of Inflammatory Skin Diseases”
by Hala Dawud and Aiman Abu Ammar
Pharmaceutics 2023, 15(2), 526; https://doi.org/10.3390/pharmaceutics15020526
Available online: https://www.mdpi.com/1999-4923/15/2/526
6. “Metal–Organic Frameworks and Their Biodegradable Composites for Controlled Delivery of Antimicrobial Drugs”
by Tayah C. Livesey, Lila A. M. Mahmoud, Maria G. Katsikogianni and Sanjit Nayak
Pharmaceutics 2023, 15(1), 274; https://doi.org/10.3390/pharmaceutics15010274
Available online: https://www.mdpi.com/1999-4923/15/1/274
7. “Controlled Drug Release from Nanoengineered Polysaccharides”
by Ilker S. Bayer
Pharmaceutics 2023, 15(5), 1364; https://doi.org/10.3390/pharmaceutics15051364
Available online: https://www.mdpi.com/1999-4923/15/5/1364
8. “Plant-Derived Extracellular Vesicles as a Delivery Platform for RNA-Based Vaccine: Feasibility Study of an Oral and Intranasal SARS-CoV-2 Vaccine”
by Margherita A. C. Pomatto, Chiara Gai, Federica Negro, Lucia Massari, Maria Chiara Deregibus, Cristina Grange, Francesco Giuseppe De Rosa and Giovanni Camussi
Pharmaceutics 2023, 15(3), 974; https://doi.org/10.3390/pharmaceutics15030974
Available online: https://www.mdpi.com/1999-4923/15/3/974
9. “Biodistribution of Intratracheal, Intranasal, and Intravenous Injections of Human Mesenchymal Stromal Cell-Derived Extracellular Vesicles in a Mouse Model for Drug Delivery Studies”
by Anna Maria Tolomeo, Gaia Zuccolotto, Ricardo Malvicini, Giada De Lazzari, Alessandro Penna, Chiara Franco, Federico Caicci, Fabio Magarotto, Santina Quarta, Michela Pozzobon et al.
Pharmaceutics 2023, 15(2), 548; https://doi.org/10.3390/pharmaceutics15020548
Available online: https://www.mdpi.com/1999-4923/15/2/548
10. “Polysarcosine-Functionalized mRNA Lipid Nanoparticles Tailored for Immunotherapy”
by Christoph Wilhelmy, Isabell Sofia Keil, Lukas Uebbing, Martin A. Schroer, Daniel Franke, Thomas Nawroth, Matthias Barz, Ugur Sahin, Heinrich Haas, Mustafa Diken et al.
Pharmaceutics 2023, 15(8), 2068; https://doi.org/10.3390/pharmaceutics15082068
Available online: https://www.mdpi.com/1999-4923/15/8/2068
11. “Low-Level Laser Treatment Induces the Blood-Brain Barrier Opening and the Brain Drainage System Activation: Delivery of Liposomes into Mouse Glioblastoma”
by Oxana Semyachkina-Glushkovskaya, Denis Bragin, Olga Bragina, Sergey Socolovski, Alexander Shirokov, Ivan Fedosov, Vasily Ageev, Inna Blokhina, Alexander Dubrovsky, Valeria Telnova et al.
Pharmaceutics 2023, 15(2), 567; https://doi.org/10.3390/pharmaceutics15020567
Available online: https://www.mdpi.com/1999-4923/15/2/567
12. “Amorphous Pterostilbene Delivery Systems Preparation—Innovative Approach to Preparation Optimization”
by Natalia Rosiak, Ewa Tykarska and Judyta Cielecka-Piontek
Pharmaceutics 2023, 15(4), 1231; https://doi.org/10.3390/pharmaceutics15041231
Available online: https://www.mdpi.com/1999-4923/15/4/1231
23 May 2024
Transfer Service in MDPI
We are pleased to announce MDPI’s Transfer Service.
This service provides a convenient method of transferring your manuscript file, along with any reviewer comments, to another journal within our publishing portfolio.
We are committed to helping authors find the right home for their research, and we will provide authors with guidance and technical support through all stages of the transfer process. Authors will be able to choose to transfer in the following two situations:
1. Select alternative journals on submission.
2. Authors are encouraged to transfer manuscripts to other MDPI journals.
More details about the Transfer Service can be found at the following link:
21 May 2024
Prof. Dr. Francisco Javier Otero-Espinar Appointed Section Editor-in-Chief of Section “Drug Delivery and Controlled Release” in Pharmaceutics
We are pleased to announce that Prof. Dr. Francisco Javier Otero-Espinar has been appointed Section Editor-in-Chief of the “Drug Delivery and Controlled Release” Section in Pharmaceutics (ISSN: 1999-4923). With an extensive background in scientific research and publishing, he will bring a wealth of knowledge and expertise to this prestigious role.
Prof. Dr. Francisco Javier Otero-Espinar is a pharmacist and a pharmaceutical scientist at the Faculty of Pharmacy, at the University of Santiago de Compostela, Spain. He is a member of the Institute of Materials (iMATUS) and the Health Research Institute (IDIS) of Santiago de Compostela. His scientific endeavors primarily focus on biopharmaceutics, pharmacokinetics, and pharmaceutical technology. He specializes in the development of drug-controlled release systems for various routes of administration, including oral, parenteral, dermal, ophthalmic, and others. Additionally, he works on the development of release systems for biological drugs and their physicochemical, biopharmaceutical, and pharmacokinetic characterization.
He is a Fellow of the Spanish Society of Industrial and Galenical Pharmacy (SEFIG), where he served as a Secretary and later, President. Additionally, he is a member of the Spanish–Portuguese CRS local chapter and various networks associated with controlled release and nanomedicine. Formerly, he has served as the Dean of the Faculty of Pharmacy in Santiago de Compostela and, presently, coordinates the research group PARAQUASIL.
Throughout his career, he has actively engaged in projects and contracts with the pharmaceutical industry, accumulating substantial experience in technology transfer and knowledge dissemination to the public and private sector.
The following is a short Q&A with Prof. Dr. Francisco Javier Otero-Espinar, who shared his vision for the journal with us, as well as his views on the research area and open access publishing:
1. What appealed to you about the journal that made you want to become its Section Editor-in-Chief?
I have been involved in Pharmaceutics for several years, serving as a member of its Editorial Board. Pharmaceutics aligns closely with my scientific interests, and I have consistently encountered highly interesting and high-quality articles and papers that have supported my research endeavors.
2. What are your plans and vision for the journal?
I believe that Pharmaceutics should persist in publishing high-quality articles concerning pharmaceutical development, biopharmaceutics, pharmaceutical technology, and pharmacology. Specifically, the advancement of novel dosage forms and controlled drug release mechanisms should be prioritized. To this end, I intend to collaborate in attracting top scientists working in these fields to consider Pharmaceutics as a prime outlet for disseminating their research.
3. What does the future of this field of research look like?
New drug discovery is becoming progressively more expensive, thus highlighting the significant potential of specialized controlled release systems to enhance current treatments. Conversely, the emergence of new biological drugs has fundamentally altered the principles governing the design, formulation, and regulation of delivery systems for these molecules. This represents an emerging field necessitating a fresh perspective in research methodologies.
4. What do you think of the development of open access literature in the publishing field?
Open access publications have significantly broadened access to information for numerous scientists and laboratories, thereby facilitating the dissemination of knowledge. However, a challenge arises for scientists and organizations lacking the financial resources to afford open access publication fees. In such cases, the initiatives of certain journals to waive or reduce publication costs are greatly valued. It is also very important to maintain a high ethical standard of open access publications to ensure the quality and interest of researchers in this type of publication model.
We warmly welcome Prof. Dr. Francisco Javier Otero-Espinar as the Section Editor-in-Chief of “Drug Delivery and Controlled Release” and look forward to his contribution to the continued success of the journal.
17 May 2024
Prof. Dr. Dimitrios A. Lamprou Appointed Section Editor-in-Chief of Section “Physical Pharmacy and Formulation” in Pharmaceutics
We are pleased to announce that Prof. Dr. Dimitrios A. Lamprou has been appointed Section Editor-in-Chief of the Section “Physical Pharmacy and Formulation” in Pharmaceutics (ISSN: 1999-4923). With his extensive background in scientific research and publishing, he will bring a wealth of knowledge and expertise to this prestigious role.
Prof. Dr. Dimitrios A. Lamprou (Ph.D., MBA) is the Chair of Biofabrication and Advanced Manufacturing, and Director of MSc Industrial Pharmaceutics at Queen's University Belfast, UK. He is also the Chair of the United Kingdom and Ireland Controlled Release Society (UKICRS). Moreover, he is an expert in emerging biopharmaceutical and pharmaceutical technologies, with over 160 peer-reviewed publications and over 450 conference abstracts, and has delivered over 180 invited talks at institutions and conferences across the world.
Prof. Dr. Lamprou is a recognized world leader in 3D printing and microfluidics, with PubMed-based algorithms placing him in the top 0.1% of scholars writing about 3D printing and in the top 0.07% of scholars writing about microfluidics over the past 10 years. He has also been named in Stanford University's list of the World's Top 2% Scientists for several consecutive years thanks to his research on pharmaceutics and biomedical engineering. His research and academic leadership have been recognized through a range of awards, including the Royal Pharmaceutical Society (RPS) Science Award, the Scottish Universities Life Sciences Alliance (SULSA) Leaders Scheme Award, and Doctor Honoris Causa Award by Semmelweis University (Hungary). More info can be found at www.emergingtechnologieslab.com.
The following is a short Q&A with Prof. Dr. Dimitrios A. Lamprou, who shared his vision for the journal with us, as well as his views on the research area and open access publishing:
1. What appealed to you about the journal that made you want to become its Section Editor-in-Chief?
I am very familiar with the journal as I have been serving as an editor of Pharmaceutics for many years, checking 50+ papers, editing 10+ Special Issues, and organizing two successful webinars. With this appointment, I will be able to further support the journal, weed out low-quality contributions, guarantee the caliber of the articles that are published, and, at the same time, boost the topic.
2. What are your plans and vision for the journal?
“Physical Pharmacy and Formulation” examines the physicochemical properties of liquid and semi-solid pharmaceutical dosage forms to deliver an active pharmaceutical ingredient (API), and the research on the topic is crucial in drug discovery research for new molecules and excipient development. The topic is also very important for the development of safer drug delivery systems (DDSs) for future medicines. The main vision of this open access section is to make this important research more visual to researchers in the field by bringing fundamental and advanced research to them, supporting the development of advanced DDSs.
3. What does the future of this field of research look like?
This field was always very important and a hot topic. To keep the rise in research with coherent and strong manuscripts, we must make sure that new Special Issues are introduced with improved standards and selectivity. The topic to be developed needs high-quality manuscripts, and to achieve this there need to be strict regulations and higher standards.
4. What do you think of the development of open access literature in the publishing field?
Currently, the majority of traditionally subscription-based journals offer open access as an option, which is great since research must be available to everyone. For journals that are offering only open access, there needs to be a focus on the quality of the manuscripts. There are so many open access journals these days, with more advertised every day; therefore, one needs to be continuously creative and strictly monitor and uphold publishing ethics.
We warmly welcome Prof. Dr. Dimitrios A. Lamprou as the Section Editor-in-Chief of “Physical Pharmacy and Formulation” and look forward to his contribution to the continued success of the journal.
17 May 2024
Tu Youyou Award—Open for Nominations
In acknowledgment of the groundbreaking achievements of Professor Tu Youyou, the Nobel laureate credited with the discovery of artemisinin, MDPI is proud to announce the Tu Youyou Award. This award, inaugurated in 2016, seeks to honor scholars who excel in the fields of natural products chemistry and medicinal chemistry.
Prize:
- CHF 100,000 in total (If there is more than one winner, the prize will be divided equally amongst the winners);
- An award medal for each winner.
Who should be nominated?
- Scientists with outstanding achievements and contributions in the fields of natural products chemistry and medicinal chemistry.
Who can submit a nomination?
- Academic research institutes
- Universities
- Academic societies
Any personal nominations are not accepted.
How do I submit a nomination?
Candidates’ institutional affiliations need to submit their nominations for final candidates to the Tu Youyou Award Team directly by email after internal screening, and each institution can only nominate a maximum of two candidates for each edition of the Tu Youyou Award. Please note that the nominations cannot be modified once they are submitted and confirmed by the Tu Youyou Award Team.
Required nomination materials:
Nomination Form (Download)
Schedule:
Nomination deadline: 31 December 2024;
Winner announcement: 30 April 2025.
Contact:
Tu Youyou Award Team ([email protected])
More information can be found on the Tu Youyou Award official website. For any inquiries, do not hesitate to contact the Tu Youyou Award Team.
16 May 2024
MDPI Romania Author Training Academic Events in April
MDPI Romania sponsored four events over the month of April, contributing author training sessions to each event.
The NutriSciLabs 2024 conference was held at the Carol Davila University of Medicine and Pharmacy on 12 April 2024. Organized by the Association of Students from the Faculty of Pharmacy Studies, the conference aimed to enhance students’ academic writing and research skills, and bolster their confidence in participating in the academic world. Ioana Paunescu, journal relations specialist for MDPI Romania, led the training session. Paunescu first outlined MDPI’s history and core values, then explained academic writing techniques, ethics, and similarity percentages. The presentation covered the entire editorial process, highlighting the amount of attention paid to details throughout manuscript processing. Paunescu also discussed common errors that authors make while writing, and how to avoid such errors.
On 13 April 2024, the NextGEN 2.0 Student Conference took place at the Babes-Bolyai University of Cluj-Napoca. NextGen Healthcare organized this event with the university’s European Students’ Society to discuss European and international current affairs. MDPI Romania contributed an author training session called Steps of the Publication Process. Irina Codruta Zaharia, journal relations specialist, began the session with a general introduction of MDPI before diving into different article types, different layout formats, possible journals to submit to, the MDPI submission checklist, and the MDPI editorial process. By explaining the fundamentals of writing and publishing academic papers, Zaharia imparted valuable industry knowledge to the curious minds present. Participants were eager to engage with Zaharia in the subsequent Q&A session.
Celebrating its 20th anniversary this year, the International Conference “Students for Students” has long been a gathering place for undergraduate and postgraduate students of all nationalities to present their work and exchange ideas with each other. This year’s conference was held on 18 April 2024, with MDPI Romania contributing an author training session called The World of Open Access. Key speakers included Dr. Norbert Kiss from MDPI Romania and Prof. Dragos Horvath from Strasbourg University. Dr. Kiss discussed the history of open access, differences between open access publishing and traditional publishing, and implications for open access in the future. Attendees expressed keen interest in the subject, approaching Dr. Kiss with questions about academic publishing as well as his career trajectory.
Most recently, on 26 April 2024, MDPI Romania sponsored the National Symposium of Students from Geology and Geophysics Faculties. The AAPG Students Chapter at the Babes-Bolyai University organized this event as an opportunity for geology students from all Romanian universities to present their work and confer with other researchers. Dr. Kiss gave his lecture The World of Open Access at this event as well.
MDPI is thankful to all the participants, speakers, and organizers who attended these events. Through their enthusiasm and dedication, these events were great successes.
2 May 2024
MDPI Insights: The CEO's Letter #11 - 2023 Annual Report, MDPI Awards, STM
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
2023 Annual Report
This is an exciting time of year at MDPI, as we have just released our annual report 2023, recapping the past year and sharing the progress and changes that took place during it.
Stefan Tochev (CEO, MDPI)
Reflecting on 2023, I can't help but think of the changes that have occurred not only at MDPI but also within our industry as a whole. In light of this, I’m reminded that change is the only constant, and that for a publishing enterprise that has experienced rapid growth, adapting to change becomes not only a necessity but also a catalyst for sustained success.
Looking back on the significant ground we covered in 2023, I am pleased to report that the year was marked by a rise in paper submissions, along with a range of initiatives aimed at improving our internal processes and delivering top services to our scientists.
2023 Top-line MDPI Numbers
An important priority for 2023 was to strengthen our editorial policies. Despite a notable increase in the number of papers submitted from 603,000 to 655,000 (+8.6%), there was a decrease in the number of papers published from 303,000 to 285,000 (-5.9%), consistent with the overall trend in the scholarly publishing market. MDPI’s market share in gold open access articles published reached 17% in 2023 (according to Dimensions data).
2023 Open Access Numbers
For over two decades, MDPI has been at the forefront of reshaping the academic publishing landscape, with OA surpassing subscription-based publishing in 2020. This trajectory is deeply rooted in our history and reflects our unwavering commitment to, and vision for, an open future. This momentum continued in 2023, with 39% of the 4.16 million articles and reviews published as gold full-OA, 15% as gold hybrid-OA, 8% as bronze-OA, and 3% as green-OA, relative to 35% behind a paywall. In terms of gold OA (full or hybrid) articles and reviews published, MDPI leads the way in terms of total articles published in 2023.
MDPI is the trusted and preferred OA publisher for the scholarly community
However, in 2023, we saw a downward trend in publication numbers compared to 2022. This trend was also seen in total OA publications. While the number of submissions increased, the decline in MDPI publications can be attributed to several factors, such as improved scrutiny in our peer-review process, including the evaluation of content scope and higher rejection rates, and a post-pandemic decrease in research related to COVID-19 papers.
Download 2023 MDPI Annual Report.
Access 2023 Digital Report.
Impactful Research
Recognizing Scholars – MDPI Awards
MDPI is committed to empowering young researchers as they embark on their careers. In 2023, our journals hosted a total of 400 awards, receiving 8,839 applications and nominations. The evaluation committees selected 959 winners, with the total budget for these awards amounting to CHF 546,500.
For more information about MDPI awards, applications, and winners, please click here
The following awards recognize scholars and the impact of their research, including Young Investigator Awards, Best PhD Thesis Awards, and Travel Awards for junior researchers.
MDPI Awards – The following awards require an application or a nomination.
Young Investigator Award (CHF 1000–2000 for each winner)
This award acknowledges the achievements of young investigators in research areas relevant to the journal’s scope. Candidates must have received their PhD no more than 10 years prior to the award announcement date and must be nominated.
Best PhD Thesis Award (CHF 500–800 for each winner)
This award recognizes young scholars who have completed outstanding PhD theses in research areas relevant to the journal’s scope. It aims to encourage them to continue their excellent work and make further contributions to their field.
Travel Award (CHF 500–800 for each winner)
This award encourages junior scientists to present their latest research at academic conferences relevant to the journal’s scope, thereby increasing their impact.
Distinguished Scholars
Additionally, 220 awards were granted to the most distinguished authors and reviewers in our journals through Best Paper Awards and Outstanding Reviewer Awards. The following awards are selected by the editorial staff of the journal and do not require an application or a nomination. They exemplify the excellent contributions made by our authors, reviewers, and editors.
These awards exemplify the excellent contributions made by our authors, reviewers, and editors
Best Paper Award (CHF 200–500 for each winner)
This award is granted annually to highlight publications of high quality, scientific significance, and extensive influence.
Outstanding Reviewer Award (CHF 500 for partial winners)
This award is given annually to recognize reviewers who generously contribute their time to reviewing papers and demonstrate thoroughness, professionalism, and timeliness in their reviews.
MDPI also offers awards for specific topics in various research fields:
Carbon Neutrality Award (CHF 500–800 for each winner)
Sponsored by MDPI journal Sustainability, this award recognizes applicants who have made exceptional academic or societal contributions to carbon neutrality, either in general or in relation to a specific carbon-neutrality-related issue.
Intelligent Manufacturing Award (CHF 500–800 for each winner)
Administered by MDPI journal Machines, this award is presented to an individual who has made outstanding academic or societal contributions to the field of intelligent manufacturing.
Granted: World Sustainability Awards
Inside MDPI
MDPI Opens Office in Seoul, Korea and Appoints Claude Seo as Office Manager
As CEO of the world’s leading OA publisher, I am pleased to announce the official opening of our Korean branch office. With this addition, MDPI now operates 21 offices in 12 countries worldwide, improving on our position as a truly global publisher. This expansion represents more than just an increase in our physical footprint; it is a pivotal step in our ongoing commitment to making scientific knowledge more accessible across the globe.
MDPI now operates 21 offices in 12 countries worldwide, improving on our position as a truly global publisher
Claude Seo (MDPI Korea Office Manager, Seoul)
Claude Seo, who has over 15 years of experience in the academic publishing industry, has been appointed as the Office Manager of the Seoul office. The launch of our Seoul office allows us to better support the Korean scientific community and to further promote the publication of OA journals in the region.
Reflecting on his role, Claude shared that he is:
“Delighted to have been entrusted with this position within MDPI, the no. 1 scholarly OA publisher. As we establish our presence in Korea, we are dedicated to integrating ourselves into the local community and contributing to its vibrant culture. Our commitment goes beyond business growth; it is about creating a more informed and innovative society by embracing and promoting diversity within the scientific community.”
Sungkyunkwan University Joins MDPI’s Institutional Open Access Program
Additionally, I am pleased to share that Sungkyunkwan University has joined MDPI’s Institutional Open Access Program (IOAP). This program offers free access to MDP’s online submission system for institutions and provides APC discounts to affiliated authors. Thirteen major Korean universities, including Sungkyunkwan University, Kyunghee University, Chung-Ang University, and the Catholic University of Korea, have adopted IOAP in Korea.
Learn more about MDPI’s collaboration in Korea in my previous CEO Letter, in which I recap our visit to Seoul, South Korea.
Coming Together for Science
4th MMCS: Harnessing the Power of New Drug Modalities
Our conference team successfully managed the 4th Molecules Medicinal Chemistry Symposium, held from 24–26 April in Barcelona, Spain. It was chaired by Prof. Dr. Diego Muñoz-Torrero from the Institute of Biomedicine (IBUB), University of Barcelona, Spain, and Prof. Dr. Simona Collina from the University of Pavia, Italy. In total, there were 84 accepted abstracts and 102 conference attendees from 22 different countries.
From left to right: Prof. Dr. Rino Ragno (Scientific Committee), Dr. Maria Emilia Sousa (Scientific Committee), Prof. Dr. Claudio Viegas Jr. (Scientific Committee), Prof. Dr. Simona Collina (Chair), Prof. Dr. Diego Muñoz-Torrero (Chair), Alvina Wu (Managing Editor, MDPI), Prof. Dr. Roman Dembinski (Scientific Committee), Prof. Dr. Mariana Spetea (Scientific Committee).
The event comprised 12 Invited Speakers, 35 Selected Talks, 10 Flash Poster Presentations, and 39 Posters. The overarching topic of the conference was the impact of the emergence of new drug modalities on drug discovery, with thematic sessions covering topics such as photoactivatable drugs, candidates targeting RNA and epigenetic targets, covalent modifiers, and the development of new anti-cancer agents, among other medicinal chemistry projects.
We are pleased to have received feedback from attendees highlighting the professional approach of the conference chairs and participants, the high quality of the talks, and the overall outstanding organization on the part of the MDPI conference team.
Thank you to the conference sponsors, Fluorochem and IBUB, and to our partnering societies, The Spanish Society for Biochemistry and Molecular Biology (SEBBM), and the Spanish Society of Medicinal Chemistry (SEQT).
Upcoming In-Person Event
28–31 May, 2024
Polymers 2024 – Polymers for a Safe and Sustainable Future
Location: Athens, Greece
Conference Chairs: Prof. Dr. Dimitrios Bikiaris, Prof. Dr. Konstantinos Triantafyllidis, Dr. Ioanna Deligkiozi
We look forward to welcoming experts Prof. Damià Barceló, Prof. Minna Hakkareinen, and Prof. Armando J. D. Silvestre to this event.
Find more upcoming MDPI events here.
Organize Your Event with MDPI’s Sciforum
Sciforum is MDPI’s platform dedicated to the organization of scientific events. In line with our mission to promote science, Sciforum supports scholars, societies, research networks, and universities at all stages of organizing in-person events, virtual events and webinars. Our platforms are efficient, user-friendly, and cost-effective. We handle all steps related to event management. Contact us for details.
Closing Thoughts
A Report from the Future – STM US Annual Conference 2024
Stefan Tochev (CEO, MDPI), Dr. Giulia Stefenelli and Dr. Ioana Craciun from MDPI’s Scientific Office Board.
MDPI has for a long time been a sponsor of the STM Annual Conferences, held yearly in the US and Frankfurt, and is a trusted partner and supporter of the STM organization. While I have attended the Frankfurt conference for the past three years, this was my first time visiting the Washington, DC session, and I am glad I did.
Although it was a brief trip, I greatly appreciated the opportunity to attend in the company of my colleagues Dr. Giulia Stefenelli and Dr. Ioana Craciun from MDPI’s Scientific Office Board. They always help map some of the new industry trends against MDPI’s operational framework and guidelines. It’s a great group for kicking ideas back and forth on what we can apply at MDPI.
In my experience, STM never fails to deliver. It’s always a great conference for reconnecting with fellow publishers, industry friends, and vendors. As usual, STM this year curated a diverse range of speakers and panels, who proferred valuable knowledge and insights from outside our industry, delivering thought-provoking insights into our field. An example of this was the ‘Trust Panel’ session, which included Alan Schiffres (Managing Director, InfoLinx), who shared a number of the learnings about fraud and risk management from his 40 years in financial services, to help address some of the challenges we are currently facing in the area of publishing integrity.
Launch of STM Trends 2028 Panel
I particularly enjoyed the ‘Launch of STM Trends 2028 Panel’, which presented a report focused on the integration of humans and machines in scholarly publishing. The session highlighted themes such as AI, digitization, and the evolving research ecosystem. The report envisions a future where technology blurs the lines between human and machine involvement in research processes, with significant implications for trust, reputation, and equity. While this presents opportunities for connectivity and knowledge dissemination, it also poses challenges such as disinformation, fragmentation, and geopolitical tensions. We must rely on a wise combination of technology and human agency to navigate this complex landscape and will have to carefully examine its potential impacts on communication and scholarly publishing.
MDPI has joined the STM Integrity Hub. Click here to learn more.
While every presenter brought their own knowledge and personal touch, I was particularly pleased to encounter new speakers such as Heather Whitney (Research Assistant Professor, Radiology, University of Chicago) and Igor Grossmann (Professor of Psychology, University of Waterloo, Canada). Having studied Sociology at the University of Guelph, I have a soft spot for fellow social scientists from Canada, and I was very impressed by Igor’s presentation on ‘The Social Scientist: A View from the Future’ and his participation in the panel session ‘The Future Beyond the Article,’ which was one of my favourites from the conference, given the diversity of perspectives from the panel speakers.
Memorial Park in Washington, DC
On a personal note, this was my first-time visiting Washington, DC, and I’m glad we took an afternoon to visit the Memorial Park, with its incredible monuments to figures ranging from Martin Luther King, Jr. to Abraham Lincoln. The magnitude of the monuments is deeply impressive. I particularly appreciated the Thomas Jefferson memorial and the following quote, which I think speaks to the importance of change and adaptation. It’s something we can apply not only in our industry but also in our personal lives.
"I am not an advocate for frequent changes in laws and constitutions, but laws and institutions must go hand in hand with the progress of the human mind. As that becomes more developed, more enlightened, as new discoveries are made, new truths discovered and manners and opinions change, with the change of circumstances, institutions must advance also to keep pace with the times. We might as well require a man to wear still the coat which fitted him when a boy as a civilized society to remain ever under the regimen of their barbarous ancestors."
– Excerpted from a letter to Samuel Kercheval, July 12, 1816.
Chief Executive Officer
MDPI AG
30 April 2024
MDPI Opens Office in Seoul, Korea and Appoints Claude Seo as Office Manager
MDPI, the leading Open Access (OA) publisher, announced on Monday that it opened its Korean branch office on 29th April 2024. With this addition, MDPI now operates 21 offices in 12 countries worldwide. Claude Seo, with over 20 years of experience in the academic journal publishing industry, including Nature Publishing Group (NPG), has been appointed as the Office Manager of the Seoul office.
With the establishment of a Seoul office, MDPI aims to actively support Korea scientific communities to further promote the publication of OA journals in the region. As of the end of 2023, Korea ranked sixth worldwide in both submissions and publications of MDPI research papers. MDPI is the number one OA publisher in Korea.
Sungkyunkwan University Joins MDPI’s Institutional Open Access Program
In addition, MDPI announced that Sungkyunkwan University joined MDPI’s Institutional Open Access Program (IOAP). This program offers free access to MDPI online submission system for the institutions and APC discounts to affiliated authors. Thirteen major Korean universities, including Sungkyunkwan University, Kyung Hee University, Chung-Ang University and Catholic University of Korea, have adopted IOAP in Korea.
OA aims to break down barriers that have traditionally restricted access to science, ensuring that knowledge is available to all, regardless of financial situation or institutional affiliations. Authors, academia, and scientific communities are rapidly moving toward OA. MDPI has been at the forefront of reshaping the academic publishing landscape, with OA surpassing subscription-based publishing in 2020.
MDPI CEO Visits Seoul, Korea
In March, Stefan Tochev, Chief Executive Officer (CEO) of MDPI, visited Korea and met with various stakeholders including government agencies, research and academic institutions, universities. During his visit, Stefan highlighted that MDPI continues to pave the way for a world where science is accessible to all, supporting a global community of inclusive innovation and collaborative solutions.
Stefan expressed excitement about the new venture, stating, "Today marks a significant milestone for MDPI as we celebrate the opening of our new office in Seoul, Korea. This expansion is more than just an increase in our physical footprint, it is a pivotal step in our ongoing commitment to making scientific knowledge more accessible, participatory, and inclusive across the globe."
Claude Seo, reflecting on his new role, commented, "I am delighted to have been offered this position of trust within MDPI, the no. 1 scholarly OA publisher. As we establish our presence in Korea, we are dedicated to integrating into the local community and contributing to its vibrant culture. Our commitment goes beyond business growth; it is about creating a more informed and innovative society by embracing and promoting diversity within the scientific community.”
For further inquiries, please contact our Seoul office directly.
About MDPI
A pioneer in scholarly, open access publishing, MDPI has supported academic communities since 1996. MDPI is leading the transition to open science by making more research free and accessible to everyone. Over 3.3 million researchers have entrusted MDPI with publishing their scientific discoveries. MDPI’s editorial process is bolstered by a network of dedicated reviewers, a team of 6000 diligent, well-trained staff members, and an in-house article submission platform that was designed to ensure efficient processes within its 430 fully OA titles.
10 April 2024
Meet Us at the 48th FEBS Congress, 29 June–3 July 2024, Milan, Italy
Conference: The 48th FEBS Congress
Date: 29 June–3 July 2024
Location: Milan, Italy
MDPI will be attending the 48th FEBS Congress at Booth #30, and we welcome researchers from different backgrounds to visit us and share their latest ideas.
The Italian Society of Biochemistry and Molecular Biology (SIB), founded in 1951, will host the event. The 48th FEBS Congress—“Mining biochemistry for human health and well-being”—welcomes scientists from Europe and other parts of the world.
The 48th FEBS Congress will present a broad-spectrum and ground-breaking scientific program in a fruitful collaboration with FEBS journals and representatives from FEBS Constituent Societies. The SIB and biochemical community are focusing on human health and well-being through molecular and cellular science approaches; this is a key social issue amid ongoing global transitions. Besides presenting the latest and emerging developments in biochemical sciences, the Congress will include dedicated education-oriented sessions, symposia organized by young biochemists, and biochemistry-related economic discussions. Industry representatives will also give presentations on the latest advances in commercial instrumentation.
The following MDPI journals will be represented:
- Biomedicines;
- IJMS;
- JMP;
- Antioxidants;
- Applied Biosciences;
- BioMedInformatics;
- Biomolecules;
- Dietetics;
- Life;
- Medical Sciences;
- Molecules;
- Biology;
- Cancers;
- CIMB;
- Pharmaceutics.
If you plan to attend this conference, please start an online conversation with us. Our delegates look forward to meeting you in person and answering your questions. For more information about the conference, please visit the following website: https://2024.febscongress.org/.
8 April 2024
Meet Us at the 2024 ASCO Annual Meeting, 31 May–4 June 2024, Chicago, IL, USA
The 2024 ASCO Annual Meeting will take you to discover state-of-the-art research, groundbreaking treatments, and visionary insights, igniting your passion for oncology. This year's program will feature over 200 sessions, complementing Dr. Lynn Schuchter’s Presidential theme “The Art and Science of Cancer Care: From Comfort to Cure”.
The following MDPI journals will be represented:
- Cancers;
- JPM;
- Pharmaceutics;
- Healthcare;
- JCM;
- CIMB;
- Medical Sciences;
- Clinics and Practice;
- Onco;
- Current Oncology;
- Dermato;
- Pharmacy;
- Biomedicines;
- Diseases;
- Immuno;
- Biologics;
- Vaccines;
- Diagnostics;
- Hemato;
- Venereology.
If you are attending this conference, please feel free to start an online conversation with us. Our delegates look forward to meeting you in person at the booth at the conference and answering any questions you may have. For more information regarding the conference, please visit the following link: https://conferences.asco.org/am/attend.
7 April 2024
Pharmaceutics Webinar | Where Are We Now and Where Is Antimicrobial Therapy Headed?, 24 April 2024
A welcome message from Dr. Fábio Fernandes, the webinar chair:
Dear Colleagues,
It is my pleasure to welcome each of you to this webinar! As Chair, I am pleased to see the convergence of research aimed at understanding “Where Are We Now and Where Is Antimicrobial Therapy Headed?”.
Antimicrobial resistance poses more of a concern today than ever before. Our collaborative efforts, insights, and inventions are critical in navigating this difficult world. This meeting provides an opportunity for us to exchange ideas, examine breakthroughs, and plot a course for a future in which effective antimicrobial therapy remains a cornerstone of modern medicine.
Our schedule for this webinar is packed with interesting talks, from antimicrobial dendrimer and lipid nanoparticles to the regulation of biofilms by RNA. I encourage all of you to actively engage in the sessions, contribute your views, and take advantage of the opportunity to network with our panel of experts and other researchers.
Again, welcome to this webinar!
Dr. Fábio Fernandes
Date: 24 April 2024 10.00 a.m. CEST | 4:00 a.m. EDT | 4:00 p.m. CST Asia
Webinar ID: 841 5162 0647
Webinar Secretariat: [email protected]
Webinar Announcement: https://sciforum.net/event/Pharmaceutics-3
Register for free:
After registering, you will receive a confirmation email containing information on how to join the webinar. Registrations with academic institutional email addresses will be prioritized.
Unable to attend? Register anyway and we will inform you when the recording is available.
Speaker/Presentation | Time in CEST | Time in EDT |
Dr. Fábio Fernandes Chair Introduction |
10:00 a.m.–10:10 a.m. | 4:00a.m.–4:10 p.m. |
Dr. Sandra Pinto Introducing the topic: “Where Are We Now and Where Is Antimicrobial Therapy Headed?” |
10:10 a.m.–10:30 a.m. | 4:10 a.m.–4:30 a.m. |
Dr. Maria Manuela Gaspar The Key Role of Liposomes as Delivery Systems for the Management of Infectious Diseases |
10:30 a.m.–10:50 a.m. | 4:30a.m.–4:50 a.m. |
Dr. Vasco Bonifácio Polyurea Pharmadendrimers: The Next Generation of Antimicrobials |
10:50 a.m.–11:10 a.m. | 4:50 a.m.–5:10 a.m. |
Dr. Vânia Pobre How RNA Regulators Influence Biofilm Formation |
11:10 a.m.–11:30 a.m. | 5:10 a.m.–5:30 a.m. |
Q&A Session | 11:30 a.m.–12:00 p.m. | 5:30 a.m.–6:00 a.m. |
Dr. Fábio Fernandes Closing of Webinar |
12:00 p.m.–12:05 p.m. | 6:00 a.m.–6:05 a.m. |
Webinar Chair and Keynote Speakers:
- Fábio Fernandes (Chair), Institute for Bioengineering and Biosciences (IBB) and Associate Laboratory, Institute for Health and Bioeconomy (i4HB), Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal;
- Sandra Pinto, Institute for Bioengineering and Biosciences (IBB) and Associate Laboratory, Institute for Health and Bioeconomy (i4HB), Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal;
- Maria Manuela Gaspar, Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal;
- Vasco Bonifácio, Institute for Bioengineering and Biosciences (IBB) and Associate Laboratory, Institute for Health and Bioeconomy (i4HB), Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal;
- Vânia Pobre, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa (ITQB NOVA), Oeiras, Portugal.
Relevant Special Issue:
“Where Are We Now and Where Is Antimicrobial Therapy Headed?”
Guest Editor: Dr. Sandra N. Pinto
Deadline for manuscript submissions: 20 June 2024
2 April 2024
Pharmaceutics | Top 10 Cited Papers in 2022
We are pleased to invite you to read the top 10 cited papers of Pharmaceutics (ISSN: 1999-4923) in 2022. We hope this announcement will provide useful information for this field. The list of papers is as follows:
1. “Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives”
by Teresa Pardo-Moreno, Anabel González-Acedo, Antonio Rivas-Domínguez, Victoria García-Morales, Francisco Jose García-Cozar, Juan Jose Ramos-Rodríguez and Lucía Melguizo-Rodríguez
Pharmaceutics 2022, 14(6), 1117; https://doi.org/10.3390/Pharmaceutics14061117
Available online: https://www.mdpi.com/1999-4923/14/6/1117
2. “Recent Fabrication Methods to Produce Polymer-Based Drug Delivery Matrices (Experimental and In Silico Approaches)”
by Anna Procopio, Elena Lagreca, Rezvan Jamaledin, Sara La Manna, Brunella Corrado, Concetta Di Natale and Valentina Onesto
Pharmaceutics 2022, 14(4), 872; https://doi.org/10.3390/Pharmaceutics14040872
Available online: https://www.mdpi.com/1999-4923/14/4/872
3. “A Historical Review of Brain Drug Delivery”
by William M. Pardridge
Pharmaceutics 2022, 14(6), 1283; https://doi.org/10.3390/Pharmaceutics14061283
Available online: https://www.mdpi.com/1999-4923/14/6/1283
4. “Emerging Albumin-Binding Anticancer Drugs for Tumor-Targeted Drug Delivery: Current Understandings and Clinical Translation”
by Hanhee Cho, Seong Ik Jeon, Cheol-Hee Ahn, Man Kyu Shim and Kwangmeyung Kim
Pharmaceutics 2022, 14(4), 728; https://doi.org/10.3390/Pharmaceutics14040728
Available online: https://www.mdpi.com/1999-4923/14/4/728
5. “Hard, Soft, and Hard-and-Soft Drug Delivery Carriers Based on CaCO3 and Alginate Biomaterials: Synthesis, Properties, Pharmaceutical Applications”
by Yanqi Huang, Lin Cao, Bogdan V. Parakhonskiy and Andre G. Skirtach
Pharmaceutics 2022, 14(5), 909; https://doi.org/10.3390/Pharmaceutics14050909
Available online: https://www.mdpi.com/1999-4923/14/5/909
6. “Promising Therapeutic Strategies for Colorectal Cancer Treatment Based on Nanomaterials”
by Natalia Krasteva and Milena Georgieva
Pharmaceutics 2022, 14(6), 1213; https://doi.org/10.3390/Pharmaceutics14061213
Available online: https://www.mdpi.com/1999-4923/14/6/1213
7. “The Potential of Cell-Penetrating Peptides for mRNA Delivery to Cancer Cells”
by Yelee Kim, Hyosuk Kim, Eun Hye Kim, Hochung Jang, Yeongji Jang, Sung-Gil Chi, Yoosoo Yang and Sun Hwa Kim
Pharmaceutics 2022, 14(6), 1271; https://doi.org/10.3390/Pharmaceutics14061271
Available online: https://www.mdpi.com/1999-4923/14/6/1271
8. “Cyclooxygenase-Inhibiting Platinum(IV) Prodrugs with Potent Anticancer Activity”
by Aleen Khoury, Jennette A. Sakoff, Jayne Gilbert, Kieran F. Scott, Shawan Karan, Christopher P. Gordon and Janice R. Aldrich-Wright
Pharmaceutics 2022, 14(4), 787; https://doi.org/10.3390/Pharmaceutics14040787
Available online: https://www.mdpi.com/1999-4923/14/4/787
9. “3D Printed Mini-Floating-Polypill for Parkinson’s Disease: Combination of Levodopa, Benserazide, and Pramipexole in Various Dosing for Personalized Therapy”
by Hellen Windolf, Rebecca Chamberlain, Jörg Breitkreutz and Julian Quodbach
Pharmaceutics 2022, 14(5), 931; https://doi.org/10.3390/Pharmaceutics14050931
Available online: https://www.mdpi.com/1999-4923/14/5/931
10. “Chitosan-Hyaluronan Nanoparticles for Vinblastine Sulfate Delivery: Characterization and Internalization Studies on K-562 Cells”
by Carmela Cannavà, Federica De Gaetano, Rosanna Stancanelli, Valentina Venuti, Giuseppe Paladini, Francesco Caridi, Corneliu Ghica, Vincenza Crupi, Domenico Majolino, Guido Ferlazzo et al.
Pharmaceutics 2022, 14(5), 942; https://doi.org/10.3390/Pharmaceutics14050942
Available online: https://www.mdpi.com/1999-4923/14/5/942
You are invited to view and submit relevant papers to the journal Pharmaceutics via the following link: https://www.mdpi.com/journal/pharmaceutics.
Pharmaceutics Editorial Office
2 April 2024
MDPI Insights: The CEO's Letter #10 - South Korea, IWD, U2A, Japan
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
Left to right: Dr. Jisuk Kang (Scientific Officer, MDPI), Stefan Tochev (CEO, MDPI), and Dr. Giulia Stefenelli (Chair of Scientific Office Board, MDPI), during media meetings at Prain Agency office in Seoul, South Korea.
Visit to Seoul, South Korea
During my recent visit to South Korea, I had the privilege of meeting various stakeholders, including representatives of government, research institutions, and academia, to understand their needs and communicate MDPI’s commitment to accessible science. Accompanied by my colleagues Dr. Giulia Stefenelli and Dr. Jisuk Kang, I engaged with the Korean scientific community, which is increasingly embracing open access (OA).
As the leading OA publisher in South Korea, MDPI is trusted by local authors and in 2023 enjoyed an approximately 30% share of the OA market. South Korea ranks sixth globally for MDPI in terms of research papers submitted and published.
MDPI and South Korea by Numbers
As at 30 March, over 76,000 MDPI articles have been authored by individuals affiliated with Korean institutions. We have over 1,800 active editorial board members (EBMs) from South Korea, with more than 880 EBMs having an H-index between 26 and 50, including 10 serving as Chief Editors.
“South Korea is the sixth-largest contributor to our total publications”
Over the past five years (2019–2023), nearly 120,000 authors affiliated with South Korean institutes have published with MDPI. Specifically in 2023, we received approximately 25,000 submissions from South Korean authors, publishing close to 13,000 articles, resulting in a rejection rate of 47.4%, which is not far below MDPI’s overall rejection rate of 56.4% in 2023.
Institutional Partnerships with South Korea
I am pleased to share that MDPI has more than 825 institutional partnerships worldwide, with 12 in South Korea, including Kyunghee University, Chung-Ang University, and Inha University, among others.
Left to right: Dr. Jisuk Kang (Scientific Officer, MDPI), Dr. Giulia Stefenelli (Chair of Scientific Office Board, MDPI), and Stefan Tochev (CEO, MDPI) fielding media questions at Prain PR Agency office in Seoul, South Korea.
Over the past three years (2021–2023), we have had some of the most prestigious academic universities ranked among the top 10 Korean institutions publishing with MDPI. Seoul National University had the highest number of publications with MDPI during those three years, publishing nearly 6,000 papers. Universities such as Korea University and Yonsei University also rank among the top 10 Korean institutions publishing with MDPI.
MDPI Hosts Seminar for Academia and Media
As the world’s leading OA publisher, MDPI is actively democratizing science. This is reflected in the seminars we hosted on 21 March to address questions about our editorial processes and ethical standards. The visit garnered media coverage, reflecting our mission to providing high-quality services and fostering open dialogue in the community.
“MDPI is actively democratizing science”
MDPI in the News
Stefan Tochev (CEO, MDPI) leading a seminar on OA and MDPI at Prain PR Agency office in Seoul, South Korea.
Media coverage generated by our visit to Seoul included the following stories:
“Open access is an unstoppable trend…it will lead the development of the knowledge ecosystem.”
I greatly appreciate the contributions of everyone who took the time to meet with us, share their stories, and hold us accountable for continuing to provide high-quality publishing services while identifying areas for improvement. I am also excited to announce that we have opened an MDPI office in Seoul and will release a press release on MDPI.com, with details, by the end April 2024. The purpose of the office is to establish a local presence to connect with and support the South Korean academic community through institutional partnerships, conferences, author workshops, stakeholder communications, and more.
Impactful Research
Featured Articles on Women’s Leadership and Healthcare
In celebration of International Women’s Day (8 March 2024), MDPI curated a collection of research articles on various topics, including women’s leadership, reproductive health, preventive healthcare, and a selection of articles from our journal Women.
Women’s Leadership
- Women Entrepreneurship and Sustainable Development: Bibliometric Analysis and Emerging Research Trends
Sustainability 2022, 14, 9160. https://doi.org/10.3390/su14159160 - Refugee Women Business Mentors: New Evidence for Women’s Empowerment
Sustainability 2022, 14, 9154. https://doi.org/10.3390/su14159154 - Women and Leadership in Higher Education: A Systematic Review
Soc. Sci. 2023, 12, 555. https://doi.org/10.3390/socsci12100555 - Understanding Needs and Potentials for Gender-Balanced Empowerment and Leadership in Climate Change Adaptation and Mitigation in Africa
Sustainability 2022, 14, 9410. https://doi.org/10.3390/su14159410 - Challenges Women Experience in Leadership Careers: An Integrative Review
Merits 2023, 3, 366-389. https://doi.org/10.3390/merits3020021
Women’s Reproductive Health
- Recreational Female Athletes’ Understanding of and Perceived Impact of the Menstrual Cycle on Physical Performance, Mood, and Sleeping Behaviour
Women 2023, 3, 445-456. https://doi.org/10.3390/women3030034 - Difficulties in Adaptation of the Mother and Newborn via Cesarean Section versus Natural Birth—A Narrative Review
Life 2023, 13, 300. https://doi.org/10.3390/life13020300 - The Main Theories on the Pathogenesis of Endometriosis
Int. J. Mol. Sci. 2023, 24, 4254. https://doi.org/10.3390/ijms24054254
Women’s Preventive Healthcare
- Insulin Metabolism in Polycystic Ovary Syndrome: Secretion, Signaling, and Clearance
Int. J. Mol. Sci. 2023, 24, 3140. https://doi.org/10.3390/ijms24043140 - Assessing Barriers Encountered by Women in Cervical Cancer Screening and Follow-Up Care in Urban Bolivia, Cochabamba
Healthcare 2022, 10, 1604. https://doi.org/10.3390/healthcare10091604 - Updates on HPV Vaccination
Diagnostics 2023, 13, 243. https://doi.org/10.3390/diagnostics13020243
Featured Articles in MDPI Journal Women
Below are a few articles from Women, our journal focused on women’s health, the social determinants of health, and the healthcare system that serves women. The aim of Women is to encourage academics to publish their experimental and theoretical results in detail, to aid reproducibility, and in an engaging style, to aid comprehensibility.
- Premenstrual Syndrome and Exercise: A Narrative Review
Women 2023, 3, 348-364. https://doi.org/10.3390/women3020026 - Increasing Awareness of the Human Papillomavirus (HPV) Vaccine for Women 18–45 Years of Age
Women 2023, 3, 365-373. https://doi.org/10.3390/women3030027 - Addressing Women’s Needs with Human Immunodeficiency Virus (HIV) and Enhancing the Visibility of Pharmacists in the Public Health Arena
Women 2022, 2, 346-352. https://doi.org/10.3390/women2040032
Inside MDPI
Championing Women’s Healthcare and Access to Healthcare Information
MDPI colleagues from our offices joined in celebrating #IWD2024. In doing so, we emphasized key missions that encompass:
- Empowering women to assume leadership and decision-making roles in both business and science.
- Helping women and girls make informed decisions about their health.
- Recruiting and developing female talent and fostering inclusive workplace environments.
“We are thrilled to recognize the accomplishments of women scientists”
I am proud to see our colleagues enthusiastically supporting the International Women’s Day call to ‘Inspire Inclusion!’ The heart-hands in the collage below symbolize our appreciation of the achievements of women researchers and the recognition of the trailblazers who have courageously made a mark on societies past and present.
We are thrilled to recognize the accomplishments of women scientists through our many MDPI awards and by highlighting success stories. As inspirational figures, female scientists are paving the way for the next generation of women aspiring to pursue careers in engineering, life sciences, computing, and various other STEM fields.
“I consider myself lucky because I work with incredibly talented women who inspire me every day.”
– Dr. Alessandra Pasut, Winner of MDPI's ‘Biology 2023 Young Investigator Award’
“It’s really important to find a supportive and enabling environment in which to do your science; it would have a big impact on you as a person and on your scientific outputs.”
– Dr. Rhea Longley, Winner of the ‘Pathogens 2023 Young Investigator Award’
Open-access publishing, in particular, allows early-career women researchers to share their work more widely, potentially attracting mentorship opportunities and collaborations. This support is crucial for career development and advancement.
Coming Together for Science
MDPI Joins United2Act in Collective Fight to Stop Paper Mills
In my February 2024 CEO Letter, I highlighted some of our recent initiatives aimed at bolstering our commitment to research integrity, including joining the STM Integrity Hub and expanding our Research Integrity and Publication Ethics team (RIPE). Continuing our efforts in coming together for science, I am pleased to share our participation in the United2Act initiative.
The text below is taken from our official announcement:
United2Act represents an international group of stakeholders in the publishing industry committed to addressing the collective challenge posed to research integrity by paper mills.
Scientists and academic publishers have increasingly noted the alarming proliferation of paper mills, recognized as fraudulent entities seeking to manipulate the publication process for financial profit. These entities engage in fraudulent practices such as falsifying or fabricating data, selling co-authorship of fake papers, manipulating peer review, and including inappropriate citations. These actions pose a significant threat to the integrity of the scholarly record, prompting widespread concern among those involved in the academic community.
MDPI has been actively contributing to combat the undermining of the scientific record. Our editors employ a set of tools to detect potential ethical breaches within a manuscript and to tackle the issue of fake papers.
United2Act’s consensus statement is the outcome of a virtual summit held in May 2023. It involved the participation of research bodies, publishers, researchers/sleuths, universities, and publishing infrastructure from 15 countries and resulted in a Consensus Statement outlining five key areas of action for all stakeholders:
- Education and awareness
- Improve post-publication corrections
- Facilitate and organise research on paper mills
- Enable the development of trust markers
- Facilitate dialogue between stakeholders
MDPI is committed to promoting transparency and integrity in scholarly publishing and is continuing to work closely with the scientific community toward this goal.
Closing Thoughts
Left to right: Ryo Hirayama (Marketing Specialist, MDPI), Takashi Sasabe (Marketing Specialist, MDPI), Dr. Giulia Stefenelli (Chair of Scientific Office Board, MDPI), Dr. Izumi Yamamoto (Marketing Manager, MDPI), and Stefan Tochev (CEO, MDPI), at MDPI’s office in Tokyo, Japan.
Visit to Tokyo and Kyoto, Japan
In March, I had the opportunity to visit our Tokyo office and engage with stakeholders in Tokyo and Kyoto. During the visit, I also recorded a video message to welcome Japanese scholars working with MDPI and to highlight our operations in Japan.
We held meetings with Editors-in-Chief, librarians, scholars, and external consultants to gather feedback on our efforts to enhance our reputation and explore additional steps we can take in that direction. Japan's rich cultural heritage, characterized by tradition, respect, and formality, provided valuable insights into meeting the publishing needs specific to Japan.
Japan’s Open Access statistics
Over the years, we have seen a shift from subscription-only to gold OA publishing in Japan, despite the lack of an official mandate. Here are some statistics:
- 2012: 68% of articles were subscription-only, 6% were green Open Access, and 8% were gold Open Access.
- 2016: 55% of articles were subscription-only, 6% were green Open Access, and 20% were gold Open Access.
- 2022: 43% of articles were subscription-only, 7% were green Open Access, and 39% were gold Open Access.
To learn more about the history of OA in Japan as well as about future trends, please read this blog post.
“Japan is the ninth-largest contributor to our total publications”
Left to right: Stefan Tochev (CEO, MDPI), Dr. Izumi Yamamoto (Marketing Manager, MDPI), and Dr. Giulia Stefenelli (Chair of Scientific Office Board, MDPI) visiting Kyoto University in Kyoto, Japan.
MDPI and Japan by Numbers
As at 1 April, over 50,000 MDPI articles have been authored by scholars affiliated with Japanese institutions, making the country the ninth-largest contributor to our total publications. Over the past three years (2020–2023), nearly 90,000 authors affiliated with Japanese institutes have published with MDPI, and we have collaborated with over 4,600 Guest Editors from Japan.
In 2023, we published over 8,200 papers from authors associated with Japanese institutions. MDPI collaborates with 41 institutional partnerships in Japan, including the University of Tokyo, Hokkaido University, and Nagoya University. We have over 2,100 active EBMs from Japan, more than 1,050 EBMs having an H-index between 26 and 50, including 13 serving as Editors-in-Chief.
General Feedback – a side note
A general takeaway from our discussions with stakeholders from around the world is that negative perceptions of MDPI often stem from misinformation, misconceptions, or misunderstandings about MDPI and our practices. While we acknowledge our mistakes and work diligently to address them, maintaining a strong editorial procedure and robust peer-review process, I find that educating stakeholders about our how we do what we do and our ongoing improvements tends to help shift opinions.
That said, we recognize the importance of addressing individual concerns. We take feedback seriously and are continuously working to get better while not compromising the core principles that millions of authors appreciate about MDPI.
Chief Executive Officer
MDPI AG
4 March 2024
MDPI Insights: The CEO's Letter #9 - Romania, Research Integrity, Viruses
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
Reka Kovacs (Deputy Office Manager, MDPI), Stefan Tochev (CEO, MDPI), and Sandra Ana Spatariu (Office Manager, MDPI) at the MDPI office in Cluj, Romania.
MDPI’s Impact on Romania
In February, I visited our office in Cluj, Romania. I worked closely with our senior office managers and various teams, including the departments of training, marketing and conferences, as well as our journal relationship specialists, reviewing our service to the local scholarly community. During the visit, I also met with representatives from Babes-Bolyai University and the Technical University of Cluj-Napoca. Our multifunctional Romanian office plays an important role in supporting our collaborations with the local market as well as helping to meet MDPI’s overall business needs.
Feedback and strategy meeting with a group of MDPI’s Journal Relationship Specialists at the MDPI office in Cluj, Romania.
With 22,436 articles, Romania ranks as a top 20 contributing country to MDPI’s total number of papers published as at 28 February 2024. This highlights the importance of our collaboration with Romanian-affiliated authors and the growing opportunity to support their publishing needs. MDPI is one of the few academic publishers with a significant presence in Romania, boasting over 360 colleagues across our offices in Bucharest and Cluj. We are also proud to hire colleagues from local institutions to launch their careers within publishing.
Romania ranks as a top 20 contributing country.
The Numbers: 2019–2023
MDPI has seen a healthy increase in submissions from Romanian authors over the past three years, from 8,439 in 2021 to 11,866 by end of 2023, with most submissions going to journals such as Sustainability, Medicina, Diagnostics, IJMS, Applied Sciences, and JCM. From 2019 to 2023, MDPI published articles from 32,145 authors affiliated with Romanian institutions. Over those years, we have worked with Romanian Guest Editors on nearly 3,000 occasions to support their Special Issue and Topical collections.
With more than 300 Editorial Board Members from Romania, 34 appear on the board of Mathematics, 27 on Materials, 19 on Polymers, 18 on Coatings, and 16 on Molecules, while three serve as Section Editors-in-Chief (SEiC) on our journals Coatings (3.4 IF, 4.6 Citescore), Magnetochemistry (2.7 IF, 3.5 Citescore), and Chemosensors (4.2 IF, 3.9 Citescore).
Institutional Open Access Programs
Our commitment to working with institutions is evident in Romania, where we have established eight Institutional Open Access Programs (IOAP) with esteemed institutions such as the University of Bucharest, the University of Medicine and Pharmacy Cluj-Napoca, and most recently the National Institute for Laser, Plasma and Radiation Physics.
Our growth and presence in Romania are a true testament.
We also have IOAP agreements with Babes-Bolyai University and the Technical University of Cluj-Napoca, where I had the opportunity to meet senior stakeholders during my visit. Below are a few photos capturing our meeting with Prof. Radu Silaghi-Dumitrescu (Head of Faculty of Chemistry, Babes-Bolyai University) at the MDPI office in Cluj, Romania, along with a photo from our meeting with Vice Deans Nicoleta Cobarzan, Nicoleta Ilies, and Hoda Gavril, from the faculty of Civil Engineering at the Technical University of Cluj, Romania.
Our growth and presence in Romania are a true testament to the service we provide to the scholarly community and the relationships we foster in that region. We look forward to continuing to support Romanian scholars and institutions by providing a valuable and trusted experience with MDPI, the leader in open access publishing.
Impactful Research
MDPI Joins the STM Integrity Hub
MDPI has long been a supporter and partner of STM, with our involvement ranging from sponsoring and attending events to helping organize event programs. By joining the STM Integrity Hub, we aim to further our commitment to STM initiatives aimed at safeguarding the integrity of science.
“We are pleased to welcome MDPI as the 35th organisation participating in the Hub. This expansion is critical, as every new member enhances our capacity to prevent fraudulent submissions from entering the academic record.”
Joris van Rossum, Director of Research Integrity, STM
MDPI operates in full alignment with STM Integrity Hub's values of shared data and experiences. We strongly believe in collaboration and open exchange for the purposes of creating a holistic approach to support research integrity at MDPI itself and across the entire academic publishing industry. The Integrity Hub is an excellent example of how publishers can come together to jointly address industry-wide challenges related to research integrity, such as manuscripts that breach research integrity standards and paper-mills.
I look forward to our Research Integrity and Publication Ethics Team (RIPE) team immersing themselves in this initiative, exchanging information, best practices, and tools for the benefit of the entire scholarly ecosystem. We believe that ethical publishing standards should be implemented across the board, and we aim to be rigorous in our approach, addressing research integrity issues and improving the impact of published research.
Inside MDPI
MDPI Expands Research Integrity and Publication Ethics Team (RIPE)
In addition to external collaborations and joint initiatives aimed at further strengthening our commitment to research integrity, we are also enhancing our internal efforts. This includes improving our processes and guidelines and expanding our teams and departments to ensure quality assurance throughout our publishing process.
We are pleased to announce the expansion of our Research Integrity and Publication Ethics Team (RIPE) at MDPI. The RIPE team has recently welcomed new colleagues, each bringing unique skills and a personal commitment to prioritize ethical considerations in all our work.
The demand for research integrity and high ethical standards in academic publishing is steadily rising across our industry. Our expanded RIPE team will work to enhance and align our practices with industry best practices, ensuring excellence in research integrity and publication ethics.
Stefan Tochev (CEO, MDPI) introduces Dr. Tim Tait-Jamieson (Research Integrity Lead, MDPI) for his presentation on MDPI’s Retraction and Approval Process to a group of Journal Relationship Specialists at the MDPI office in Cluj, Romania: “The demand for research integrity and publication ethics is steadily rising across our industry.”
Introducing our Research Integrity and Publication Ethics Team
Led by Dr. Tim Tait-Jamieson (Research Integrity Lead), the RIPE team comprises Dr. Ivana Resanovic (Research Integrity Manager), Dr. Lavinia Rogojina (Research Integrity Manager), Ms. Diana Apodaritei (Research Integrity Specialist), Dr. Zoltan Mihaly (Research Integrity Specialist), Mr. Aleksandar Đukić (Research Integrity Specialist), Ms. Ana Stankovic (Research Integrity Specialist), and Ms. Anna Pena (Publication Ethics Assistant).
Please click here to access everything that you need to know about MDPI’s Research and Publication Ethics.
With this span of complementary roles, the RIPE team collaborates directly with journal editorial teams and works closely with various departments, including our Scientific Office Board and our Journal Relationship Specialists. The team’s primary objectives are to help prevent issues regarding research integrity and publication ethics during peer review, uphold MDPI’s ethics policies, adhere to industry standards, and resolve publication ethics and research integrity issues and complaints.
Quality Updates to Special Issues Oversight
At MDPI, we are committed to reviewing policies pertaining to the quality of research. In this blog post, Shaheena Patel (Communications Associate, MDPI), outlines two recent updates to MDPI journal processes. These updates pertain to Special Issue (SI) quality guidelines, in line with criteria provided by COPE and DOAJ. Alongside the SI updates, details regarding the new minor corrections policy introduced in 2024 are provided in the blog.
The two updates we implemented include greater oversight and the verification of Guest Editor credentials. These guidelines require that Editors-in-Chief (EiCs) and Editorial Board Members (EBMs) take responsibility for overseeing SIs.
PS. Thank you, James Butcher, for featuring this up in your 67th issue of the Journalogy newsletter.
Read more:
Coming Together for Science
Viruses 2024 – A World of Viruses
I am pleased to share the success of our MDPI conference Viruses 2024 – A World of Viruses, held 14-16 February, in Barcelona. With 240 registrations, this event brought together top scientists, researchers, and industry experts from 40 countries to share their findings on the latest developments in viral pathogenesis and immune responses.
Attendees gathered for the 5th edition of the Viruses’ conference, where we hosted influential keynote speeches from Nobel Prize laureate Dr. Charles M. Rice and ‘Distinguished Senior Virologist’ Prof. Luis Enjuanes, along with 14 invited speakers, 47 selected speakers, and nine flash poster presenters, to discuss the most significant issues in virology today.
Recap on the #Viruses2024 Conference
Take a look at the key moments from MDPI’s Viruses event and please join us in commemorating a gathering for global knowledge and cooperation. A heartfelt thank-you to all attendees; their passion and engagement played a crucial role in making this event an engaging success!
Below are calls to action from the keynote speakers encouraging collaboration and communication:
“There’s never been a better time than now to really take the power that we have both in terms of basic research and also in biotech and pharma to develop antiviral agents.” - Dr. Charles M. Rice, The Rockefeller University, New York, USA
“The collaboration between labs is absolutely essential. Improving initial detection and improving communication is a must for all of us working in science.” - Prof. Dr. Luis Enjuanes, National Center of Biotechnology (CNB-CSIC), Madrid, Spain
Our thanks go to our sponsors and partnering societies, our Viruses journal and editorial team, our Barcelona colleagues, and the social media, conference and other MDPI teams for making this event a memorable occasion. View the event gallery here.
Upcoming In-Person Event
24–26 April, 2024
4th MMCS – Harnessing the Power of New Drug Modalities
Location: Barcelona, Spain
Esteemed speakers at MMCS 2024 include Prof. Arun K. Ghosh, the mind behind the Darunavir molecule, and Prof. Paul Brennan, CSO of Alzheimer's Research UK Oxford Drug Discovery Institute.
Find more upcoming MDPI events here.
Organize Your Event with MDPI’s Sciforum
Sciforum is MDPI’s platform dedicated to the organization of scientific events. In line with our mission to promote science, Sciforum supports scholars, societies, research networks, and universities at all stages of organizing in-person events, virtual events and webinars. Our platforms are efficient, user-friendly, and cost-effective. We handle all steps related to event management. Contact us for details.
Closing Thoughts
Researcher to Reader (R2R) Conference
From 20–21 February 2024, I had the pleasure of attending the Researcher to Reader (R2R) conference in London, which MDPI has proudly sponsored over the years. The conference programme offered a variety of session formats, including workshops, panel discussions, debates, interviews, presentations, and lightning talks, with opportunities to discuss relevant topics.
We take pride in supporting the scientific community, bringing researchers across the world together to network, exchange ideas and share the latest in science and publishing. In 2023, MDPI invested close to 2 million CHF in sponsoring over 2,000 scientific and publishing-related conferences worldwide.
R2R Peer Review Innovations Workshop
I found the R2R conference to be engaging, with the workshops being particularly enjoyable. My colleague Giulia Stefenelli (Chair of Scientific Office Board) and I participated in the “Peer Review Innovations” workshop, which spanned four sessions over the two days. These sessions explored the future of peer review and how we can improve the peer review process for everyone involved. Notably, the large majority of attendees expressed their opinion that peer review, as currently practiced, requires significant improvement. Together, we collaborated on potential immediate and long-term improvements and innovative processes, aiming to create an ecosystem beneficial to all stakeholders by strengthening submission systems with the aim of reducing threats and making authors more responsible for their work. We also discussed the opportunity for academic institutions to better scrutinize the quality of the work produced and submitted to journals.
Our group comprised publishers, software providers, librarians, and more, bringing diverse perspectives to the discussions. These interactions were relevant to MDPI’s ongoing conversations, providing insights to our efforts. The session also made me appreciate that MDPI is doing well, as the group discussions included the subject of various quality checks that we have already embedded in our processes, ensuring that we keep abreast of industry standards.
The need for an optimized system to incentivize the activities of editors and reviewers was also a focus of discussion, as well as the support that reviewers need from publishers via the provision of strong reports through fixed forms, questionnaires and training.
At MDPI, we are currently auditing our reviewer program to improve reviewer recognition, guidelines, and methods for identifying suitable reviewers, while maintaining our commitment to quality and timeliness.
Congratulations to Mark Carden, Conference Director, and the R2R team for organizing a productive and successful event. PS: The break times were greatly appreciated as well!
Chief Executive Officer
MDPI AG
23 February 2024
Meet Us at the 144th Annual Meeting of the Pharmaceutical Society of Japan, 28–31 March 2024, Yokohama, Japan
Conference: The 144th Annual Meeting of the Pharmaceutical Society of Japan
Date: 28–31 March 2024
Location: Yokohama, Japan
MDPI will be attending the 144th Annual Meeting of the Pharmaceutical Society of Japan at Booth #79, and we welcome researchers from different backgrounds to visit and share their latest ideas with us.
The theme of the 144th Annual General Meeting is: “Creation of a Pharmaceutical Culture that Co-prosperity with “Genes” and “Environment”: Toward the Integration of Sustainable “Digital Therapy”.
With the introduction of vaccines, the sale of therapeutic drugs, and the establishment of treatment systems, the fight against COVID-19 has become a coexistent situation. We hope that this annual general meeting will be an opportunity for many researchers, medical professionals, and educators involved in pharmaceutical research to gather, present the latest research results, and discuss how pharmaceutical education should be. We hope that it will be an opportunity to create sustainable innovations for the future.
The following MDPI journals will be represented:
- Biomedicines;
- JPM;
- Molecules;
- Pharmaceuticals;
- Pharmaceuticals.
If you are planning on attending this conference, please do not hesitate to start an online conversation with us. Our delegates look forward to meeting you in person and answering any questions that you may have. For more information about the conference, please visit the following website: https://confit.atlas.jp/guide/event/pharm144/top.
5 February 2024
Acknowledgment of the Reviewers of Pharmaceutics in 2023
In recognizing the exceptional efforts of our reviewers in 2023, we express our sincere gratitude for upholding the high standards of Pharmaceutics. Their commitment ensured the rigorous peer review that is integral to quality academic publishing.
In 2023, Pharmaceutics received 11020 review reports, from 6532 reviewers. This past year, we worked with reviewers from 94 countries and regions, reflecting the diversity in our collaboration with research communities. Their dedication shapes scholarly discourse and advances global research. The editorial team expresses gratitude for the vital role played by each reviewer in the Pharmaceutics family throughout 2023, and we look forward to their continued support in 2024.
The following are the reviewers who have consented to show their names:
A. Berenice Aguilar-Guadarrama | Krista Delviks-Frankenberry |
A. F. M. Motiur Rahman | Kristijan Skok |
Aamir Jalil | Kristina Kantminienė |
Abbirami Elangovan | Krisztina Takacs-Novak |
Abdelbary Elhissi | Krzysztof Kuczera |
Abdul Aleem Mohammed | Krzysztof Zborowski |
Abdullah Assiri | Ksenia Tereshkina |
Abdulqadir Nashwan | Kui Zhang |
Abhishek Anant Kulkarni | Kuldeep Bansal |
Abhishek Juluri | Kuldeep Gupta |
Abhishek Kandwal | Kumar Katragunta |
Abhishek Kumar | Kyriakos Kachrimanis |
Abi Jenkins | Kyuichi Kawabata |
Achilleas Garoufis | Lacramioara Popa |
Adam Kern | Lalit Kumar |
Adam Oberstein | Lamiaa M. A. Ali |
Adam Reich | Lara Baticic |
Adel Al Fatease | László Hazai |
Adelina Vlad | Laszlo Jicsinszky |
Adina Magdalena Musuc | László Szilák |
Adina Popa | Lateef Ahmad |
Aditi Mulgaonkar | Laura Endres |
Aditya Sarode | Laura Melendez-Alafort |
Aditya Singh | Laura Orian |
Adrian Florin Spac | Laura Vicaș |
Adrián Matencio | Laura-Marinela Ailioaie |
Adrían Rodríguez-Carlos | Laurentiu M. Pop |
Adrian Topolski | Layla Pires |
Adriana Erica Miele | Le Minh Tu Phan |
Afang Zhang | Leander Corrie |
Affiong Iyire | Leda Guzmán |
Afrooz Rashnonejad | Lei Li |
Afzal Hussain | Lei Nie |
Afzal Shaik | Lei Zhang |
Agata Wawrzyńczak | Lenuţa-Maria Şuta |
Agnieszka Szczepek | Leonard Ionut Atanase |
Agnieszka Szewczyk | Leonid Kustov |
Agnieszka Wiącek | Leszek Szablewski |
Agnishwar Girigoswami | Leto-Aikaterini Tziveleka |
Ahlam Zaid Alkilani | Li Liang |
Ahmed Abdel Moneim | Lídia Gonçalves |
Ahmed Abu-Zaid | Liewei Wen |
Ahmed El Ghorab | Lifo Ruan |
Ahmed El-Fiqi | Lijun Wang |
Ahmed Fatimi | Liliya Logoyda |
Ahmed Hassan | Lilya Dzhemileva |
Ahmed Noreldin | Lim Hwee San |
Ahmed Shalabi | Linda Hazlett |
Ahmet Kertmen | Lipeng Qiu |
Aidar Gubaidullin | Lisa Ryan |
Aidin Bordbar-Khiabani | Liting Wang |
Aiman Abu Ammar | Liudmyla V. Garmanchuk |
Aisha Farhana | Liviu Steier |
Aixiang Ding | Ljubisa Nikolic |
Ajmer Singh Grewal | Loredan Niculescu |
Akira Yamasaki | Loredana Brioschi |
Alain Le Faou | Lorella Giovannelli |
Alanood Almurshedi | Lorena Ciumărnean |
Alberto Baldelli | Lorenzo Vannozzi |
Alberto Di Renzo | Lu Cai |
Alberto García-Peñas | Lu Xiao |
Alejandro Casas-Alvarado | Lubos Cipak |
Alejandro Islas-Jácome | Luca De Stefano |
Alejandro J. Alvarez | Luca Filippi |
Alejandro Ruiz-Picazo | Luca Giannella |
Aleksandar Shkondrov | Luca Liviu Rus |
Aleksandar Ž. Kostić | Luca Palugan |
Aleksander Czogalla | Luca Potestio |
Aleksander Mendyk | Lucia Baldino |
Aleksandra Bondžić | Lucia Montenegro |
Aleksandra Bukhovets | Luciana D'Apice |
Aleksandra Józefczyk | Luciana Malavolta |
Aleksandra Volod'ko | Lucinda Bessa |
Alena Stupar | Lucretia Udrescu |
Alessandra Maroni | Ludmila Kazdova |
Alessandra Sinopoli | Luidmila Yakimova |
Alessandra Zizzari | Luis Alves |
Alessandro Parodi | Luis Apaza Ticona |
Alessandro Venditti | Luis Ibarra |
Alexa Guglielmelli | Luis Oriol |
Alexander Bunev | Luis Puig |
Alexander Demin | Luis Soto-Rojas |
Alexander Dullenkopf | Luis Villarreal-Gómez |
Alexander Ewe | Łukasz Grabowski |
Alexander Lykov | Łukasz Szeleszczuk |
Alexander Muravsky | M. Begoña Delgado-Charro |
Alexander Novikov | M. Carmen Morán |
Alexander Shtil | Maciej Przybyłek |
Alexander Trujillo | Maciej Serda |
Alexander Vasil’kov | Mafalda Sarraguça |
Alexander Yusipovich | Magda Abdellattif |
Alexandra Zakharenko | Magdalena Gierszewska |
Alexandre Vetcher | Magdalena Matysiak-Kucharek |
Alexandrina Nan | Magdalena Mizerska-Kowalska |
Alexey Chubarov | Maha Nasr |
Alexey Sokolov | Mahmoud Elsayed |
Alexios Vlamis | Mahmoud Kandeel |
Alexis Oliva | Mahmoud Khalil |
Alexis Stamatikos | Mahmoud Younis |
Ali Dehshahri | Maja Nešić |
Ali Hassan | Makoto Tsunoda |
Ali Ibrahim | Maksim Burkin |
Ali Mujtaba | Małgorzata Jeleń |
Ali Raza | Małgorzata Przybyło |
Ali Zarrabi | Małgorzata Starek |
Aliaa ElMeshad | Małgorzata Sznitowska |
Alicia Mansilla | Manesh Nautiyal |
Alicia Rodríguez-Gascón | Manikandan Sivan |
Alin Laurentiu Tatu | Manoj Neog |
Alina Grigor'eva | Manolis Fousteris |
Alison Luce-Fedrow | Mansoor-Ali Vaali-Mohammed |
Amanda Iglesias | Manuel Cordoba-Diaz |
Amany Abdel-Rahman | Manuel José Lis Arias |
Amardeep Awasthi | Manuel Rodríguez-Ortega |
Amelia Silva | Manuel Sureda |
Ami Mehta-Doshi | Manuela Chiper |
Amir Mellati | Mara Mihai |
Amjad Khan | Marc C. A. Stuart |
Ammad Ahmad Farooqi | Marc-André Lécuyer |
Amr Abu lila | Marcela-Elisabeta Barbinta-Patrascu |
Ana Carolina Gonçalves | Marcello Locatelli |
Ana Cazacu | Marcio Alvarez-Silva |
Ana Dascalu | Marcio Basilio |
Ana Duarte | Marco Antonio Meraz-Ríos |
Ana Feregrino-Perez | Marco Cavaco |
Ana Fernandes | Marcus Mareel |
Ana Figueiras | Marcus Scotti |
Ana Isabel Fraguas-Sánchez | Marek Mirowski |
Ana Maria Carmona-Ribeiro | Marek Pokorny |
Ana Mornar | Marek Staszewski |
Ana Podolski-Renić | Marek Wesolowski |
Ana Popovic Bijelic | Margarete Odenthal |
Ana Rita Jesus | Margarida Miranda |
Anamaria Brozovic | Margherita De Rosa |
Anand Joshi | Margherita Eufemi |
Anand Kumar Pandey | Margherita Neri |
Anbazhagan Sathiyaseelan | Maria A. Bonifacio |
Anders Larsson | Maria Addolorata Mariggiò |
András Bilkei-Gorzó | Maria Angeles Rojo |
Andre Luis Barros | Maria Antonietta Panaro |
André Moreira | María Del Rayo Camacho-Corona |
André R. T. S.Araujo | María Del Rocío Reyes-Montes |
Andrea Lipińska | Maria Elena Martín |
Andrea Mastinu | María Esperanza Ruiz |
Andrea Mezzetta | Maria Gazouli |
Andrea Ragusa | Maria Giulia Cangi |
Andreas Kalogirou | Maria Guembe |
Andreas Koschella | María I. Rodríguez-López |
Andreas Ouranidis | Maria Ignat |
Andreas Tzakos | María Isabel Lucío |
Andrei Potapov | Maria João Moreno |
Andrei Sarbu | Maria João Ramalho |
Andreia Pereira | Maria Jose De Jesus Valle |
Andrés G. Santana | Maria Julia Lamberti |
Andrew Kolarik | Maria Lepore |
Andrew Redfern | Maria Lucibello |
Andrey Bogomolov | Maria Manuela Gaspar |
Andrey Glotov | Maria Mirabelli |
Andrey Gorshkov | María Paula García |
Andrey Nagdalian | Maria Pia Ferraz |
Andrey V. Sybachin | Maria Scavo |
Andrey Zamyatnin | Maria V. Chatziathanasiadou |
Aneta Ostróżka-Cieślik | Maria Xilouri |
Angel Guillermo Bracamonte | Mariana Palage |
Angel Josabad Alonso-Castro | Mariano Francesco Caratozzolo |
Angel M. Cuesta | Mariano Venanzi |
Angela Capocefalo | Marieta Constantin |
Angela Papa | Marija Gizdavic-Nikolaidis |
Angela Suárez-Jacobo | Marija Jankunec |
Ángela-Patricia Hernández | Marilisa Leone |
Angeliki Angelidi | Marin Simeonov |
Angeliki Chroni | Marina Abuçafy |
Angelina Angelova | Marina Spinu |
Anik Karan | Mario D'Acunto |
Anilkumar Thaghalli Shivanna | Mario F. C. Santos |
Aninidta De | Mario Fruschelli |
Anjan Motamarry | Mário Rosado |
Anjuman Begum | Mario Simirgiotis |
Ankur Bothra | Mario Valenti |
Anna Angela Barba | Marios Spanakis |
Anna Drabczyk | Marisa Colone |
Anna Jurowska | Marival Bermejo |
Anna Karewicz | Mark Heitz |
Anna Lewinska | Marko Jovic |
Anna Marabotti | Marko Krstić |
Anna Mielańczyk | Markus Leo |
Anna Rita Bilia | Marta Camprubí Rimblas |
Anna Shipovskaya | Marta Gallo |
Anna Siemiątkowska | Marta Kepinska |
Anna Syguda | Marta Slavkova |
Anna Trusek | Marta Szekalska |
Anna Tsaantili | Martin Šíma |
Anna V. Vologzhanina | Martin Ward |
Anna W. Sobańska | Mary Luz Uribe |
Anna Wiktorowska-Owczarek | Mary Maj |
Annalisa Chiavaroli | Marya Ahmed |
Annalisa D'Arco | Marzia Di Donato |
Annamaria Aloisio | Masoumeh Ghalkhani |
Annarita Stringaro | Massimo Conese |
Anne Kasus-Jacobi | Mateusz Szudzik |
Anne-Marie Caminade | Mattias Paulsson |
Anthony Harker | Maurice Collins |
Anton Ivanov | Mawieh Hamad |
Anton Larenkov | Md Khalid Anwer |
Anton S. Tsybko | Md Sofiqul Islam |
Antonella Casiraghi | Md. Azad |
Antonella Rosa | Mehmet Gumustas |
Antonello Barresi | Melgardt De Villiers |
Antonio Barbato | Melissa Barker-Haliski |
Antonio Di Martino | Melissa Burmeister |
Antonio Massa | Melville Vaughan |
Antonio Portoles | Meng He |
Antreas Kantaros | Mengliang Zhang |
Anu Rahal | Mengze Lyu |
Ao Shi | Mengze Xu |
Apipa Wanasathop | Mercedes Lopez-Santalla |
Apratim Jash | Mershen Govender |
Arasu Ganesan | Micaela Reddy |
Arianna De Mori | Michael Arkas |
Arif Nuryawan | Michael Gray |
Ari-Pekka Koivisto | Michael Leitges |
Aris Giannakas | Michael Schirmer |
Aristides Dokoumetzidis | Michael Seidenstuecker |
Arkadij Sobolev | Michał Rachwalski |
Arnaldo Santos | Michele Galluccio |
Aron Nemeth | Mick Welling |
Arpita Roy | Miguel Cabrera-Pérez |
Artem Rogachev | Miguel García-Castro |
Artur Khannanov | Miguel Hueso |
Artur Ratkiewicz | Miha Moškon |
Artur Ribeiro | Mihaela Balas |
Arun Kharat | Mihaela Deaconu |
Arun Kumar Shukla | Mihaela Ileana Ionescu |
Arun Thirumurugan | Mihaela Violeta Ghica |
Aruna Dhathathreyan | Mihalj Poŝa |
Arvind Negi | Mikaeel Young |
Ashish Kabra | Mikhail Proskurnin |
Ashu Johri | Mikhail Tsurkan |
Asif Mahmood | Milada Šírová |
Asmaa Khafaga | Milica Aćimović |
Aswani Dutt Vadlapudi | Milica Lukic |
Athanasios A. Panagiotopoulos | Milica Pešić |
Athanasios Papakyriakou | Milka Mileva |
Athina Angelopoulou | Milos Kojic |
Athina Giannoudis | Miloš Mitić |
Atsushi Kawahara | Miloš Ognjanović |
Atul Agrawal | Ming-Chi Lu |
Aura M. Jiménez Garduño | Ming-Wei Lin |
Aurica Precupas | Miran Ki |
Avi Schroeder | Miranda Sertić |
Aydi Abdelkarim | Mircea Ioan Popa |
Aykut Aksit | Miren Altuna |
B. H. Jaswanth Gowda | Mirna Jovanović |
Badr M. Thamer | Miroslav Živić |
Bahaa Jawad | Miroslava Špaglová |
Bai-Yan Li | Mitsutaka Kitamura |
Balakrishna Pai | Moganavelli Singh |
Balázs Sarkadi | Mohamad Hamdi Zainal-Abidin |
Barbara De Filippis | Mohamed Balaha |
Barbara Giordani | Mohamed Ibrahim |
Barbara Hausott | Mohamed Jaber |
Barbara Ruaro | Mohamed M. Badran |
Barbara Schnierle | Mohamed Orabi |
Barbara Stella | Mohamed S. A. Darwish |
Barbara Strzalka-Mrozik | Mohamed Shaalan |
Bartłomiej Potaniec | Mohammad Ansari |
Basant Puri | Mohammad Ashfaq |
Basanth Babu Eedara | Mohammad Azad |
Baskar Venkidasamy | Mohammad Doroudian |
Bassam Elgamoudi | Mohammad Kamal |
Beata Morak-Młodawska | Mohammad Mobashir |
Beata Zadykowicz | Mohammad Momin |
Béla Kovács | Mohammad Oves |
Belén Altava | Mohammed El-Magd |
Belen Begines | Mohammed Emran |
Bence Sipos | Mohammed Gamal |
Benjamin Valdez | Mohammed Mehanna |
Bennett Elzey | Mohd Imran |
Berenice Fernández-Rojas | Moises Leon Juarez |
Bernardo Ribeiro | Monica Gomaraschi |
Bernhard Spingler | Monica Raduly |
Bharadwaja Srimat Tirumala Peddinti | Monika Krasowska |
Bhavani Prasad Vinjamuri | Monika Prakash |
Bhupendra Prajapati | Moon Nyeo Park |
Bianca-Maria Tihauan | Mostafa Hussien |
Biljana Arsic | Mounir M. Salem Bekhit |
Bin Liu | Moustafa Fouda |
Binoy Maiti | Mrinal Bhattacharjee |
Bissera Pilicheva | Mrinmoy Das |
Blanca Ocampo-García | Muhammad Abdel Ghafar |
Bo Liu | Muhammad Hammad Butt |
Boaz Mohar | Muhammad Ijaz |
Bojana Vasiljevic | Muhammad Latif |
Bojarska Joanna | Muhammad Mohsin |
Boleslaw T. Karwowski | Muhammad Sajid Hamid Akash |
Boris Dzantiev | Muhammad Shafiq |
Boryana Nikolova-Mladenova | Mustapha Imam |
Boya Liu | Muzaffar Iqbal |
Brendan Duggan | Myron Szewczuk |
Briatico-Vangosa Francesco | N. Siddiqi |
Brigitte Hantusch | Nada Mostafa |
Bruce Spittle | Nader Tanideh |
Bruno Miguel Neves | Nadine Darwiche |
Bryan Troxell | Nae-Cherng Yang |
burak tüzün | Nafisa Gull |
Bwalya Witika | Nagavendra Kommineni |
C. Cabello-Alvarado | Nagendra Chauhan |
Cameron Metcalf | Nagesh Peddada |
Candace Day | Nageswara Pilli |
Candan Hizel | Naoya Kondo |
Carla Lucia Esposito | Naozumi Teramoto |
Carla Zannella | Napoleão Argôlo Neto |
Carlemi Calitz | Narendar Dudhipala |
Carlo Aprile | Naresh Duvva |
Carlo Diaferia | Narimantas Čėnas |
Carlos Alonso-Moreno | Natalia Belosludtseva |
Carlos Caro Salazar | Natalia Cheshenko |
Carlos Cerdán Santacruz | Natalia Inada |
Carlos F. Geraldes | Natalia Linkova |
Carlos Garcia Santos-Gallego | Natalia Shnayder |
Carlos Martinez-Boubeta | Nataliya Sumbatyan |
Carlos Torres-Torres | Nathachit Limjunyawong |
Carlotta Marianecci | Nathalie Van Den Berge |
Carly Filgueira | Nauman Khan |
Carmelo Sgarlata | Naveed Ahmed |
Carmen Del Toro Sánchez | Nawal Abd EL-Baky |
Carmen Ferrero | Nawaz Muhammad |
Carole D. Thomas | Nayden Naydenov |
Carolina Otero | Neal Davies |
Catarina Pereira-Leite | Nebojsa Pavlovic |
Cátia Ramalhete | Neda Baghban |
Cecilia Zavala-Tecuapetla | Neelesh Mehra |
Céline Deraeve | Neeraj Kumar Sethiya |
Cemil Aydoğan | Neeraj Thakur |
Chadarat Ampasavate | Neha Garg |
Chandra Mishra | Nemat Ali |
Chandrabose Selvaraj | Nenad Ignjatović |
Chandramani Pathak | Nesrin Horzum |
Chang Lei | Nesrine El Sayed |
Chang Li | Nethaji Muniraj |
Changli Zhao | Nhu-Nang Vu |
Changshan Niu | Nianfeng Sun |
Chang-Tong Yang | Nicholas Peake |
Chao Liu | Nicola Carter |
Chao Wang | Nicola Marziliano |
Chao Yin | Nicolas Joubert |
Charalampos Sarafidis | Nicoleta Radu |
Charitha Thambiliyagodage | Nicoleta Todoran |
Charles Norton | Nicoleta Vedeanu |
Chen Xie | Nicoletta Cordani |
Cheng Chen | Nikita Minaev |
Chengyu Wu | Nikita Tsvetov |
Chenyu Li | Nikita Yabbarov |
Chenzhen Zhang | Nikolai Paul Pace |
Cheol Moon | Nikolaos Bouropoulos |
Chia-Che Chang | Nikolaos Lougiakis |
Chiara Brignole | Nikolaos Naziris |
Chiara Calabrese | Nikolaos Politakos |
Chiara M. Motta | Nikolay Goncharov |
Chiara Migone | Nikolay Polyakov |
Chiara Moltrasio | Nikolay Pyataev |
Chie Kojima | Nina Melnikova |
Chien Ing Yeo | Ning Li |
Chie-Shaan Su | Ningnagouda Patil |
Chiranjeev Sharma | Nirav Patel |
Chis Adriana Aurelia | Nisar Ul Khaliq |
Chiung-Hui Liu | Nishad Thamban Chandrika |
Choo Hock Tan | Nobuhito Hamano |
Christian Barbato | Noé Ontiveros |
Christian Lehmann | Noopur Bhatnagar |
Christian Wiraja | Norazlinaliza Salim |
Christie Ying Kei Lung | Noriaki Iijima |
Christina Oetzmann Von Sochaczewski | Noriko Sato |
Christine Dufès | Norma Sofía Torres Pabón |
Christopher William | Nour E. A. Abd El-Sattar |
Christos Georgiou | Noureddine Issaoui |
Christos Rahiotis | Numan Majeed |
Chrysoula Voidarou | Nuno Ferreira |
Chulhun Park | Nunzia Gallo |
Chunhong Dong | Nurbubu Moldogazieva |
Claire Jean-Quartier | Oksana Velgosova |
Clara Gomes | Oleg Shuvalov |
Cläre Von Neubeck | Olga Kopach |
Cláudia Mouro | Olga Krestinina |
Claudio Ferrante | Olga Zubkova |
Claudiu Morgovan | Olivier Escaffre |
Claudiu N. Lungu | Oliviu Vostinaru |
Claus-Michael Lehr | Oluwatoyin Adeleke |
Concetta Altamura | Omid Akhavan |
Conicet Axel Hollmann | Ondrej Kostov |
Constantin Itin | Osama Kishta |
Constantinos Giaginis | Oscar Wiklander |
Costanza Maria Cristiani | Otávio Augusto Chaves |
Costica Caizer | Ovidiu Samoila |
Cristian Peptu | Ovidiu-Cristian Oprea |
Cristian Sandoval | Oyuna Kozhevnikova |
Cristian Scheau | Ozgul Gok |
Cristina Alina Silaghi | P. Ulrich Biedermann |
Cristina Chircov | Pai Peng |
Cristina Lavinia Nistor | Paloma De La Torre-Iglesias |
Cristina Martin Sabroso | Panagiotis Mallis |
Cristina Mas-Bargues | Pantelis Zebekakis |
Cristina Nastasă | Paola De Luca |
Cyril Fersing | Paola Faraoni |
Cyril Nicolas | Paolo Benna |
Daali Youssef | Paolo Coghi |
Damien Lannoy | Paolo Trucillo |
Dana Ciobanu | Paraskev Nedialkov |
Dana Copolovici | Partha Narayan Dey |
Dancho Danalev | Pasquale Stano |
Dandan Tu | Pasqualina D'ursi |
Daniel Arcanjo | Patricia Graves |
Daniel Bäcker | Patrícia Pires |
Daniel Fernández-Quiroz | Patricio Fernandez-Silva |
Daniel Guendel | Patrick Arbuthnot |
Daniel M. Kamiński | Patrick Martin |
Daniel Otto | Paul Malik |
Daniela De Vita | Paul Selzer |
Daniela Elena Serban | Paul Soto |
Daniela Hanganu | Paula Pinto |
Daniela Meleleo | Paula Soares |
Daniela Montesarchio | Paulo Carmo |
Daniela Opriş-Belinski | Paulo De Morais |
Daniela Rusu | Pavel Ivchenko |
Daniele Nogueira-Librelotto | Pavel Makarevich |
Daniil Bratashov | Pavel Nazarov |
Danijela Cvetković | Pavel Padnya |
Danijela Laketa | Pawan Kumar |
Danilo Vona | Paweł Zmarzły |
Daodao Hu | Payal Ganguly |
Dapeng Chen | Pedro Costa |
Dario Lirussi | Pegi Grabnar |
Dario Mizrachi | Peihong Ni |
Dave Mangindaan | Peng Gao |
David Aebisher | Peng Quan |
David Facal | Peng Zou |
David Gewirtz | Petar Ozretić |
David Greenhalgh | Peter Dubovskii |
David Leavesley | Peter Gaengler |
David Limón | Peter Hauser |
David P. Lin | Peter Jervis |
David Sánchez-García | Peter O'Connell |
De Gong | Peter Piko |
Deanna Mudie | Peter Timmins |
Deepak Ahire | Petr Ryapolov |
Dejan Stojkovic | Petr Zamostny |
Delly Ramadon | Petras Prakas |
Demetrios Arvanitis | Philip Anderson |
Denisa Circioban | Philip Hublitz |
Devapriya Sinha | Philippe Espeau |
Dezhi Yang | Philippe Lecomte |
Di Wu | Pia Giovannelli |
Diana Ciolacu | Pietro Cacialli |
Diana Mostafa | Pietro Valerio Foti |
Diana Pinto | Pingyuan Wang |
Dianbao Zhang | Piotr Dobrowolski |
Diego Romano Perinelli | Piotr Kurcok |
Dignesh Khunt | Piotr Michel |
Diletta Ami | Piyush Baindara |
Dilip Singh | Piyush Gondaliya |
Dina Kassem | Piyush Mehta |
Dinesh Jaishankar | Polliana Mihaela Leru |
Dinesh Upadhya | Po-Wen Chen |
Dinesh Verma | Prabhanjan Giram |
Dmitrii Maltsev | Pradeep Panda |
Dmitriy Serov | Pradipta Ranjan Rauta |
Dmitry Gruzdev | Prasenjit Mondal |
Dmitry Karpov | Prashant Kumar |
Dmitry Shulga | Prashanth Ravishankar |
Dmitry Stetsenko | Prasopchai Patrojanasophon |
Dmitry Verbenko | Pratibha Gopalkrishna |
Doaa Alshora | Prem Kushwaha |
Doaa Zineldeen | Priyanka Ray |
Dominika Szkatuła | Professor Sinclair |
Dominique Lunter | Pushpa Raj Sharma |
Donald Fernandes | Pyung-Hwan Kim |
Dong Zhang | Qi Cai |
Dongliang Yang | Qi Manlin |
Dongyang Zhang | Qifan Li |
Dorianna Sandonà | Qingsen Shang |
Doriano Lamba | Qixuan Zheng |
Dorin Dragoş | Quan Pan |
Dorota Bartusik-Aebisher | Quoc-Viet Le |
Dorota Chełminiak-Dudkiewicz | Rabia Arshad |
Dorota Latek | Rachael Crist |
Duangjai Tungmunnithum | Rachid Touzani |
Dusan Dimic | Radoslaw Starosta |
Dzmitry Shcharbin | Radu Albulescu |
Ecevit Bilgili | Radu Claudiu Fierascu |
Eckart Haneke | Radu Racovita |
Eder Lilia Romero | Rafael Baltiérrez-Hoyos |
Edit Csapó | Rafael Castillo |
Edson Da Silva | Raffaele Palmirotta |
Eduardo Guzmán Solís | Raffaele Simeoli |
Eduardo Molina | Raghunadharao Digumarti |
Edward Sayers | Ragwa Farid |
Egor Verbitskiy | Raheel Ahmad |
Eiji Yuba | Rahul Mandal |
Eirini Christodoulou | Raisa N. Krasikova |
Eishin Morita | Raj Kumar |
Ekapol Limpongsa | Rajavel Krishnamoorthy |
Ekaterina F. Kolesanova | Rajeev K Singla |
Ekaterina Naumenko | Rajith Singh Manan |
Ekaterina Obluchinskaya | Rajiv Pathak |
Ekaterina Prikhozhdenko | Rajmohan Dharmaraj |
Ekaterina Yurchenko | Rajni Verma |
Ekaterini Goudouris | Raju Senthil Kumar |
Elaine Dunlop | Rakesh Patel |
Elamparuthi Ramasamy | Raluca Nicu |
Elena Dantes | Ram Sagar |
Elena Dinte | Ramanjaneyulu Rayala |
Elena Matei | Ramendra Pandey |
Elena Nikolskaya | Ramesa Bhat |
Elena Pincu | Ramiro López-Medrano |
Elena Ryabchikova | Ramon Barnadas-Rodríguez |
Elena Shipitsyna | Ramón Garduño-Juárez |
Elena Tchetina | Ramona Meanti |
Eleni Mavrogonatou | Ramya Tokala |
Eleonora Alfinito | Ran Zhang |
Eleonora Russo | Randal Buddington |
Eleonore Fröhlich | Rania Hamed |
Elham Kazemirad | Ranjit De |
Elina Genina | Raquel Bridi |
Elisa Belluzzi | Ravi Pratap Barnwal |
Elisa Zavattaro | Ravichandran Manickam |
Elisabete M. S. Castanheira | Ravindra Samarth |
Elisabete Santos | Raviraj Vankayala |
Elisabetta Gavini | Rebeca Busto |
Elise Margaretha Adriana Slob | Reda F. M. Elshaarawy |
Elrashdy Redwan | Reet Kurg |
Elsa Chan | Regina Kasperek |
Elvira Crescenzi | Renata Novak Kujundžić |
Elvira Grigorieva | Rene Buchet |
Elvira Rozhina | René Huber |
Elżbieta Grześk | Reza Shirazi |
Elzbieta Salinska | Rhitajit Sarkar |
Eman Mehanna | Ricardo Castro |
Emanuel Hernández Núñez | Ricardo Ferraz |
Emerson Coy | Riccardo Beltrami |
Emilia Janiszewska-Turak | Riccardo Di Corato |
Emilio Viñuelas-Zahínos | Richard Haynes |
Emma Adriana Ozon | Rimantas Daugelavicius |
Enas Eltamany | Ripon Sarkar |
Ener Dinleyici | Rita Muzzalupo |
Engy Elekhnawy | Rizwan Wahab |
Eric Chappel | Roald M. Tiggelaar |
Eric Ho | Rob Hunter |
Eric Huet | Robert Kleszcz |
Erik Alpizar-Reyes | Robert Lafrenie |
Erin Reed-Geaghan | Robert Liefke |
Eszter Ducza | Roberta Rocca |
Eugene V. Radchenko | Roberto Fabiani |
Eugenio Ragazzi | Robin Cooper |
Eun Ji Lee | Rodica Olar |
Éva Szökő | Rogerio Buchaim |
Evangelia Vouvoudi | Roman Lesyk |
Evgen Multia | Rong Lu |
Evgenia Sitnikova | Rong-Fu Chen |
Ewa Gniazdowska | Rosa María Oliart-Ros |
Ewa Huszcza | Rosanna Mallamaci |
Ewa Oledzka | Rosario Gulias Cañizo |
Ewa Piotrowska | Rosario Mare |
Ewoud B. Compeer | Roshan Katekar |
Fabrício S. Campos | Rossana Sirabella |
Fabrizio Martora | Rossen Todorov |
Facultad Farmacia | Rostyslav Bilyy |
Fa-Guang Zhang | Roxana Jijie |
Faisal Alzahrani | Roxana Liana Lucaciu |
Fangyu Zhang | Roxana Racoviceanu |
Fasih Bintang Ilhami | Ruggero Bettini |
Fateh Mebarek Oudina | Rui Han |
Fátima Martel | Rui Pereira |
Fatma El-Demerdash | Rui Tada |
Fatouma Mohamed Abdoul-Latif | Rui Zhou |
Federica Fogacci | Rumyana Simeonova |
Felicia Gabriela Gligor | Runze Li |
Felipe Chaves | Ruoxing Wang |
Fenglin Zhang | Ruslan Kashapov |
Feng-Qing Yang | Ruth Prieto-Montero |
Fernando Cardona | S. Ganguly |
Fernando Notario-Pérez | Sabina Fijan |
Filipa Mascarenhas-Melo | Sabine Matou-Nasri |
Filipe Sosa | Sabya Sachi Das |
Filippo Pierini | Saeed Bahadorikhalili |
Fiona McCartney | Sahar Zinatloo-Ajabshir |
Fiorenza Rancan | Sainitin Donakonda |
Fioretta Asaro | Sajal Sen |
Firzan Nainu | Sajjad Ahmad |
Flávia Leão Barbosa | Saket Patel |
Flavia Zacconi | Salvatore Gallo |
Fleming Martinez Rodriguez | Salvatore Magazu |
Florence Siepmann | Samad Nejad Ebrahimi |
Fortunato Iacovelli | Samet Özdemir |
Fotios Tsopelas | Samir Chtita |
Franc Vrečer | Samo Fokter |
Franca Zanardi | Samrita Dogra |
Francesca Buttini | Samuel Samnick |
Francesca Persano | Samuele Raccosta |
Francesco Ciccarese | Samy Jambon |
Francesco Maria Fusco | Sandeep Kumar Reddy Adena |
Francesco Sessa | Sandeep Urandur |
Francine Johansson Azeredo | Sandile Songca |
Francisco Alexandrino-Junior | Sandra Cabo Verde |
Francisco Arriagada | Sandra Cvijic |
Francisco Cortes-Benitez | Sandra Donnini |
Francisco Javier De La Mata | Sandy Eldridge |
Francisco José Ostos Marcos | Sanith Cheriyamundath |
Francisco Otero-Espinar | Sanjay Patel |
Franciska Erdő | Santiago Daniel Palma |
Frank Erdmann | Santiago Imperial |
Frank Krause | Sara Abdel Gaber |
Frank Rosenau | Sara Carmo |
František Trejtnar | Sara Granja |
Frédérique Servin | Sara Metwally |
Fredrik Huss | Sara Nava |
Fulden Ulucan Karnak | Sara Nicoli |
Fulvio Saccoccia | Sarah Tettamanti |
Furong Tian | Saravana Kumar |
Gábor Katona | Sarmad Al-Marsoummi |
Gabor Pethö | Sascha Rohn |
Gabriel De Lima | Sashi Debnath |
Gabriela Mellado-Sanchez | Sathish Dharani |
Gabriela Vochita | Saurabh Mishra |
Gabriele Maria Fortunato | Saverio Muscoli |
Gagandeep Saggu | Sawittree Sahakijpijarn |
Gajendra Jogdand | Sayali Onkar |
Gamaleldin Harisa | Sayed Goda |
Gangqiang Yang | Sayed Sartaj Sohrab |
Gangwei Pan | Sebastian Schwaminger |
Gantumur Battogtokh | Selestina Gorgieva |
Gareth R. Williams | Sergei Grishin |
Garry Kerch | Sergey Ilyin |
Garry Laverty | Sergey Kudryashov |
Geanina Voicu | Sergey Makarenko |
Geetha Bolla | Sergey Netesov |
Gema Navarrete | Sergey Sedykh |
Gennaro Lettieri | Sergio Caserta |
George Mihai Nitulescu | Sergio Comincini |
George Sharbeen | Serhii Holota |
Georgia Valsami | Serkan Yílmaz |
Georgios Pampalakis | Seunghoon Han |
Georgios Pappas | Shadma Wahab |
Gerardo Barbero | Shahinaze Fouad |
Gergő Tóth | Shahla Mirzaeei |
Gert Fricker | Shane Austin |
Gesmi Milcovich | Shang Su |
Ghassan Ghssein | Shantanu Gupta |
Ghulam Abbas | Shaobin Wang |
Gian Luigi Russo | Shaobo Ruan |
Giancarlo Morelli | Shawky Aboelhadid |
Gianina Dodi | Sheng Zhang |
Gil Fraqueza | Shengshuai Shan |
Giorgio Mangino | Sher Singh Meena |
Giorgio Treglia | Sherien Eldaly |
Giovanna Bruni | Sherif Fahmy |
Giovanna Della Porta | Shichao Ding |
Giovanna Rassu | Shigeru Kawakami |
Giovanna Rigillo | Shikha Agarwal |
Giovanni Colonna | Shingen Nakamura |
Giovanni Ribaudo | Shin-ichi Hirano |
Girish Kumar Gupta | Shinji Kawabata |
Girolamo Casella | Shinji Kobuchi |
Girum Getachew | Shinji Takamatsu |
Giulia Baldini | Shintaro Fumoto |
Giulia Bonacucina | Shiva Hemmati |
Giulia Di Prima | Shivani Rai Shivani |
Giulio Fracasso | Shu Yuan |
Giulio Sancini | Shuang Yang |
Giuseppe Biagini | Shubhra Saha |
Giuseppe Cirillo | Sibusiso Alven |
Giuseppe La Verde | Silvestre Bongiovanni Abel |
Giuseppe Perna | Silvia Bittner Fialová |
Giuseppe Pizzolanti | Silvia Carvalho |
Giuseppe Trapani | Silvia Tampucci |
Giuseppina Ioele | Silvio Naviglio |
Gopan Gopalakrishnan | Simona Căprărescu |
Gordana Wozniak Knopp | Simona Dedoni |
Graham Burgess | Simona Tomaselli |
Gratiela Tihan | Simona-Delia Nicoara |
Groo Anne-Claire | Simonetta D'Ercole |
Grzegorz Bartosz | Simons Svirskis |
Grzegorz Cieślar | Siriporn Okonogi |
Grzegorz Grześk | Siu Hong Dexter Wong |
Guanglin Zhang | Siva Rama Raju Kanumuri |
Guan-Jun Yang | Sivashanmugam Amirthalingam |
Guankui Wang | Slawomir Jakiela |
Guendalina Zuccari | Snehasis Bhakta |
Guilan Quan | Snježana Kaštelan |
Gulali Aktas | Sobhi Gomha |
Guo-Fu Li | Socorro Espuelas |
Guoping Guan | Sofia Lima |
Guoying Zhang | Sohail Mumtaz |
Guru Raghavendra Valicherla | Solomon Viswas Raja |
Guzel Ziyatdinova | Somdutt Mujwar |
Györgyi Műzes | Sonia Di Gaetano |
Hadel Abo El Enin | Sonia Gera |
Haijun Liu | Sónia Martins |
Hailong Qiu | Sophelia Hoi Shan Chan |
Hala B. El-Nassan | Sophia Borisevich |
Halilibrahim Ciftci | Sophia Hatziantoniou |
Hamed Nosrati | Søren Christensen |
Hamid Osman | Soubantika Palchoudhury |
Hamilton Cabral | Soumyarwit Manna |
Hamzah Babkair | Sounak Bagchi |
Hanady Nada | Spyridon Mourtas |
Hanan Elnahas | Sreekanth Reddy Obireddy |
Hani Naseef shtaya | Sreekumar Othumpangat |
Han-Joo Maeng | Srijit Das |
Hanna Harant | Srinivasa Reddy Bonam |
Hans Bäumler | Stanislav Naryzhny |
Hao Hu | Stanislaw Ołdziej |
Hao Wu | Stefan Kranz |
Harald Mischak | Stefan Oswald |
Harish Ramachandramoorthy | Stefania Galdiero |
Harm HogenEsch | Stefania Scialla |
Hashem Alsaab | Stefano Bacci |
Hassan Almoazen | Stefano Castellani |
Haya Lorberboum-Galski | Stefano Fais |
He Yin | Stefano Giovagnoli |
Heba Sahyon | Stelian Sergiu Maier |
Héctor García-Ortega | Stéphanie Briançon |
Hee Eun Kang | Stephen Atkin |
Helioswilton Sales-Campos | Stephen Baker |
Hend Abdel Bar | Stephen Inbaraj |
Herman Woerdenbag | Stephen Morris |
Hexiao Wang | Stephen Tomlin |
Hicham Elmsellem | Steven F. Gameiro |
Hidehiro Uekusa | Steven Shave |
Hidekazu Hiroaki | Subba Cheekatla |
Hideo Kato | SubbaRao Madhunapantula |
Hideyuki Kawauchi | Subhadip Mukhopadhyay |
Hiroki Ide | Subhankar Singha |
Hiromu Kondo | Subhas Karki |
Hiroshi Ueda | Sucharat Limsitthichaikoon |
Ho-Jin Lee | Sudarshan Singh |
Hong Wan | Sueli Fumie Yamada-Ogatta |
Honghua Hu | Suhaili Shamsi |
Hongli Li | Sukanya Saha |
Hongliang Wang | Sulev Kõks |
Hongping Deng | Suman Dutta |
Hongwei Cheng | Sumeet Patiyal |
Hooi-Leng Ser | Sung-Wook Nam |
Hossam Hassan | Supandeep Hallan |
Hossein Roghani-Mamaqani | Supriya Chakraborty |
Hsiang-Ning Luk | Suresh Babu Naidu Krishna |
Hua Wei | Suresh Verma |
Huan Pang | Susanne Haga |
Hugh Byrne | Susanne Muschert |
Hugo Espinosa Andrews | Susanne Wiedmer |
Hugo Lisboa | Susi Burgalassi |
Huihua Yuan | Suttipun Keawsompong |
Hussein Touliabah | Svetlana Jeremić |
Hyuck Jin Lee | Svetlana Saikova |
Ian Burgess | Svetoslav Todorov |
Ichiro Takada | Swarbhanu Sarkar |
Ichwaku Rastogi | Swarup Roy |
Ignacija Vlašić | Syed Ali Raza Naqvi |
Ignacio Rintoul | Syed Mahmood |
Ignacio Rodríguez-García | Syed Mohd Faisal |
Igor Eliseev | Syed Nasir Abbas Bukhari |
Igor Slivac | Sylva Holešová |
Ik-Hwan Kim | Syoichi Tashiro |
Ilaria Cacciotti | Tachita Vlad-Bubulac |
Ilaria Rubino | Taiki Miyazawa |
Iliana Medina-Ramirez | Takashi Yazawa |
Iliyan Ivanov | Takayuki Furuishi |
Ilkay Erdogan Orhan | Takehisa Hanawa |
Illimar Altosaar | Takemichi Fukasawa |
Ilya Khodov | Takumi Abe |
Ilya Klabukov | Tamara Lazarevic-Pasti |
Ilya Ozhogin | Tamas Kalai |
Iman Alfagih | Tamas Lazar |
Indranil Chakraborty | Tamás Sovány |
Innokenty Mokhosoev | Tamás Szabó |
Ioana Corina Bocsan | Tamer Sakr |
Ioana Stanculescu | Tanja Jurkin |
Ioana-Mirela Vasincu | Tanja Miličić |
Ioannis Nikolakakis | Tao Wang |
Ioannis Tsamesidis | Tarsila Castro |
Iolanda De Marco | Tatiana Rakitina |
Ion Calina | Tejeshwar Rao |
Irena Nalepa | Telbisz Ágnes |
Irene Buj-Corral | Teresa Esteves |
Irene Ottaviani | Teresa Vinuesa |
Irfan Khan | Teruo Murakami |
Irina Balalaeva | Thawatchai Phaechamud |
Irina Le-Deygen | Theofanis Vavilis |
Irina Terekhova | Thomas Mürdter |
Isaac Boateng | Tianyu Jiang |
Islam Khalil | Tilahun Debele |
Ismael Hernández-Ávalos | Tim Mahony |
Ismaheel Lawal | Timothy Hubin |
Issa Al-Amri | Tina Kauss |
István Antal | Tivadar Kiss |
István Budai | Tomas Etrych |
Istvan Csarnovics | Tomasz Gębarowski |
Istvan Lekli | Tomasz M. Karpinski |
Itziar Chapartegui-González | Tomasz Szymborski |
Ivan Gitsov | Tomislav Tosti |
Ivan Koprivica | Tonghe Zhu |
Ivan Savic | Tongran Qin |
Ivan Stoikov | Toni Todorovski |
Ivana Aleksić | Tony Le Gall |
Ivana Drvenica | Toshi Nagata |
Ivaylo Dimitrov | Toyofumi Suzuki |
Iwona Golonka | Triantafyllos Didangelos |
Iyan Sopyan | Tudor Pop |
Izabel Cristina Rodrigues Da Silva | Tzung-Han Chou |
Izabela Zakrocka | Ubaldo Armato |
Iztok Grabnar | Udaya Sree Dakarapu |
Jacek Wilczyński | Ugo D'Amora |
Jack Kottwitz | ugo de Grazia |
Jaejong Park | Ulf Anderegg |
Jafar Rezaie | Urmi Roy |
Jagpreet Singh | Usman Ghafoor |
Jaime Charris | V. H. Giang Phan |
Jaime Conceição | Vadim Elagin |
Jaime Mella-Raipán | Vahid Jahed |
Jaime Santoyo-Salazar | Valdir Veiga-Junior |
Jamal Rafique | Valentina Dini |
James Chow | Valentina Madia |
James G Hecker | Valeria Milam |
Jamie Rausch | Valérie Vanhoorne |
Jan Kamps | Valery V. Likhvantsev |
Jan Zidek | Van Du Nguyen |
Jandeep Singh | Van-An Duong |
Janet Kumita | Vanessa Bergamin Boralli Marques |
Janice Aldrich-Wright | Vangelis Daskalakis |
Janja Trček | Vangelis Economou |
Jarek Baran | Vangelis Karalis |
Jaroslav Pejchal | Vanja Tadić |
Jarosław Przybył | Vanja Travičić |
Jasna Prlić Kardum | Vanya Bogoeva |
Javed Iqbal | Vanya Mantareva |
Jayakumar Rangasamy | Vasanthan Ravichandran |
Jayanta Kumar Patra | Vasil Garamus |
Jean-Philippe Therrien | Vasileios P. Papadopoulos |
Jeffrey Bryant Travers | Vasileios Papavasileiou |
Jeffrey Wang | Vasilii Otvagin |
Jelena Radovanović | Vasily Aleshin |
Jelena Roganovic | Vassya Stefanova Bankova |
Jennifer Patterson | Veera Venkat Shivaji Rama Rao Edupuganti |
Jennifer Walsh | Velichka Andonova |
Jens Andre Hammerl | Venerando Pistarà |
Jeong Heo | Venkat Chirasani |
Jeremy Robertson | Venkata Krishna Kowthavarapu |
Jesús Adrián López | Victor I. Sevastianov |
Jesús Hernández | Victor Kuz'min |
Jia Xian Law | Victor Martin |
Jiafu Cao | Victor Seledtsov |
Jian Wu | Viet-Khoa Tran-Nguyen |
Jianan Zhao | Vikas Anand Saharan |
Jiangjiang Gu | Vikas Bali |
Jianlin He | Vikram Dalal |
Jiao Sun | Viktor Zvarych |
Jiawei Wang | Viliana Gugleva |
Jie Tian | Vinh Le Ba |
Jie Wang | Violeta-Carolina Niculescu |
Jin Gao | Vishakha Tambe |
Jinbo Fei | Vjekoslav Peitl |
Jing Zhang | Vladimir Ivanov |
Jingan Li | Vladimir Korshun |
Jing-Jie Wang | Vladimir Tikhonov |
Jinlong Liu | Volodymyr Oberemok |
Jintamai Suwanprateeb | Vrinda Gote |
Jinxiang Xi | Wajid Rehman |
Jinzhi Han | Wakako Fujita |
Jitendra Kumar Tripathi | Waldemar Wagner |
Joachim Storsberg | Walied Abdo |
Joanna Czerwińska | Wanderley Oliveira |
Joanna Jaworska | Wangxiao He |
Joanna Sadowska | Wanhe Wang |
Joanna Sobiak | Waqas Alam Mir |
Joanna Wessely-Szponder | Wei Huang |
João Basso | Wei Jiang Goh |
João Henrique G. Lago | Wei Min Min |
Joao Silva | Wen Hai Shao |
Joaquim C. G. Esteves Da Silva | Wen Shi |
Joaquim Jaumot | Wendy Bollag |
Joaquim Suñer-Carbó | Wenjie Zhou |
Joaquin González-Marrero | Wenjing Tao |
Jochen Maurer | Wenliang Song |
Joe Viljoen | Wenqiang Wei |
John Dirk Vestergaard Nieland | Wenyi Li |
John Jackson | Wing Wong |
John M. Perry | Wojciech Szlasa |
John Mack | Xiangxian Ying |
Jolanta Gawałek | Xiaogang Zhang |
Jongho Park | Xiaoguang Liu |
Joni H. Ylostalo | Xiaoming Lyu |
Jörg Opitz | Xiaosheng Tan |
Jorge Feito | Xiaoshu Pan |
Jorge Padrão | Xiaoyang Liu |
Jørn Bolstad Christensen | Xiaoyu Yan |
José A. García-Sanz | Xin Li |
José B. Fariña | Xin Tong |
José Catita | Xinhong Chen |
Jose Escobar Chavez | Xinquan Liu |
José Fernando Fierro | Xinyu Ling |
José Justicia | Xueqin Gao |
Jose M Mendez-Arriaga | Xun Tao |
José Rafael de Almeida | Yamini Krishnan |
José Ramiro Fernandes | Yan Li |
José Ramón Moyano-Mendez | Yan Zhang |
Jose Tudela | Yan Zubavichus |
Jose V. Parambil | Yan-Ming Xu |
Josefa Gonzalez-Santos | Yannick Vallée |
José-María Sánchez-González | Yannis Dotsikas |
Joseph Govan | Yannis Karamanos |
Josip Matić | Yanyan Cui |
Josué Juarez | Yanyan Dong |
Jovana Vunduk | Yaohua Wei |
Juan Guzman-Flores | Yara MichelacciI |
Juan J. Torrado | Yasemin M. Akay |
Juan Lázaro-Martínez | Yashpal Singh Chhonker |
Juan Manuel Germán-Acacio | Yasin Tülüce |
Juan Pablo Rigalli | Yasser Shahzad |
Jue Ling | Yasushi Arano |
Jui-Hung Yen | Yen-Ho Chu |
Julian Freen-van Heeren | Yifei Jin |
Julian Muñoz | Yimei Jia |
Juliana Faria | Yin Zhao |
Julijana Kristl | Yingbin Hu |
Jun Liu | Yinghuai Zhu |
Junbo He | Yishen Zhu |
Junmei Wang | Yogesh Sutar |
Junwei Shi | Yogeswaran Lokanathan |
Junzi Wu | Yohann Corvis |
Juraj Piestansky | Yolanda Moliner |
Jurca Tunde | Yong Hu |
Jyawei Cheng | Yongjun Sui |
Kabirullah Lutfy | Yongmin Yan |
Kaili Ma | Yongsheng Chen |
Kamil Gareev | Yordanka Uzunova |
Kamil J. Kuder | Yoshiyuki Kubo |
Kamyar Khoshnevisan | Yosuke Senju |
Kang Lei | Youness Limami |
Karel Allegaert | Young Hwa Soung |
Karen Liby | Young Zoon Kim |
Karim Osouli Bostanabad | Young-Whan Choi |
Karl Tsim | Youssef Ibrahim |
Karol Wróblewski | Yu Toyoda |
Karola Vorauer-Uhl | Yu Zhang |
Karthik Kanagaraj | Yuriy Knyazev |
Katalin Sipos | Yuan Liu |
Katarina Smiljanić | Yuanyuan Shi |
Katarzyna Krukiewicz | Yücel Ba̧spinar |
Katarzyna Malarz | Yuchao Lu |
Katarzyna Sosnowska | Yuerou Zhang |
Katarzyna Turecka | Yuhki Satou |
Katerina Takova | Yuh-Yih Lin |
Katharina M. Rentsch | Yuichi Ohya |
Katherine Wall | Yulia Kondratenko |
Kathiravan Suppan | Yung-Hsiang Chen |
Katie Ardipradja | Yunhai Cui |
Katsuhisa Inoue | Yunia Verónica García Tejeda |
Kausik Bishayee | Yunwen Tao |
Kavindra Nath Tiwari | Yuqin Zhang |
Kazuhiro Tsuchiya | Yutaka Ohsedo |
Kazuomi Sato | Yutian Ma |
Ke Cheng | Yutian Zou |
Kejun Dong | Yuyan Jiang |
Kemao Xiu | Yuyang Jiang |
Kenji Hayashida | Yves Bayon |
Kenji Ono | Zacharoula Iatridi |
Kentaro Kato | Zeid ALOthman |
Kenzo Koike | Zeljko Petrovski |
Keumhan Noh | Zhanchao Li |
Keun-Yeong Jeong | Zhanying Hu |
Kevin Dzobo | Zhaoqing Cong |
Kevin Ita | Zhao-Ying Liu |
Kevin T. Batty | Zhen Xiao |
Kevin Ward | Zheng Jiao |
Khalil Karimi | Zhengwei Huang |
Ki-cheong Park | Zhengzhong Tan |
Kifayat Ullah Shah | Zhenjia Wang |
Kim Van Vliet | Zhenyu Wang |
Kiran Lokhande | Zhixin Jia |
Kirill Cherednichenko | Zhiyong He |
Kirill Laptinskiy | Zhiyuan Xu |
Kishwor Poudel | Zhonglei Wang |
Kit-Leong Cheong | Zihua Wang |
Kohei Yamada | Zihua Zeng |
Kok Lun Pang | Zilvinas Anusevicius |
Konstantin Volcho | Ziwan Xu |
Konstantinos Dimas | Zofia Mazerska |
Konstantinos Gardikis | Zoltán Bánóczi |
Kordali Saban | Zoltan Szucs |
Koteshwara Mudigonda | Zorana Dobrijević |
Koyeli Girigoswami | Zuohui Zhang |
Krishna Sharma | Zuoxu Xie |
Krishna Yadav | Zvezdelina Yaneva |
Krishnan Sriram | Zygmunt Warzecha |
Krist V. Gernaey |
31 January 2024
MDPI Insights: The CEO's Letter #8 - Altmetric and Flat Fee Agreement
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
MDPI and Digital Science Meeting
At MDPI, we are committed to providing our authors with the essential tools to publish, promote, and track their research. In line with this commitment, we have established a longstanding collaboration with Digital Science, a company specializing in research data and analytical insights for the research community. Our collaboration integrates their Altmetric tool, offering us and our authors the ability to track a variety of sources that monitor and report attention surrounding publications.
As part of our collaboration, we recently hosted Cathy Holland, Director of Global Publisher Business Development, and Helen Cooke, Managing Director of Publisher Sales, from Digital Science, at our MDPI headquarters in Basel, Switzerland.
Left to right: Facundo Santomé (Senior Marketing Manager, MDPI), Constanze Shelhorn (Indexing Manager, MDPI), Cathy Holland (Director of Global Publisher Business Development, Digital Science), Helen Cooke (Managing Director of Publisher Sales, Digital Science), and Stefan Tochev (CEO, MDPI) in front of MDPI headquarters in Basel, Switzerland.
During our meeting, we discussed MDPI’s publishing philosophy and explored further avenues for collaboration. We look forward to continuing our partnership with Digital Science, aiming to improve our services yet further and meet the needs of our authors more closely than ever.
What is Altmetric?
You will notice that MDPI articles feature an Altmetric score, a colourful doughnut capturing the score in the upper right corner of the article page. This score represents ‘alternative metrics,’ as distinct from traditional metrics such as Impact Factor, CiteScore, and Scimago Journal Rank.
Altmetrics complement traditional citation-based metrics by capturing online discussions related to a specific research topic. By analyzing both sets of data, we can obtain a comprehensive understanding of the attention a particular research output receives and the sources in which it is mentioned.
“Almetric provides visual insights into where research is being discussed”
Sources Tracked by Altmetric
Altmetric badge showing the Altmetric score and colour-coded mention sources.
Altmetric monitors various sources, categorizing them into segments such as policy documents, peer reviews, Wikipedia, news and blogs, and social media, among other sources. Each category is identifiable by a specific colour.
The Altmetric badge provides visual insights into where the research is being discussed. A more colourful badge indicates broader mentions across multiple platforms. Such tracking enables us to gauge the extent of an article’s online dissemination, noting that increased visibility may correlate with higher citation rates.
Read more:
Impactful Research
Ten High-Altmetric Articles Published by MDPI
As at 30 January 2024, Altmetric has tracked 670,500 MDPI research outputs from MDPI, resulting in over 4.3 million mentions. This includes over 71,894 mentions in policy and patents and 294,714 mentions in news and blogs, with some achieving an Altmetric score as high as 28,754.
So, what is a good Altmetric score? There are various ways to put this score into context. You can find out more about the score in context and how to evaluate your work by this means.
Here are ten MDPI papers ranking in the top 5% of all research outputs scored by Altmetric.
“Accuracy in Wrist-Worn, Sensor-Based Measurements of Heart Rate and Energy Expenditure in a Diverse Cohort” J. Pers. Med. 2017, 7(2), 3; https://doi.org/10.3390/jpm7020003 Altmetric page: https://mdpi.altmetric.com/details/20477344 Altmetric shows that this article appeared in 253 news stories from 209 outlets including Forbes, BBC, and Fox News. |
|
“Daylight Saving Time and Acute Myocardial Infarction: A Meta-Analysis” J. Clin. Med. 2019, 8(3), 404; https://doi.org/10.3390/jcm8030404 Altmetric page: https://mdpi.altmetric.com/details/57654628 Altmetric shows that this article appeared in 295 news stories from 207 outlets including Forbes, The Atlantic, and New York Times. |
|
“The Preliminary Analysis of Cave Lion Cubs Panthera spelaea (Goldfuss, 1810) from the Permafrost of Siberia” Quaternary 2021, 4(3), 24; https://doi.org/10.3390/quat4030024 Altmetric page: https://mdpi.altmetric.com/details/111086701 Altmetric shows that this article appeared in 182 news stories from 134 outlets including CBC News, CNN, and National Geographic. |
|
“Not the Cat’s Meow? The Impact of Posing with Cats on Female Perceptions of Male Dateability” Animals 2020, 10(6), 1007; https://doi.org/10.3390/ani10061007 Altmetric page: https://mdpi.altmetric.com/details/83796184 Altmetric shows that this article appeared in 124 news stories from 98 outlets including VICE, CNN and The Guardian. |
|
“Behaviour and Welfare Impacts of Releasing Elephants from Overnight Tethers: A Zimbabwean Case Study” Animals 2022, 12(15), 1933; https://doi.org/10.3390/ani12151933 Altmetric page: https://mdpi.altmetric.com/details/133463915 Altmetric shows that this article appeared in 192 news stories from 186 outlets. |
How do I use altmetrics?
Altmetric Explorer provides a detailed step-by-step guide and instruction video for first-time users of the tool. The guide includes useful diagrams that make it easy to get started.
Sharing Research Online
For research to be tracked across different sources, Altmetric needs a research output with a persistent identifier: a DOI, ISBN, PubMed ID, handle ID, etc. When sharing research, it is important to include a link to the original research output.
“An Update on Eukaryotic Viruses Revived from Ancient Permafrost” Viruses 2023, 15(2), 564; https://doi.org/10.3390/v15020564 Altmetric page: https://mdpi.altmetric.com/details/142929875 Altmetric shows that this article appeared in 250 news stories from 180 outlets including CTV, Fox News, and CNN. |
|
“The Global Problem of Insufficient Sleep and Its Serious Public Health Implications” Healthcare 2019, 7(1), 1; https://doi.org/10.3390/healthcare7010001 Altmetric page: https://mdpi.altmetric.com/details/53406248 Altmetric shows that this article appeared in 252 news stories from 168 outlets including BBC, Harvard Business Review, and Forbes. |
|
“A Detailed Review Study on Potential Effects of Microplastics and Additives of Concern on Human Health” Int. J. Environ. Res. Public Health 2020, 17(4), 1212; https://doi.org/10.3390/ijerph17041212 Altmetric page: https://mdpi.altmetric.com/details/86529137 Altmetric shows that this article appeared in 197 news stories from 150 outlets including BBC, The Tribune, and World Economic Forum. |
|
“An Empirical Study of Chronic Diseases in the United States: A Visual Analytics Approach to Public Health” Int. J. Environ. Res. Public Health 2018, 15(3), 431; https://doi.org/10.3390/ijerph15030431 Altmetric page: https://mdpi.altmetric.com/details/34714141 Altmetric shows that this article appeared in 232 news stories from 149 outlets including Forbes, New York Times, and Harvard Business Review. |
|
“Garden Scraps: Agonistic Interactions between Hedgehogs and Sympatric Mammals in Urban Gardens” Animals 2023, 13(4), 590; https://doi.org/10.3390/ani13040590 Altmetric page: https://mdpi.altmetric.com/details/142934305 Altmetric shows that this article appeared in 172 news stories from 168 outlets including BBC. |
Inside MDPI
MDPI Annual Meeting Celebrations in China
On Thursday 25 January, over 1,300 MDPI colleagues from our two offices in Beijing gathered to kick off MDPI’s traditional ‘Annual Meetings.’ These celebrations take place in MDPI’s offices across China, including Dalian, Tianjin, Wuhan, and Nanjing.
The evenings include performances, informative talks and presentations, awards, and entertainment, providing an ideal platform to recognize our colleagues, celebrate their achievements, and set our sights on the future.
“It is essential that we stay connected and share best practices”
I sent a video congratulating everyone on their work and sharing our vision of building MDPI into the most trusted OA publisher, highlighting the roles each of us has to play in achieving that goal.
Unfortunately I could not join in person, but you may recall my recent trip, when I visited our offices in Beijing and Wuhan, which I look forward to visiting again this year.
Although our headquarters are in Basel, Switzerland, and we are expanding throughout Europe and North America, the majority of MDPI’s workforce is in China and throughout the Asia-Pacific region, including offices in Singapore, Thailand, Japan, and newly opened office in South Korea. It is essential that as a global organization, we stay connected and share best practices in order to grow collectively and continue providing the exceptional service to our authors.
The Annual Meeting is a moment to reflect and enjoy the year’s hard work and dedication.
I extend our best wishes to all for the Chinese New Year (Xīnnián kuàilè)!
Coming Together for Science
MDPI and TU Delft Adopt Flat Fee Model in Extended Partnership
We are excited to announce a renewed three-year partnership with Delft University of Technology (TU Delft) in the Netherlands. This collaboration introduces a fixed lump-sum fee, covering publishing costs from 2024 to 2026.
“This initiative reflects our dedication to transparent and inclusive publishing”
TU Delft-affiliated authors will enjoy cost-free publishing in any MDPI journal during this period, aligning with our commitment to removing barriers for open access publishing. The agreement supports Plan S compliance and facilitates a seamless publishing process for TU Delft corresponding authors. This initiative reflects our dedication to transparent and inclusive publishing, providing stability and predictability both for authors and for institutions.
For further details on our Institutional Open Access Program (IOAP), please contact us.
Benefits to MDPI’s IOAP
At MDPI we have a long tradition of partnerships, including our Institutional Open Access Program (IOAP). IOAP supports institutions through simplification, access, transparency, APC discounts, and institutional repository deposits. The program simplifies administrative processes, offers central payment, and allows easy opting in and out. Participants gain free access to Susy, MDPI’s online submission system, with extensive article metadata and exportable data. APC discounts and Book Processing Charge discounts are available for affiliated authors. Automated deposits to institutional repositories and streamlined matching of papers to IOAP participants enhance the overall experience.
For further information, see our IOAP FAQ.
Closing Thoughts
Reflections on the 2024 APE Conference
MDPI was proud to co-sponsor the Academic Publishing in Europe (APE) 2024 Conference that took place in Berlin, Germany, from 9–10 January 2024.
The conference theme, ‘Keep the Conversation Going!’, explored the evolving landscape of scholarly communication. APE is one of the key conferences I make a point to attend each year. January offers a valuable opportunity to engage with new contacts, reconnect with familiar faces, and participate in impactful discussions and presentations among professionals, scholars, and practitioners in the field.
“It's fascinating to see how other publishers are leveraging AI”
Highlights
Some of the standout panels for me include: the role of the UN Sustainable Development Goals (SDGs) within the publishing industry. It was encouraging to hear the current status quo, though I was eager also to learn about the exciting projects planned for 2024 and beyond. These will allow us to track progress in subsequent years. At MDPI, we remain committed to promoting Open–Access (OA) content on SDGs through scientific articles and books. Furthermore, we extend our commitment to sustainability by financially supporting researchers through initiatives such as the World Sustainability Award and the Emerging Sustainability Leader Award, as well as waiving the APC for feature papers on each SDG.
In recent years, discussions on AI have become increasingly prominent at such conferences. It’s fascinating to see how other publishers are leveraging AI to meet the evolving needs of their audiences while at the same time using it to safeguard the scientific process. Other engaging panels that I enjoyed included updates on transformation beyond transformative agreements, the principles of lean change, incentive structures related to research integrity, and the panel on reviewer incentives.
“We can share best practices and lessons learned”
Incorporating MDPI’s Insights into Conferences
I must confess that I sometimes feel overlooked when MDPI is not invited to participate in crucial industry discussions. As the leading open access publisher and the third-largest publisher overall, we possess extensive experience in many of these areas and can offer valuable contributions to these discussions. We can share best practices, lessons learned, and our thinking about future trajectories. For instance, in panels discussing reviewer incentives, at MDPI we offer a discount voucher to reviewers for future submissions, reflecting our commitment to fostering a robust peer review process. In 2022 alone, MDPI collected over 1.4 million peer review reports, informing the decision-making processes of our editors. Given our expertise in these areas, it would be natural to include MDPI in such discussions. I therefore extend an invitation to future conference organizers to consider MDPI for speaking engagements and collaborative opportunities.
Chief Executive Officer
MDPI AG
9 January 2024
Meet Us at the 14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 18–21 March 2024, Vienna, Austria
Conference: The 14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology
Date: 18–21 March 2024
Location: Vienna, Austria
MDPI will be attending the 14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology at Booth #06, and we welcome researchers from different backgrounds to visit and share their latest ideas with us.
This conference has had an ever-increasing impact among pharmaceutical scientists, and it is organized every two years, in March or April of even years.
The entire spectrum of topics ranging from engineering aspects of the manufacturing process, the portfolio of commercially available excipients enabling the formulation of a large variety of medicinal products, the underlying physico-chemical principles, cutting-edge characterization techniques as well as potential pitfalls and hurdles to be overcome during product development, manufacturing and characterisation will be addressed.
Young and experienced scientists from academia and industry will present their latest research achievements in the form of poster presentations, allowing for fruitful scientific exchanges with the authors.
The meeting is intended to bring together people working in fundamental and applied academic research, in the chemical and pharmaceutical industry and the regulatory field, offering the opportunity to initiate fruitful discussions and collaborations.
The following MDPI journals will be represented:
- Pharmaceutics;
- Pharmaceuticals;
- IJMS;
- DDC;
- Molecules;
- Biomedicines;
- CIMB;
- Applied Biosciences;
- BioMedInformatics;
- Medicines;
- Cosmetics;
- Biomolecules.
2 January 2024
MDPI Insights: The CEO's Letter #7 - Nobel Laureates Entrust MDPI with Their Research
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
Nobel Prize Laureates Entrust MDPI with Their Research
The Nobel Prize stands as a hallmark of distinction, honouring ground-breaking research across disciplines. Annually, the Nobel Prizes are awarded in six categories: Physics, Chemistry, Medicine or Physiology, Literature, Peace, and Economic Sciences.
Through the years, renowned scholars have entrusted MDPI with their work. As at December 2023, 26 Nobel laureates have contributed to more than 75 articles across 25 MDPI journals, including: Antibiotics, Applied Sciences, Biology, Biomedicines, Cancers, Catalysts, Cells, Crystals, Entropy, Games, IJMS, Life, Materials, Micromachines, Molecules, Pharmaceuticals, Pharmaceutics, Photonics, Quantum Beam Science, Remote Sensing, Sensors, Solids, Universe, Vaccines, and Viruses.
The best of the best trust us with their work.
Nobel Prize Laureates Who Have Published with MDPI
We are proud to list the names of Pierre Agostini, Hiroshi Amano, Werner Arber, Aaron Ciechanover, Robert H. Grubbs, Oliver Hart, Gerard ‘t Hooft, Michael Houghton, Harald zur Hausen, Katalin Karikó, Jean-Marie Lehn, Gérard Mourou, Ferid Murad, Shuji Nakamura, William Nordhaus, Kostya S. Novoselov, Giorgio Parisi, Charles M. Rice, Alvin E. Roth, Donna Strickland, K. Barry Sharpless, George F. Smoot, Anne L’Huillier, Drew Weissman, Kurt Wüthrich, Ada Yonath.
The privilege of hosting such contributors resonates deeply with our editorial teams. For instance, in this interview, the Editor-in-Chief (EiC) of Universe speaks on the significance of publishing a paper by Nobel laureate Gerard ’t Hooft within the journal.
2023 Nobel Prize Winners Published by MDPI
Nobel Prize Winners, 2023: Katalin Karikó, Drew Weissman, Anne L’Huillier (Ill. Niklas Elmehed © Nobel Prize Outreach)
Three laureates from the 2023 Nobel Prize cohort have trusted MDPI as their publishing platform. Notably, in a 2022 Pharmaceutics paper, molecular biologist Katalin Karikó and her team presented a methodology for evaluating mRNA capping efficiency, pivotal for therapeutic applications. Pharmaceutics had previously dedicated a Special Issue to “mRNA Therapeutics: A Themed Issue in Honor of Professor Katalin Karikó”, spotlighting ten articles from August 2021 to February 2022.
In the journal Vaccines, Professor Drew Weissman, collaborating with scholars from Pennsylvania University and George Mason University, contributed an influential review titled “Nanomaterial Delivery Systems for mRNA Vaccines”. His collaborative efforts spanned five papers across MDPI journals between 2021 and 2023.
Furthermore, Anne L'Huillier of Lund University, only the fifth female recipient of the Physics Prize, co-authored an article in Applied Sciences focusing on "Advanced EUV and X-Ray Optics". Similarly, Pierre Agostini, an Emeritus Professor from Ohio State University, co-authored an article featured in the special issue "Attosecond Science and Technology: Principles and Applications".
We extend heartfelt congratulations to all Nobel Prize laureates and express sincere gratitude for their confidence in MDPI as a platform for their scholarly contributions.
Read more:
Impactful Research
MDPI Journals Newly Indexed in 2023
The aim of indexing is to enhance the quality and credibility of published research, ensuring that researchers access the most credible resources available. While the principle behind citation indexing is straightforward, it remains one of the most dependable methods for tracking an idea's evolution across various scientific disciplines.
Throughout the year, MDPI works to expand the reach of our publications across premier multidisciplinary databases like Web of Science, Scopus, EBSCO, and ProQuest. This initiative is spearheaded by MDPI's Indexing team, under the leadership of Dr. Constanze Schelhorn.
In 2023, MDPI achieved 54 new acceptances in Scopus, 29 in Web of Science, 52 in EBSCO, and 83 in DOAJ: Directory of Open Access Journals.
The team prioritizes ensuring that our journals feature in numerous specialized databases, including PMC, PubMed, MEDLINE, Inspec, CAS, and FSTA, among others. Currently, MDPI collaborates with over 65 renowned international databases, consistently enhancing our database affiliations annually.
MDPI’s journals are indexed in all major global databases.
Furthermore, we collaborate with universities and government organizations to list our journals in country-specific ranking lists and relevant institutional repositories. This ensures compliance with requirements often set by funders or institutions for authors to publish in specific journals.
Web of Science Adds 24 MDPI Journals to Emerging Sources Citation Index (ESCI)
Clarivate recently analysed MDPI’s new journals, resulting in 24 journals, mainly established in 2020, being added to the ESCI in November and December 2023. Additionally, five journals passed this assessment earlier in the year. For a complete list of our journals in Web of Science, refer here. Journals in the ESCI meet 24 quality criteria, ensuring editorial rigor. They may be considered for inclusion in broader indices like the Science Citation Index Expanded (SCIE), the Social Sciences Citation Index (SSCI), or the Arts and Humanities Citation Index (AHCI), based on four impact criteria.
Read more:
Inside MDPI
MDPI Appoints New Chief Operating Officer (COO)
Alistair Freeland returned to MDPI and assumed the role of Chief Operating Officer in November 2023, a position he previously held from 2013 to 2019. He succeeds Dr. Yu Lin, who will remain a member of MDPI’s Board of Directors, overseeing significant financial decisions for the company. I would like to express my sincere thanks to Dr. Yu Lin for his service as COO.
Alistair brings extensive experience not only in scholarly publishing but also in technology and business management. Prior to rejoining MDPI, he was associated with SIX Group, the entity responsible for Switzerland's financial market infrastructure. There, he played a pivotal role in developing the blockchain-based platform SDX (SIX Digital Exchange), which has gained traction among major Swiss banks and the Swiss National Bank.
As COO, Alistair will collaborate with the MDPI management team to improve the practices and services we offer to scholarly communities. I am pleased to welcome Alistair back to MDPI and look forward to his contributions going forward.
Coming Together for Science
MDPI’s 2024 In-Person Academic Events Schedule
MDPI's Conference Team is dedicated to organizing and hosting in-person academic events across Europe, Asia-Pacific, and North America. We recognize conferences as invaluable platforms for scientific collaboration, scholarly exchange, discussions on contemporary topics, networking, and forging collaborations.
Here's a glimpse of the notable events we currently have scheduled for 2024:
14–16 February, 2024 |
|
24–26 April, 2024 |
|
28–31 May, 2024 |
|
1–4 August, 2024 |
Upcoming events with details to be announced:
- September 2024, Materials 2024 – Basel, Switzerland
- 19–21 September 2024, International Conference on Nanomaterials Sciences 2024 – Beijing, China
- October 2024, ncRNA 2024 – Basel, Switzerland
- November 2024, Pharmaceuticals 2024 – Barcelona, Spain
- 22–26 November 2024, International Conference on Science of Electronics – Wuhan, China
- Stay tuned for more details on the Sustainable Publishing Forum 2024.
Click here for all upcoming MDPI events.
Organize Your Event with MDPI’s Sciforum
Sciforum is MDPI’s platform dedicated to the organization of scientific events. In line with our mission to promote science, Sciforum supports scholars, societies, research networks, and universities at all stages of organizing in-person events, virtual events and webinars. Our platforms are efficient, user-friendly, and cost-effective. We handle all steps related to event management. Contact us for details.
Closing Thoughts
Reflecting on 2023 and Looking Ahead to 2024
As we approach 2024, I reflect on the incredible journey we’ve had together at MDPI this year. The past 12 months have been marked by ambitious projects and initiatives to improve our internal processes, and a commitment to continue delivering top-notch services to our stakeholders. I’d like to thank each and every one of our staff members for contributing to the positive experiences our stakeholders have reported in our surveys. Your dedication to speed, efficiency, and effective communication with our stakeholders is very much recognized and appreciated.
Becoming a stronger organisation
While we have encountered challenges in 2023, it’s important to understand that these are a part of our growth process. Difficulties provide us with opportunities to reflect, address problems at their roots, and ultimately evolve into a stronger organization. Our stakeholders expect us to overcome tough times, and it’s an expectation that we have for ourselves.
I extend my sincere appreciation to every MDPI employee, from our editorial office and IT department to marketing, indexing, IOAP, societies, Scientific Office board, products, production, conferences, finance, operations, admin, and beyond. To our newest team members, a warm welcome; to our longstanding colleagues, your dedication is invaluable.
“I am committed to taking MDPI to a new level of excellence.”
Interacting with many of you during my visits to our offices and representing MDPI at external events has been a personal highlight. I am deeply grateful to Dr. Lin for entrusting me with the role of CEO of MDPI. Looking forward, I am committed to working closely with our management team to lead MDPI and take it to a new level of excellence, aiming to establish it as the most trusted publisher in open access worldwide. This is a collective endeavour, with each of us shaping MDPI’s reputation. I therefore encourage us to take pride in our work, as it represents not only our craft but also MDPI as a whole.
Accountability and communication
As we look forward to 2024, there’s a lot to be excited about. Together, we’ll navigate challenges, seize growth opportunities, and refine our practices. To solidify MDPI’s position as the premier open access publisher globally, we must bolster accountability, improve stakeholder communication, share MDPI’s best practices, champion the open access philosophy, and educate stakeholders about our mission, methodologies, and motivations.
Thank you for engaging with the CEO Letter over the past six months of 2023. I will continue to release this newsletter as a method of sharing the great work being done at MDPI. Please feel free to connect directly with any insights or questions.
Here’s to a joyous and prosperous 2024!
Chief Executive Officer
MDPI AG
26 December 2023
Pharmaceutics Editor-in-Chief Prof. Patrick J. Sinko Joins 2023 Class of National Academy of Inventors (NAI) Fellows
We want to congratulate Prof. Patrick J. Sinko, Pharmaceutics (ISSN: 1999-4923) Editor-in-Chief, for joining the 2023 Class of National Academy of Inventors (NAI) Fellows! The election as an Academy Fellow is the highest professional distinction awarded solely to inventors.
Dr. Patrick J. Sinko is a distinguished professor and the Parke-Davis Endowed Chair in Pharmaceutics and Drug Delivery in the Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey, USA. He is also the Editor of Martin’s Physical Pharmacy and Pharmaceutical Sciences (Fifth, Sixth, Seventh, and Eighth editions). Dr. Sinko has authored or co-authored over 540 publications, including research papers, abstracts, and book chapters (h-index = 65). He is the Principal Investigator of an active research laboratory that focuses on biopharmaceutics, pharmaceutical formulations, and molecular-, nano-, and micro-scale drug delivery with specific applications to treat or prevent HIV/AIDS, breast and lung cancer, chemical terrorism countermeasures, and TB.
“This year’s class of NAI Fellows showcases the caliber of researchers found within the innovation ecosystem. Each of these individuals is making significant contributions to science and society through their work,” said Dr. Paul R. Sanberg, FNAI President of the NAI. “This new class, in conjunction with our existing Fellows, are creating innovations that are driving crucial advancements across a variety of disciplines and are stimulating the global and national economy in immeasurable ways as they move these technologies from lab to marketplace. We are honored to welcome these highly regarded innovators to the Academy and look forward to formally inducting them at our 2024 Annual Conference in the Research Triangle of North Carolina.”
Please join us in congratulating Prof. Sinko on his meaningful work!
25 December 2023
Meet Us at the International Conference on Nanomedicine and Nanobiotechnology (ICONAN 2024), 15–17 January 2024, Barcelona, Spain
Nanomedicine and nanobiotechnology have tremendous potential for tomorrow’s patient care in a wide variety of disease management, and numerous theoretical concepts are currently being translated into preclinical and clinical studies. The fifth edition of the ICONAN conference brings together high-profile plenary speakers and world-class researchers who have successfully developed and translated nanomedicines over the last decades, offering a vibrant platform for oral and poster presentations, sponsor exhibits, and networking. The conference topics include targeted drug delivery, organ biodistribution and nanocarriers, nanomedicine for the immune system and cancer diagnosis and therapy, biological and medical nanodevices and biosensor 3D models, tissue engineering and regenerative nanomedicine toxicology, risk assessment of nanomedicine systems nano-imaging for diagnosis, etc.
MDPI will attend the International Conference On Nanomedicine And Nanobiotechnology (ICONAN 2024); we welcome researchers from different backgrounds to visit and share their latest ideas.
The following MDPI journals will be represented:
If you plan to attend this conference, please contact us online. Our delegates look forward to meeting you in person and answering any questions that you may have. For more information about the conference, please visit the following website: https://premc.org/conferences/iconan-nanomedicine-nanobiotechnology/.
18 December 2023
Editorial Board Members from Pharmaceutics Featured in the 2023 Highly Cited Researchers List Published by Clarivate
Recently, the 2023 Highly Cited ResearchersTM list was published. This is an annual recognition of globally influential scientists and social scientists, who have made significant contributions in their fields. It includes influential researchers at universities, research institutes, and commercial organizations around the world.
The evaluation and selection process identified 6,849 researchers from institutions in 67 countries and awarded 7,125 individual researchers the title of 2023 Highly Cited Researcher, making this a truly global list. These highly cited researchers were named from the top 1% of publications in the Web of ScienceTM Citation Index, by field and year of publication.
Eight members of the Editorial Board of Pharmaceutics (ISSN: 1999-4923) have been featured in the 2023 list of Highly Cited Researchers published by ClarivateTM. They have been recognized for their high-quality scientific research and outstanding contributions to the field of pharmaceutics. The Pharmaceutics Editorial Office sincerely congratulates all of the selected editorial members and hopes that they will continue to have an academically productive relationship with the journal.
Researcher |
Category |
Affiliation |
Basit, Abdul W. |
Pharmacology and Toxicology |
University College London, United Kingdom |
Kiessling, Fabian |
Pharmacology and Toxicology |
RWTH Aachen University, Germany |
Gao, Huile |
Pharmacology and Toxicology |
Sichuan University, China |
Hanes, Justin |
Pharmacology and Toxicology |
Johns Hopkins University, United States of America |
Mei, Lin |
Pharmacology and Toxicology |
Chinese Academy of Medical Sciences Peking Union Medical College, China |
Gaisford, Simon |
Pharmacology and Toxicology |
University College London, United Kingdom |
Preat, Veronique |
Pharmacology and Toxicology |
Universite catholique de Louvain, Belgium |
Weitschies, Werner |
Pharmacology and Toxicology |
Ernst-Moritz-Arndt University of Greifswald, Germany |
30 November 2023
MDPI Insights: The CEO's Letter #6 - MDPI Spain Summit and ResearchGate
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
MDPI Spain Summit
Stefan Tochev (CEO, MDPI) gives the opening speech at the MDPI Spain Summit.
On Friday 10 November 2023 I was in Barcelona, Spain, to deliver the opening presentation and participate in a panel at MDPI’s Spain Summit, a two-day event, inspired by our salon events in China.
With 16 Editors-in-Chief (EiCs) and 20 Editorial Board Members (EBMs) in attendance, the event, organized by our conference team and Barcelona office, featured presentations on open access (OA), MDPI, and publishing market trends in Spain.
The event provided a great opportunity to engage with stakeholders from various MDPI journals, including Nutrients, Vaccines, Buildings, IJMS, and others. We were able to gather feedback and have open conversations around manuscript quality, the peer-review process, and journal development, as well as accreditation agencies.
The main objective of this Summit was to bring together Editors representing MDPI journals across various disciplines within Spanish universities and research centers, primarily from the Barcelona area. The aim was to facilitate an open and fruitful discussion regarding the development of their journals, the future of OA in Spain, and to provide meaningful interactions and networking opportunities.
Connecting with Editorial Board Members
Stefan Tochev in conversation with Summit participants: "Our EBMs are passionate about the journals they serve."
Interacting with our EBMs in person provides a valuable opportunity to show how important it is to us to connect with them, hear their perspectives on their journals and learn more about their own experience collaborating with MDPI.
From my conversations, it was clear that our EBMs are passionate about the journals they serve. I know the advice they provide may sometimes involve just small tweaks, but these can lead to important improvements. As the saying goes, small hinges swing open big doors.
As at November 2023, MDPI has over 6,300 EBMs affiliated with Spanish institutions, with more than 30 of them serving as EiCs or section EiCs. Furthermore, over 68,000 Spanish scholars have contributed as reviewers in MDPI journals.
Open Access in Spain
In 2023, Spain implemented legislation mandating immediate OA for all publicly funded research, aligning with the EU’s Plan S initiative to expedite the transition to OA. The Spanish government also approved a four-year, €23.8 million annual budget for the first national OA strategy, aiming to make publicly funded research freely accessible upon publication. This strategy aims to strengthen the quality and transparency of research in Spain, and to help promote movement towards a digital, low-carbon economy.
For further details of Spain's OA policy and the history of government mandates, click here.
Spain has already seen a notable decline in subscription-only articles, decreasing by 62% over a 10-year period, while gold OA increased by 42%. Green OA slightly decreased, suggesting a shift towards publishing in gold OA journals rather than traditional subscription-based ones. Here are some statistics from Scopus.
A big thank-you to the various MDPI teams, including our conference team and the Barcelona office, for organizing this very successful event!
MDPI colleagues from various offices gathered to host and support the first MDPI Spain Summit, in Barcelona, Spain.
I think this type of gathering has the potential to become an annual event in various locations. For example, Manchester could be an option, as we have over 30 EiCs and over 3,000 EBMs in the UK, a top market for MDPI that publishes high-quality research.
Impactful Research
769 Editorial Board Members of MDPI Journals Recognized as Highly Cited Researchers in 2023
Congratulations to our 769 Editorial Board Members from 40 countries/territories who have been awarded Highly Cited Researcher status for 2023 by Clarivate. This recognition is based on their outstanding scientific research contributions and significant influence in various fields, as evidenced by Web of Science data.
Click here to view the full list of 769 Editorial Board Members.
Clarivate's Highly Cited ResearchersTM list identifies individuals with exceptional impact in scientific and social science domains over the past decade. Their papers rank in the top 1% of citations in 21 fields analysed in ‘Essential Science Indicators,’ showcasing their substantial influence.
This year, 7,125 Highly Cited Researcher 2023 designations were issued to 6,849 individuals from 67 countries, representing just 1 in 1,000 researchers worldwide.
These researchers demonstrate exceptional influence, representing a small fraction of contributors pushing the boundaries of knowledge, contributing to global well-being, sustainability, and security.
Congratulations to these scholars for their remarkable achievement: we are honoured to have them on board with our journals!
Inside MDPI
Corporate Marketing and Communications Strategy Session
Members of MDPI’s Corporate Marketing & Communications team.
For the past few years, I have led the Corporate Marketing & Communications department in our annual strategy session.
This typically involves 2–3 days of focused sessions covering key topics including budgeting, hiring targets, campaign reviews, and planning for the upcoming year, department strategy, and structure.
We are constantly exploring ways to optimize the Corporate Marketing & Communications department to support MDPI’s primary objectives and better convey the MDPI story while serving the scholarly community.
The strategy session also serves as a team-building activity, during which the team voted on bowling!
Strategy Session
In this strategy session, we looked at how to align our teams in order to better streamline our content with our campaigns, build a dedicated marketing team to strategically support our core MDPI products, expand our communications teams and functionalities to focus on company-critical campaigns and press releases, align our new brand design system with our marketing initiatives, set up a community and engagement team to support various teams with their outreach and communication efforts, and increase our use of data in the evaluation of campaign performance.
To grow in these areas, we will be hiring for various positions, including those of Public Relations Manager, Communications Manager, Internal Communications Manager, Campaign Manager, Marketing Associate, and Editorial Engagement Manager.
I am grateful for the way our Corporate Marketing & Communications department has grown and gelled over the years, and I look forward to supporting the department teams and their ideas for the future.
Coming Together for Science
ResearchGate and MDPI Partner to Boost the Visibility of Open Access Content through Journal Home
Stefan Tochev (CEO, MDPI) and Sören Hofmayer (Co-Founder and Chief Strategy Officer, ResearchGate) meet in Berlin, Germany to take their ongoing discussion further.
When I assumed the role of CEO at MDPI, my primary focus was to initiate the building of essential partnerships and collaborations within our industry. After all, I am a firm believer in achieving our goals by helping others achieve theirs and focusing on co-opetition wherever there is an opportunity. I first touched on the notion of co-opetition in MDPI Insights: The CEO's Letter #3, particularly when discussing collaborations with Elsevier.
In light of this, Sören Hofmayer (Co-Founder and Chief Strategy Officer at ResearchGate) and I connected recently to continue a discussion that had been ongoing for months. I was quickly brought up to speed and felt there was an opportunity for MDPI journals to pilot the Journal Home service that ResearchGate had launched. This would provide a new way for MDPI to engage with authors and readers and amplify the visibility of our journals.
While I receive many offers and opportunities for discussions with vendors, I am a firm believer that timing is everything, and in this case, the time for us is now. Sören and I met in person during my recent visit to Berlin and decided to proceed with piloting ten MDPI journals with the Journal Home service.
The press release below provides further details.
Press Release: Berlin (Germany) and Basel (Switzerland), 15 November 2023
ResearchGate, the professional network for researchers, and MDPI, the largest open access publisher in the world and a pioneer in open access publishing, today announced a partnership that will see ten of MDPI’s open access journals benefit from an enhanced presence on ResearchGate through its innovative Journal Home offering.
This new partnership will expand the reach and visibility of MDPI’s participating flagship journals with ResearchGate’s highly relevant community of more than 25 million researchers globally.
Around 210,000 version-of-record articles from these 10 titles will be readily available on ResearchGate, including the full archive material and all new articles as they are published. These journals also benefit from enhanced brand visibility, with dedicated journal profiles, prominent representation on all associated article pages and all relevant touchpoints across the ResearchGate network – keeping the journals top-of-mind with their reader and author audiences. All articles covered by the new partnership will automatically be added to the authors’ publication records in ResearchGate. This not only reduces MDPI authors’ needs for direct management but also offers them valuable insights into the impact of their work, including data about readership and citations.
Closing Thoughts
November is Men’s Health Awareness Month
Stefan Tochev (CEO, MDPI) listening to music as he writes at a coffee shop in Basel, Switzerland.
November is dedicated to raising awareness of various men’s health issues. I have been fortunate to have positive male role models in my life, and I strive to share my experiences with others.
I used to take part in Movember, growing my moustache throughout November to raise awareness and funds and to help “change the face of men’s health.” With male family and friends impacted by physical and mental health issues, I have recently become more interested in men’s overall well-being.
Men often face stigma involving the perceived need always to be strong and have things figured out. Recently, I’ve had meaningful conversations with male friends and colleagues about issues we rarely discuss, and it was a positive experience.
Various factors impact men’s health and well-being, all too easily leading to risky health behaviours including a lack of health awareness, poor health education, and negative, culturally induced, behaviour patterns in our work and personal lives. I hope we can break down these barriers in our work environment.
Healthy men help build healthy families and a healthy society
Men are less likely than women to seek help with their physical and mental health struggles. This is a reminder to prioritize your overall well-being. I hope that as men, we will continue to open up to one another, becoming vulnerable in order to share what we are going through. By sharing and by supporting each other, we can learn and grow together. You are not alone, and when you fall, you can still get up and stand tall.
From one broski to another, you are loved and appreciated. I hope this mindset carries into December and beyond.
Mindfulness
Our content team recently released a handful of articles on mindfulness, a practice that I believe provides a good opportunity for stress release and self-reflection:
Chief Executive Officer
MDPI AG
21 November 2023
769 Editorial Board Members of MDPI Journals Achieve Highly Cited Researcher Recognition in 2023
We extend our sincere congratulations to the 769 Editorial Board Members of our journals – from 40 different countries/territories – who have been recognized as Highly Cited Researchers for the year 2023 by Clarivate. They are being recognized for their high-quality scientific research achievements and outstanding contributions to their professional fields, as indicated by Web of Science data.
Clarivate's annual list of Highly Cited ResearchersTM identifies the most highly cited scientists for the past decade who stand out for their significant and broad influence in various scientific and social science domains. Their impactful papers are among the top 1 per cent in the citation distribution of one or more of 21 fields analyzed in the "Essential Science Indicators", distinguishing them as hugely influential among their peers.
This year, 7,125 Highly Cited Researcher 2023 designations were issued to 6,849 individuals from 67 countries, representing just 1 in 1,000 researchers worldwide.
This means that these researchers have demonstrated an incredible level of significant and broad influence in their chosen field or fields over the last decade. They represent a small fraction of the researcher population whose contributions disproportionately push the boundaries of knowledge, enhancing global well-being, sustainability, and security.
Congratulations to the scholars for their noteworthy achievement – we are honored to have them on board with our journals!
Abate, Antonio |
Jaiswal, Amit K. |
Shen, Zexiang |
20 November 2023
Pharmaceutics | Seeking Cooperation with Academic Conferences
Pharmaceutics (ISSN: 1999-4923) released its inaugural issue in 2009 and is now published monthly through MDPI. Over the years, Pharmaceutics has aimed to provide a professional publishing service to the scientific community, has strived toward the effective dissemination of high-caliber scientific work, and has evolved into a scholarly outlet. In 2013, Pharmaceutics joined PubMed, followed by inclusion in the Science Citation Index Expanded (SCIE), Web of Science, and Scopus (Elsevier) in 2017, achieving an Impact Factor of 5.4 in 2022, with a 5-Year Impact Factor of 6.0. Pharmaceutics’ CiteScore (Scopus) for 2022 reached 6.9, which equals a ranking of 50/278 (Q1) in the “Pharmacology & Pharmacy” category.
Pharmaceutics has forged affiliations with esteemed organizations, including the Academy of Pharmaceutical Sciences (APS), the Korean Society of Pharmaceutical Sciences and Technology (KSPST), the Pharmaceutical Solid State Research Cluster (PSSRC), and the Spanish Society of Pharmaceutics and Pharmaceutical Technology (SEFIG). Committed to supporting the scientific community, Pharmaceutics has cooperated with various academic conferences.
For inquiries or to express your interest in collaboration, please contact the Pharmaceutics Editorial Office at [email protected].
7 November 2023
Two Authors in Pharmaceutics Awarded the Physiology or Medicine Nobel Prize
The Nobel Prize in Physiology or Medicine 2023 was recently awarded to Prof. Dr. Katalin Karikó and Prof. Dr. Drew Weissman for their discoveries regarding nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19, saving millions of lives worldwide.
The laureates found that the chemical conversion of uridine, a nucleotide of mRNA, to pseudouridine, appeared to prevent the body from perceiving the mRNA as an intruder and destroying it, a finding reported in a 2005 seminal paper. Without the unwanted immune response, mRNA can infiltrate the cells to carry out its intended function and provide cells with plans for making proteins.
Two years ago, Pharmaceutics (ISSN: 1999-4923) released a Special Issue “mRNA Therapeutics: A Themed Issue in Honor of Professor Katalin Karikó”, featuring ten articles published between August 2021 and February 2022. Prof. Dr. Karikó and her team at the biotech company, BioNTech, published an article for this Special Issue titled “Ribozyme Assays to Quantify the Capping Efficiency of In Vitro-Transcribed mRNA”.
Prof. Dr. Weissman, in collaboration with colleagues at Pennsylvania University and George Mason University, published an article titled “Screening Libraries to Discover Molecular Design Principles for the Targeted Delivery of mRNA with One-Component Ionizable Amphiphilic Janus Dendrimers Derived from Plant Phenolic Acids” that appeared in the Special Issue “Dendrimers: A Themed Issue in Honor of Professor Donald A. Tomalia on the Occasion of His 85th Birthday for His Outstanding Achievements in Advancing the Field of Dendrimers”.
We offer our congratulations to this year's recipients of the Physiology or Medicine Nobel Prize!
1 November 2023
MDPI Insights: The CEO's Letter #5 - OA Week, UK, and Strategy
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
Open Access Week 2023 – the Global Drive to Open Continues
As the world's largest open-access (OA) publisher, we believe that unrestricted access to research findings is the cornerstone of transparency, efficiency, and quality control across scientific disciplines. At MDPI, we provide free, immediate access to scientific papers, empowering scientists to examine, validate, replicate, and build upon existing results. This minimizes redundancy, optimizes resources, and fosters innovative approaches.
International OA Week, held from 23 to 29 October 2023, provided a unique opportunity to link the global movement toward open sharing and open science with the progress of policy changes at the local level. Our mission, during OA Week and all the year round, is to offer educational resources highlighting the benefits of open-access publishing. The MDPI Blog is a valuable resource for information on open access and open science.
Core principles of OA publishing
Accessibility, transparency, and collaboration are core principles of OA publishing. OA aims to break down barriers that have traditionally restricted research access, ensuring that knowledge is available to all, regardless of financial situation or institutional affiliations. Our commitment to diverse pathways for OA publishing worldwide includes discounts for researchers. You can learn more about how MDPI supports scientific communities here.
One of the key strengths of OA publishing is its ability to facilitate interdisciplinary research. By removing paywalls and promoting knowledge-sharing across disciplines, OA encourages collaboration and innovation. Researchers from various fields can access and build upon each others’ work, fostering a holistic approach to addressing complex global challenges.
OA holds the potential to democratize knowledge, advance science, and drive positive societal change.
Policy driving change
Governments, institutions, and funding agencies have recognized the transformative potential of OA and have implemented policies to promote it. These policies often require publicly funded research to be made openly accessible, accelerating the growth of OA repositories and journals. Check out our spotlights on OA policies in the US, EU and China.
OA publishing is continuously evolving, with community-driven models and technologies shaping its future. Initiatives such as “Plan S” and “cOAlition S” promote OA publishing from the perspective of national funders, requiring grantees to publish their research openly. A new policy announced by the US administration last year mandates that, with effect from January 2026, all US federally funded research should be freely and immediately available after publication.
Additionally, preprint servers such as MDPI's Preprints.org, which allow researchers to share their findings before formal peer review, have gained popularity, enhancing the speed at which new knowledge is disseminated. The rise of blockchain technology is also being explored to ensure transparency and authenticity in scholarly publishing.
For more than two decades, OA publishing has been revolutionizing academic publishing by promoting accessibility, transparency, and collaboration. Its support for interdisciplinary research, evolving policies, and innovative practices all contribute to its growing influence in the global research community. As OA continues to expand, it holds the potential to democratize knowledge, advance science, and drive positive societal change.
MDPI is proud to lead the transition to open access.
Read more:
Impactful Research
Spotlight on Smart Cities
Smart cities will serve as a cornerstone for future human development. Their implementation will help us tackle many of the significant challenges we are facing – climate change, ageing populations, waste management, public safety, travel, and so on. Recognising the importance of this multifaceted field, MDPI launched the inaugural issue of Smart Cities in 2018 to provide an advanced forum for research into smart technology and society. Here we take a look at how this journal has developed, and its impact in this exciting field.
As at 30 October, 2023, Smart Cities has published 421 papers and has an Impact Factor of 6.4. It also has a CiteScore of 8.5, and more than one quarter of its published papers – 124 – have been cited 10 times or more.
Highly cited papers in Smart Cities
Below are several highly cited papers recently published in Smart Cities. Citation metrics are current as at 31 October 2023.
1. “Introducing the “15-Minute City”: Sustainability, Resilience and Place Identity in Future Post-Pandemic Cities”
Authors: Carlos Moreno, Zaheer Allam, Didier Chabaud, Catherine Gall and Florent Pratlong
Smart Cities 2021, 4(1), 93-111; https://doi.org/10.3390/smartcities4010006
Citations: Crossref (338), Scopus (366), Web of Science (270), Google Scholar (710)
The paper discusses the socio-economic impacts of the COVID-19 on cities, including increasing inequalities and rising unemployment. It introduces the concept of the "15-Minute City," a form of "chrono-urbanism," as a response to the challenges posed by the pandemic.
2. “A Review on Electric Vehicles: Technologies and Challenges”
Authors: Julio A. Sanguesa, Vicente Torres-Sanz, Piedad Garrido, Francisco J. Martinez and Johann M. Marquez-Barja
Smart Cities 2021, 4(1), 372-404; https://doi.org/10.3390/smartcities4010022
Citations: Crossref (359), Scopus (363), Web of Science (268), Google Scholar (558)
This paper provides an overview of the progress in Electric Vehicles (EVs), focusing on battery technology, charging methods, and emerging research challenges. It also analyzes the global EV market and its future outlook.
3. “IoT in Smart Cities: A Survey of Technologies, Practices and Challenges”
Authors: Abbas Shah Syed, Daniel Sierra-Sosa, Anup Kumar and Adel Elmaghraby
Smart Cities 2021, 4(2), 429-475; https://doi.org/10.3390/smartcities4020024
Citations: Crossref (121), Scopus (151), Web of Science (91), Google Scholar (215)
This paper gives an overview of the Internet of Things (IoT) in the context of Smart Cities, discussing the fundamental components, technologies, architectures, networking technologies, and artificial algorithms that underpin IoT-based Smart City systems.
4. “Artificial Intelligence Techniques in Smart Grid: A Survey”
Authors: Olufemi A. Omitaomu and Haoran Niu
Smart Cities 2021, 4(2), 548-568; https://doi.org/10.3390/smartcities4020029
Citations: Crossref (76), Scopus (94), Web of Science (57), Google Scholar (120)
This survey paper reviews the utilization of artificial intelligence (AI) techniques in the context of the smart grid. It covers various applications of AI in load forecasting, power grid stability assessment, fault detection, and security issues in the smart grid and power systems.
5. “The Metaverse as a Virtual Form of Smart Cities: Opportunities and Challenges for Environmental, Economic, and Social Sustainability in Urban Futures”
Authors: Zaheer Allam, Ayyoob Sharifi, Simon Elias Bibri, David Sydney Jones and John Krogstie
Smart Cities 2022, 5(3), 771-801; https://doi.org/10.3390/smartcities5030040
Citations: Crossref (72), Scopus (75), Web of Science (43), Google Scholar (176)
This paper discusses the concept of the Metaverse, a virtual world introduced by Meta (formerly Facebook), and its potential impact on urban life. It explores how emerging technologies such as AI, Big Data, IoT, and Digital Twins could reshape urban design and services in the context of the Metaverse.
Testimonial
“It was indeed a great and pleasant experience with MDPI regarding our recent publication. The submission process was very straightforward and less time-consuming than the norm. The review process was very fast compared to many other open access journals, which is praiseworthy. The support from the Editorial Office during the revision process was highly useful as well. We look forward to publishing with MDPI in the future, and I will most definitely recommend MDPI to my colleagues and collaborators.” – Dr. Luís Rosa, University of Minho
Article in Smart Cities: Mobile Networks and Internet of Things Infrastructures to Characterize Smart Human Mobility
Inside MDPI
MDPI Manchester office, UK Visit
Allie Shi (Editorial Director, MDPI), Stefan Tochev (CEO, MDPI), Jamie Anderson (Manchester Office Manager, MDPI), Michael O’Sullivan (Senior Scientific Officer, MDPI), Hushneara Akhtar, and Becky Castellon (IOAP Team Lead, MDPI), dining out in Manchester, UK.
In October, I visited MDPI’s new office in Manchester. During the visit, I connected with our English Editing (EE) managers, Scientific Officer, members of the Editorial team, the Marketing team, and IOAP Team Lead.
Our Manchester office focuses primarily on EE services and provides local support for the UK market. Additionally, we regularly visit Editorial Board members and participate in local conferences.
I would like to thank Jamie Anderson, Manchester Office Manager, and her team, for their deep commitment to our Manchester staff and to MDPI’s impact on the UK market.
The UK by numbers
The UK is a hub for the world’s top universities, making it a key market for MDPI and the publishing world in general. It is home to two of the top-five-ranked universities globally, 11 in the top 100, and 15 in the top 200.
As a result, the UK plays a key role in MDPI’s global market. As at October 2023, it ranks as the seventh-largest contributor to the total number of papers published by MDPI. We have 3,500 Editorial Board members affiliated with UK institutions, including 34 serving as Editors-in-Chief (EiCs). Our commitment to collaboration with institutions is evident in the UK, where we have successfully established some 60 Institutional Open Access Program (IOAP) agreements with esteemed institutions, such as the University of Oxford, the University of Cambridge, Imperial College London, the University of Edinburgh, and more.
According to InCites Dataset + ESCI for the period 2018–2022, as at October 2023, nearly 65% of UK papers are now published as OA. Just over 10% of total OA publications are by UK authors. UK papers are known for their high quality, with an average of 11 citations per paper. Furthermore, 2.16% of UK papers are in the top 1% of cited papers, and 14.61% are in the top 10% of cited papers, showcasing their impact.
We are currently hiring EEs in various locations worldwide.
English Editing at MDPI
Our English Editing (EE) department consists of two main branches, Quality Control and Learning and Development, reflecting our priorities. We are continuously enhancing the quality of our English Editing services and have raised the relevant standards, which now extend to company-wide communications. English editors participate in international interviews, conduct English assessments, and provide colleagues with presentations on ways to improve their use of written and spoken English.
While expanding, the EE department has proactively refocused its efforts on the quality of our work and how the English Editing department can benefit the company more broadly. We currently have approximately 140 full-time English Editors based across five offices worldwide, supplemented by over 700 freelance English editors.
Our Manchester office serves as the hub for the EE Department, with EE Managers situated there, except for Kurtis Jackson, who serves as the Head of EE and is located in our Basel office. Manchester EEs play a critical role in establishing and developing EE teams in our other offices, overseeing management and recruitment. The EE department plays a vital role in MDPI’s operations, as it is the department that touches every published paper. If this work interests you, I encourage you to explore our available EE positions, whether you are seeking full-time or freelance opportunities.
Testimonials
“MDPI provides an excellent service compared to any other previously used services. It delivers fast and high-quality results but at an affordable price.” – Ardha Apriyanto, University of Potsdam
“In my role as a professor, I consider that MDPI Author Services offer an excellent quality in the editing of Western academic writing while maintaining the required standards of clarity, precision and rigor. Additionally, delivery times are fast compared to other available services.” – Jesus Insuasti, University of Nariño
Read more:
Coming Together for Science
STM and Frankfurt Book Fair
Attending STM
MDPI has been a proud sponsor of the STM Conference for several years. The STM Conference is a dynamic event featuring interactive sessions, expert panellists, idea-sharing, and ample networking opportunities. On 16 October, the event kicked off with arrival drinks, sponsored by MDPI, followed by a welcoming dinner, providing a great chance to connect and network with industry professionals. The following day was filled with speakers, sessions, and further opportunities to connect. STM exemplifies the collaborative spirit of the scientific community, with session topics including achieving open, visible, and impactful research at scale; maintaining research integrity in a rapidly changing world; and exploring the impact of ever-evolving technology in the scholarly community.
Meeting with Web of Science
On a personal note, one of the highlights of STM was a candid and productive conversation with Nandita Quaderi, Editor-in-Chief and SVP at Web of Science. During our discussion, we talked about MDPI, Web of Science, the IJERPH delisting, and ways of moving forward. This open conversation aimed at fostering better collaboration for the future.
“We discussed ways to improve our communication and collaboration.”
I appreciated our frank discussion and felt that Nandita wholeheartedly supports open access. She also expressed her appreciation for the monthly CEO Letter, which she sees as a way to add personality to the MDPI brand and provide insight into the great work we do at MDPI. While we highlighted the positives, we also discussed ways to improve our communication and collaboration moving forward. This meeting alone made the trip worthwhile, and I hope Nandita doesn’t mind my sharing that she found our chat to be “the most honest and constructive discussion” she’s had with someone from MDPI in recent years.
75th Frankfurt Book Fair
Jelena Milojevic (Book Editor, MDPI), Jovana Dubajic (Book Editor, MDPI), Evan Escamilla (Project Manager, MDPI), Laura Wagner (Head of Books, MDPI), and Jenny Knowles (Commissioning Editor, MDPI), at the Frankfurt Book Fair in Frankfurt am Main, Germany.
For the 75th time, the Frankfurter Buchmesse opened its doors in October to celebrate exciting stories and their authors. If you haven’t yet had the chance to visit the Frankfurt Book Fair, I highly recommend it. It’s the largest book fair in the world, attracting thousands of visitors from around the globe. This is the place to gain valuable industry insights from top-class publishing professionals, connect with publishers directly, and learn about the latest trends in publishing.
MDPI Books
Our Books team was also present at the Frankfurt Book Fair, networking and learning from various panels. Did you know that our MDPI Books department publishes OA Books?
The book publishing program includes monographs, book series, edited books and reprints of special issues and topical collections, among other book types.
If you have a book proposal you would like to discuss, please feel free to contact our Books team to understand the benefits and methods of publishing your next book with the OA model.
Closing Thoughts
MDPI Strategy Meeting
As the newly appointed CEO, this is my first year leading the MDPI Senior Management Strategy session. I saw it as an opportunity to explore what MDPI has the potential to become in the next five years. Guided by the vision of its founder and President, Dr. Shu-kun Lin, the company has accomplished remarkable feats over the past 27 years and currently holds the position as the world’s third-largest academic publisher, following Springer Nature and Elsevier.
Our primary objective is to build upon the milestones of the past decades and consolidate MDPI’s position as well-established publishing brand. The two-day meeting emphasized the importance of communicating MDPI’s values more actively via its brand and adopting a straightforward yet impactful approach to managing MDPI as a mature academic publisher.
“Our primary objective is to consolidate MDPI’s position as well-established publishing brand”
As the world’s number one open-access publisher, MDPI has long been a game-changer in the scholarly community, serving millions of authors. The challenge in being a trailblazer is the need to continuously improve and at the same time explore the next blue-ocean strategy, while also maintaining the smooth operation of the business. Our collection model, featuring guest-curated thematic topics in the form of Special Issues, has disrupted the industry. Other publishers closely study us and attempt to replicate our models. The future of this collection model is something we are actively addressing – while, of course, looking ahead to what comes next!
Chief Executive Officer
MDPI AG
19 October 2023
Open Access Week 2023 – the Global Drive to Open Continues
MDPI has been a strong proponent of the open access publishing model right from the beginning. As one of the pioneering fully open access publishers, we firmly believe that unrestricted access to research findings forms the foundation for better transparency, efficiency, and quality control across all scientific disciplines.
In December 2022, we reached a significant milestone by surpassing one million articles published. That is one million articles freely available to all, to circulate and build upon!
Offering free and immediate access to scientific papers empowers scientists to examine, validate, replicate, and expand upon existing results. This not only helps prevent redundancy and optimizes how resources are used but also paves the way for innovative new approaches.
The International Open Access Week takes place from 23 to 29 October 2023, providing a unique opportunity to connect the global movement towards open sharing and open science with the progress of policy transformations at the local level.
Our goal, during Open Access Week as well as throughout the year, is to offer resources for educating people about the benefits of open access publishing. The MDPI Blog offers a wealth of information around open access and open science.
Promoting the values of accessibility, transparency, and collaboration
Open access publishing embodies the fundamental values of democratizing knowledge and fostering global accessibility. It aims to break down barriers that have traditionally limited access to scholarly work, ensuring that knowledge is available to all, regardless of their financial or institutional affiliations.
Discounts are part of our commitment to ensuring there are diverse pathways to Open Access publishing for researchers worldwide. MDPI supports scientific communities in several different ways.
One of the key strengths of open access publishing lies in its ability to facilitate interdisciplinary research. By removing paywalls and promoting the sharing of knowledge across disciplines, OA encourages collaboration and innovation. Researchers from diverse fields can access and build upon each other's work, fostering a holistic approach to addressing complex global challenges.
Funders' policies are getting aligned with open science
Governments, institutions, and funding agencies have recognized the transformative potential of open access and have implemented policies to promote it. These policies often mandate that publicly funded research should be made openly accessible. Such initiatives have accelerated the growth of open access repositories and journals, reinforcing the commitment to open access principles. Check our spotlights on OA policies in the US, EU and China.
Open access publishing is continually evolving, with innovative and community-driven models and technologies shaping its future. Initiatives like "Plan S" and "cOAlition S" promote the adoption of OA publishing from the national funders’ perspective by requiring grantees to publish their research openly. A new policy announced by the US administration last year requires that, as of January 2026, all US federally funded research be made freely and immediately available after publication.
Additionally, preprint servers such as MDPI's Preprints.org, which allow researchers to share their findings before formal peer review, have gained popularity, enhancing the speed at which new knowledge is disseminated. The rise of blockchain technology is also being explored to ensure transparency and authenticity in scholarly publishing.
For more than twenty years, open access scholarly publishing has been revolutionizing academia by promoting the values of accessibility, transparency, and collaboration. Its support for interdisciplinary research, evolving policies, and innovative practices all contribute to its growing influence in the global research community. As open access continues to expand, it holds the potential to democratize knowledge, advance science, and drive positive societal change.
MDPI is proud to be a leader in the transition to open access.
12 October 2023
Pharmaceutics | Selected Papers in 2021 in the Section “Nanomedicine and Nanotechnology”
1. “Magnetic Nanoparticles in Biology and Medicine: Past, Present, and Future Trends”
by Deanna D. Stueber, Jake Villanova, Itzel Aponte, Zhen Xiao and Vicki L. Colvin
Pharmaceutics 2021, 13(7), 943; https://doi.org/10.3390/pharmaceutics13070943
Available online: https://www.mdpi.com/1999-4923/13/7/943
2. “Evaluation and Comparison of Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs) as Vectors to Develop Hydrochlorothiazide Effective and Safe Pediatric Oral Liquid Formulations”
by Paola Mura, Francesca Maestrelli, Mario D’Ambrosio, Cristina Luceri and Marzia Cirri
Pharmaceutics 2021, 13(4), 437; https://doi.org/10.3390/pharmaceutics13040437
Available online: https://www.mdpi.com/1999-4923/13/4/437
3. “Chronic Inflammatory Diseases, Anti-Inflammatory Agents and Their Delivery Nanosystems”
by Daniela Placha and Josef Jampilek
Pharmaceutics 2021, 13(1), 64; https://doi.org/10.3390/pharmaceutics13010064
Available online: https://www.mdpi.com/1999-4923/13/1/64
4. “Chitosan Nanoparticles at the Biological Interface: Implications for Drug Delivery”
by Noorjahan Aibani, Raj Rai, Parth Patel, Grace Cuddihy and Ellen K. Wasan
Pharmaceutics 2021, 13(10), 1686; https://doi.org/10.3390/pharmaceutics13101686
Available online: https://www.mdpi.com/1999-4923/13/10/1686
5. “Drug Delivery by Ultrasound-Responsive Nanocarriers for Cancer Treatment”
by Kristin Entzian and Achim Aigner
Pharmaceutics 2021, 13(8), 1135; https://doi.org/10.3390/pharmaceutics13081135
Available online: https://www.mdpi.com/1999-4923/13/8/1135
6. “Advances in Cancer Therapeutics: Conventional Thermal Therapy to Nanotechnology-Based Photothermal Therapy”
by Sangeeta Kumari, Nilesh Sharma and Shivendra V. Sahi
Pharmaceutics 2021, 13(8), 1174; https://doi.org/10.3390/pharmaceutics13081174
Available online: https://www.mdpi.com/1999-4923/13/8/1174
7. “Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB”
by Mantosh Kumar Satapathy, Ting-Lin Yen, Jing-Shiun Jan, Ruei-Dun Tang, Jia-Yi Wang, Rajeev Taliyan and Chih-Hao Yang
Pharmaceutics 2021, 13(8), 1183; https://doi.org/10.3390/pharmaceutics13081183
Available online: https://www.mdpi.com/1999-4923/13/8/1183
8. “Osteochondral Tissue Engineering: The Potential of Electrospinning and Additive Manufacturing”
by Andreia M. Gonçalves, Anabela Moreira, Achim Weber, Gareth R. Williams and Pedro F. Costa
Pharmaceutics 2021, 13(7), 983; https://doi.org/10.3390/pharmaceutics13070983
Available online: https://www.mdpi.com/1999-4923/13/7/983
9. “Towards the Development of a Female Animal Model of T1DM Using Hyaluronic Acid Nanocoated Cell Transplantation: Refinements and Considerations for Future Protocols”
by Fernanda Zamboni, Ibrahim F. Cengiz, Ana M. Barbosa, Antonio G. Castro, Rui L. Reis, Joaquim M. Oliveira and Maurice N. Collins
Pharmaceutics 2021, 13(11), 1925; https://doi.org/10.3390/pharmaceutics13111925
Available online: https://www.mdpi.com/1999-4923/13/11/1925
10. “Design of 3D Scaffolds for Hard Tissue Engineering: From Apatites to Silicon Mesoporous Materials”
by Ana García, María Victoria Cabañas, Juan Peña and Sandra Sánchez-Salcedo
Pharmaceutics 2021, 13(11), 1981; https://doi.org/10.3390/pharmaceutics13111981
Available online: https://www.mdpi.com/1999-4923/13/11/1981
You can check all publications in the Section “Nanomedicine and Nanotechnology” at the following link: https://www.mdpi.com/search?journal=pharmaceutics§ion=1027.
12 October 2023
Pharmaceutics | Selected Papers in 2021 in the Section “Gene and Cell Therapy”
1. “Combination of Nanomaterials in Cell-Based Drug Delivery Systems for Cancer Treatment”
by Lu Tang, Shun He, Yue Yin, Hening Liu, Jingyi Hu, Jie Cheng and Wei Wang
Pharmaceutics 2021, 13(11), 1888; https://doi.org/10.3390/pharmaceutics13111888
Available online: https://www.mdpi.com/1999-4923/13/11/1888
2. “Mesenchymal Stromal Cell Secretome for the Treatment of Immune-Mediated Inflammatory Diseases: Latest Trends in Isolation, Content Optimization and Delivery Avenues”
by Elena Munoz-Perez, Ainhoa Gonzalez-Pujana, Manoli Igartua, Edorta Santos-Vizcaino and Rosa Maria Hernandez
Pharmaceutics 2021, 13(11), 1802; https://doi.org/10.3390/pharmaceutics13111802
Available online: https://www.mdpi.com/1999-4923/13/11/1802
3. “Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery”
by Magdalena M. Żak and Lior Zangi
Pharmaceutics 2021, 13(10), 1675; https://doi.org/10.3390/pharmaceutics13101675
Available online: https://www.mdpi.com/1999-4923/13/10/1675
4. “Development of siRNA-Loaded Lipid Nanoparticles Targeting Long Non-Coding RNA LINC01257 as a Novel and Safe Therapeutic Approach for t(8;21) Pediatric Acute Myeloid Leukemia”
by Patrick Connerty, Ernest Moles, Charles E. de Bock, Nisitha Jayatilleke, Jenny L. Smith, Soheil Meshinchi, Chelsea Mayoh, Maria Kavallaris and Richard B. Lock
Pharmaceutics 2021, 13(10), 1681; https://doi.org/10.3390/pharmaceutics13101681
Available online: https://www.mdpi.com/1999-4923/13/10/1681
5. “B3Pred: A Random-Forest-Based Method for Predicting and Designing Blood–Brain Barrier Penetrating Peptides”
by Vinod Kumar, Sumeet Patiyal, Anjali Dhall, Neelam Sharma and Gajendra Pal Singh Raghava
Pharmaceutics 2021, 13(8), 1237; https://doi.org/10.3390/pharmaceutics13081237
Available online: https://www.mdpi.com/1999-4923/13/8/1237
6. “Clinical Advances of siRNA-Based Nanotherapeutics for Cancer Treatment”
by Dima Hattab, Amirah Mohd Gazzali and Athirah Bakhtiar
Pharmaceutics 2021, 13(7), 1009; https://doi.org/10.3390/pharmaceutics13071009
Available online: https://www.mdpi.com/1999-4923/13/7/1009
7. “Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines”
by Saed Abbasi and Satoshi Uchida
Pharmaceutics 2021, 13(5), 644; https://doi.org/10.3390/pharmaceutics13050644
Available online: https://www.mdpi.com/1999-4923/13/5/644
8. “Hepatocellular-Targeted mRNA Delivery Using Functionalized Selenium Nanoparticles In Vitro”
by Dhireshan Singh and Moganavelli Singh
Pharmaceutics 2021, 13(3), 298; https://doi.org/10.3390/pharmaceutics13030298
Available online: https://www.mdpi.com/1999-4923/13/3/298
You can check all publications in the Section “Gene and Cell Therapy” at the following link: https://www.mdpi.com/search?journal=pharmaceutics§ion=1033.
12 October 2023
Pharmaceutics | Selected Papers in 2021 in the Section “Drug Delivery and Controlled Release”
1. “Unlocking the Power of Exosomes for Crossing Biological Barriers in Drug Delivery”
by Rebekah Omarkhail Elliott and Mei He
Pharmaceutics 2021, 13(1), 122; https://doi.org/10.3390/pharmaceutics13010122
Available online: https://www.mdpi.com/1999-4923/13/1/122
2. “Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives”
by Hyeong Min Kim and Se Joon Woo
Pharmaceutics 2021, 13(1), 108; https://doi.org/10.3390/pharmaceutics13010108
Available online: https://www.mdpi.com/1999-4923/13/1/108
3. “Peptide-Based Strategies for Targeted Tumor Treatment and Imaging”
by Abiodun Ayo and Pirjo Laakkonen
Pharmaceutics 2021, 13(4), 481; https://doi.org/10.3390/pharmaceutics13040481
Available online: https://www.mdpi.com/1999-4923/13/4/481
4. “Lipid-Based Nanocarriers for Ophthalmic Administration: Towards Experimental Design Implementation”
by Felipe M. González-Fernández, Annalisa Bianchera, Paolo Gasco, Sara Nicoli and Silvia Pescina
Pharmaceutics 2021, 13(4), 447; https://doi.org/10.3390/pharmaceutics13040447
Available online: https://www.mdpi.com/1999-4923/13/4/447
5. “Formulation Considerations for the Management of Dry Eye Disease”
by Priyanka Agarwal, Jennifer P. Craig and Ilva D. Rupenthal
Pharmaceutics 2021, 13(2), 207; https://doi.org/10.3390/pharmaceutics13020207
Available online: https://www.mdpi.com/1999-4923/13/2/207
6. “Mesoporous Silica Particles as Drug Delivery Systems—The State of the Art in Loading Methods and the Recent Progress in Analytical Techniques for Monitoring These Processes”
by Katarzyna Trzeciak, Agata Chotera-Ouda, Irena I. Bak-Sypien and Marek J. Potrzebowski
Pharmaceutics 2021, 13(7), 950; https://doi.org/10.3390/pharmaceutics13070950
Available online: https://www.mdpi.com/1999-4923/13/7/950
7. “Microemulsion-Based Media in Nose-to-Brain Drug Delivery”
by Anna Froelich, Tomasz Osmałek, Barbara Jadach, Vinam Puri and Bozena Michniak-Kohn
Pharmaceutics 2021, 13(2), 201; https://doi.org/10.3390/pharmaceutics13020201
Available online: https://www.mdpi.com/1999-4923/13/2/201
8. “Nanomaterials for Protein Delivery in Anticancer Applications”
by Anne Yau, Jinhyung Lee and Yupeng Chen
Pharmaceutics 2021, 13(2), 155; https://doi.org/10.3390/pharmaceutics13020155
Available online: https://www.mdpi.com/1999-4923/13/2/155
9. “Cationic Liposomes as Vectors for Nucleic Acid and Hydrophobic Drug Therapeutics”
by Kai K. Ewert, Pablo Scodeller, Lorena Simón-Gracia, Victoria M. Steffes, Emily A. Wonder, Tambet Teesalu and Cyrus R. Safinya
Pharmaceutics 2021, 13(9), 1365; https://doi.org/10.3390/pharmaceutics13091365
Available online: https://www.mdpi.com/1999-4923/13/9/1365
10. “Transdermal Delivery of Chemotherapeutics: Strategies, Requirements, and Opportunities”
by Rabin Neupane, Sai H. S. Boddu, Mariam Sami Abou-Dahech, Rinda Devi Bachu, David Terrero, R. Jayachandra Babu and Amit K. Tiwari
Pharmaceutics 2021, 13(7), 960; https://doi.org/10.3390/pharmaceutics13070960
Available online: https://www.mdpi.com/1999-4923/13/7/960
11. “3D-Printed Products for Topical Skin Applications: From Personalized Dressings to Drug Delivery”
by Rafaela Santos de Oliveira, Stephani Silva Fantaus, Antonio José Guillot, Ana Melero and Ruy Carlos Ruver Beck
Pharmaceutics 2021, 13(11), 1946; https://doi.org/10.3390/pharmaceutics13111946
Available online: https://www.mdpi.com/1999-4923/13/11/1946
12. “Graphene Oxide and Graphene Quantum Dots as Delivery Systems of Cationic Porphyrins: Photo-Antiproliferative Activity Evaluation towards T24 Human Bladder Cancer Cells”
by Luca Menilli, Ana R. Monteiro, Silvia Lazzarotto, Filipe M. P. Morais, Ana T. P. C. Gomes, Nuno M. M. Moura, Sara Fateixa, Maria A. F. Faustino, Maria G. P. M. S. Neves, Tito Trindade et al.
Pharmaceutics 2021, 13(9), 1512; https://doi.org/10.3390/pharmaceutics13091512
Available online: https://www.mdpi.com/1999-4923/13/9/1512
13. “Cyclodextrin-Modified Nanomaterials for Drug Delivery: Classification and Advances in Controlled Release and Bioavailability”
by Daniel Andrés Real, Karen Bolaños, Josefina Priotti, Nicolás Yutronic, Marcelo J. Kogan, Rodrigo Sierpe and Orlando Donoso-González
Pharmaceutics 2021, 13(12), 2131; https://doi.org/10.3390/pharmaceutics13122131
Available online: https://www.mdpi.com/1999-4923/13/12/2131
14. “PEGylated Mesoporous Silica Nanoparticles (MCM-41): a Promising Carrier for the Targeted Delivery of Fenbendazole into Prostrate Cancer Cells”
by Maedeh Koohi Moftakhari Esfahani, Seyed Ebrahim Alavi, Peter J. Cabot, Nazrul Islam and Emad L. Izake
Pharmaceutics 2021, 13(10), 1605; https://doi.org/10.3390/pharmaceutics13101605
Available online: https://www.mdpi.com/1999-4923/13/10/1605
You can check all publications in the Section “Drug Delivery and Controlled Release” at the following link: https://www.mdpi.com/search?journal=pharmaceutics§ion=1031.
12 October 2023
Pharmaceutics | Selected Papers in 2021 in the Section “Drug Targeting and Design”
1. “Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases”
by Claudia Riccardi, Filomena Napolitano, Daniela Montesarchio, Simone Sampaolo and Mariarosa Anna Beatrice Melone
Pharmaceutics 2021, 13(11), 1897; https://doi.org/10.3390/pharmaceutics13111897
Available online: https://www.mdpi.com/1999-4923/13/11/1897
2. “Selective CNS Targeting and Distribution with a Refined Region-Specific Intranasal Delivery Technique via the Olfactory Mucosa”
by Frank Maigler, Simone Ladel, Johannes Flamm, Stella Gänger, Barbara Kurpiers, Stefanie Kiderlen, Ronja Völk, Carmen Hamp, Sunniva Hartung, Sebastian Spiegel et al.
Pharmaceutics 2021, 13(11), 1904; https://doi.org/10.3390/pharmaceutics13111904
Available online: https://www.mdpi.com/1999-4923/13/11/1904
3. “Posterior Segment Ophthalmic Drug Delivery: Role of Muco-Adhesion with a Special Focus on Chitosan”
by Ayah Mohammad Burhan, Butsabarat Klahan, Wayne Cummins, Vanessa Andrés-Guerrero, Mark E. Byrne, Niall J. O’Reilly, Anuj Chauhan, Laurence Fitzhenry and Helen Hughes
Pharmaceutics 2021, 13(10), 1685; https://doi.org/10.3390/pharmaceutics13101685
Available online: https://www.mdpi.com/1999-4923/13/10/1685
4. “Ruthenium Complexes in the Fight against Pathogenic Microorganisms. An Extensive Review”
by Alexandra-Cristina Munteanu and Valentina Uivarosi
Pharmaceutics 2021, 13(6), 874; https://doi.org/10.3390/pharmaceutics13060874
Available online: https://www.mdpi.com/1999-4923/13/6/874
5. “Optimization of Collagen Chemical Crosslinking to Restore Biocompatibility of Tissue-Engineered Scaffolds”
by Mohammad Mirazul Islam, Dina B. AbuSamra, Alexandru Chivu, Pablo Argüeso, Claes H. Dohlman, Hirak K. Patra, James Chodosh and Miguel González-Andrades
Pharmaceutics 2021, 13(6), 832; https://doi.org/10.3390/pharmaceutics13060832
Available online: https://www.mdpi.com/1999-4923/13/6/832
6. “Hybrid 3D Printing of Advanced Hydrogel-Based Wound Dressings with Tailorable Properties”
by Marko Milojević, Gregor Harih, Boštjan Vihar, Jernej Vajda, Lidija Gradišnik, Tanja Zidarič, Karin Stana Kleinschek, Uroš Maver and Tina Maver
Pharmaceutics 2021, 13(4), 564; https://doi.org/10.3390/pharmaceutics13040564
Available online: https://www.mdpi.com/1999-4923/13/4/564
7. “Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside”
by Stephen Ahenkorah, Irwin Cassells, Christophe M. Deroose, Thomas Cardinaels, Andrew R. Burgoyne, Guy Bormans, Maarten Ooms and Frederik Cleeren
Pharmaceutics 2021, 13(5), 599; https://doi.org/10.3390/pharmaceutics13050599
Available online: https://www.mdpi.com/1999-4923/13/5/599
8. “Atorvastatin-Eluting Contact Lenses: Effects of Molecular Imprinting and Sterilization on Drug Loading and Release”
by Ana F. Pereira-da-Mota, María Vivero-Lopez, Ana Topete, Ana Paula Serro, Angel Concheiro and Carmen Alvarez-Lorenzo
Pharmaceutics 2021, 13(5), 606; https://doi.org/10.3390/pharmaceutics13050606
Available online: https://www.mdpi.com/1999-4923/13/5/606
9. “Current Insights into 3D Bioprinting: An Advanced Approach for Eye Tissue Regeneration”
by Sandra Ruiz-Alonso, Ilia Villate-Beitia, Idoia Gallego, Markel Lafuente-Merchan, Gustavo Puras, Laura Saenz-del-Burgo and José Luis Pedraz
Pharmaceutics 2021, 13(3), 308; https://doi.org/10.3390/pharmaceutics13030308
Available online: https://www.mdpi.com/1999-4923/13/3/308
10. “Neuroinflammation as a Therapeutic Target in Retinitis Pigmentosa and Quercetin as Its Potential Modulator”
by Joseph Thomas Ortega and Beata Jastrzebska
Pharmaceutics 2021, 13(11), 1935; https://doi.org/10.3390/pharmaceutics13111935
Available online: https://www.mdpi.com/1999-4923/13/11/1935
You can check all publications in the Section “Drug Targeting and Design” at the following link: https://www.mdpi.com/search?journal=pharmaceutics§ion=1034.
2 October 2023
MDPI Insights: The CEO's Letter #4 - MDPI Presence in China
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
Open Access in China
It is Saturday, 23 September, and I have just returned from an unforgettable 12-day trip to China, visiting our main offices in Beijing and Wuhan. In the wake of a packed and very enjoyable agenda of internal and external meetings, I would like to use this edition of the CEO Letter to showcase how MDPI supports the scholarly community in China.
Coincidentally, Jack McKenna, Communications Associate from MDPI’s corporate content team, has just released a blog article discussing China’s open access (OA) policy. It is a timely read, providing a concise overview of the development of the OA movement in China and reflecting on its future. I shall draw some content from Jack’s piece and use this edition of the CEO Letter to highlight the various ways in which MDPI is involved in this market. And it would be remiss of me not to include some pictures and highlights from my travels!
Open Access Policy in China
As per Jack’s post, in 2020, China became the world’s leading producer of research articles. Today, China is experiencing a “substantial growth rate in OA [Open Access] publication”. This growth is supported by the State’s commitment to research & development and its policy “requiring the promotion of open science”.
Over the past two decades, there have been gradual developments in China’s OA framework, with repositories and platforms being developed in a consistent manner. Currently, key institutions across China – including the National Science Library, the National Science and Technology Library, and the Natural Science Foundation of China – support OA. The State aims to establish consistent policies across government agencies – a framework for a more encompassing embrace of OA across institutions.
In China, the number of subscription-only articles decreased by nearly 30% over the 10-year period of 2011–2021, while gold OA increased by 22%. Between 2017 and 2020 alone, China published 800,921 academic papers in an OA format.
In 2023, as the leading publisher of academic research, China is pursuing “self-reliance”. Therefore, the State will be establishing consistent policies across government agencies, including those related to OA. Additionally, it will want to ensure that Chinese people can access the research that is supported by Chinese funding and produced by Chinese academics. For this reason, “Open Access is a matter of priority in China”.
MDPI Offices in China
While the history of MDPI begins in Basel, Switzerland, the story of MDPI’s founder is very much rooted in China. Dr. Shu-kun Lin, Founder and President of MDPI, graduated with a BSc from Wuhan University in 1982. He also studied physical chemistry at the Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences (1982–1986; MSc in 1985), and at the University of Louisville, USA (1987–1989). Dr. Lin completed his doctorate in organic chemistry at the Swiss Federal Institute of Technology (ETH-Zürich) in 1992.
Stefan Tochev (CEO, MDPI) at MDPI’s Wuhan office.
In 2002, MDPI’s Basel headquarters moved to Matthäusstrasse 11, 4052 Basel, and Dr. Lin opened an editorial office in Qingdao, China, which launched the journal Marine Drugs in the following year. Below is a list of MDPI’s current offices in China and their respective dates of inauguration:
- 2008: Beijing (Tongzhou, Haidian)
- 2013: Wuhan (Hankou, Guanggu)
- 2019: Tianjin
- 2021: Dalian
- 2021: Nanjing
Our Strength is in Our People
With over 6,000 MDPI staff, across 20 offices in 11 countries, MDPI is able to offer authors responsive and efficient round-the-clock support, enabling a rapid publication process.
In my experience, stakeholders are genuinely surprised when they realize the extent of our global operations. My response is to reiterate that our people are our strength. This is why we have fast and efficient processes and top-notch responsiveness. Our global presence ensures that your manuscript is constantly attended to, rather than sitting on someone’s desk. We prioritize our authors’ needs and act quickly to move things through the various stages of publication. MDPI is built on speed, convenience, and competence, which I believe are core pillars for success in any industry. We continually strive to improve our systems and processes on the basis of these core strengths. We literally have over 6,000 staff worldwide dedicated to serving your needs. It’s not magic: it’s people; it’s real.
Impactful Research
MDPI Awards
To support the academic community, and especially young researchers, and also to enhance communication among scientists, MDPI journals offer various awards in specific fields. We serve the scientific community by funding research to facilitate the development of sustainable global solutions through our annual World Sustainability Award and Emerging Sustainability Leader Award.
In 2022, MDPI made awards totalling over US$1 million in recognition and support of researchers worldwide.
Across our journal catalogue, we have granted over 2,000 awards to recognize and support researchers from all disciplines. Since 2016, these awards have served as a source of recognition, acknowledging the impact of research by heightening the influence of talented individuals. The award types mainly include the Young Investigator Award, the Best PhD Thesis Award, the Best Paper Award, and the Outstanding Reviewer Award.
To learn more about MDPI Awards and to find out which are currently available, please click here.
MDPI Awards to Scholars from China
Since 2021, there have been 23 Best Paper Awards granted to authors affiliated with Chinese institutions, identifying their papers as having high-quality scientific impact. A total of 45 Chinese scholars have received awards such as the Young Investigator Award, the Best PhD Thesis Award, the Outstanding Reviewer Award, and the Tu Youyou Award, among others. Prizes for these awards include MDPI grants for paid publications, totalling over CHF 70,000 for scholars affiliated with Chinese institutions.
MDPI’s Tu Youyou Award
Prof. Tu Youyou (left), Dr. Shu-Kun Lin (President, MDPI).
In 2015, Professor Tu Youyou was awarded the Nobel Prize in Physiology or Medicine “for her discoveries concerning a novel therapy against Malaria.” In order to commemorate Professor Tu’s contributions to human health and to promote the passion and spirit conveyed by her experiences, MDPI in 2016 established the ‘Tu Youyou Award’, which runs biennially to recognize outstanding scholars dedicated to the research of natural products and medicinal chemistry.
The 2022 Tu Youyou Award was granted to Prof. Dr. Xiaoguang Lei of Peking University. Click here to access the interview with the winner.
2015 Nobel Prize for Medicine Awarded to Professor Youyou Tu
Professor Tu’s work was celebrated in a Special Issue from Molecules on the occasion of her 80th birthday. The Special Issue: 'Artemisinin (Qinghaosu): Commemorative Issue in Honor of Professor Youyou Tu on the Occasion of her 80th Anniversary” was created five years before she won the Nobel Prize, highlighting the visibility MDPI provides researchers and their work.
Highly Cited Articles by Chinese Scholars Published in MDPI
Click here to access the most cited MDPI papers published by scholars affiliated with Chinese institutions. This list presents the most influential research from the more than 287,000 MDPI papers published by Chinese scholars. With over 9 million total citations, I encourage you to maximize your visibility and impact by publishing with MDPI, the number one most cited open access publisher.
Read more:
- Tu Youyou Award
- World Sustainability Awards
- Available Awards
Inside MDPI
Stefan Tochev (CEO, MDPI) with the Beijing Marketing team.
Marketing Department in China
During my visit to our offices in Beijing and Wuhan, I had the opportunity to meet with, and to present to, our local marketing teams. These teams are responsible for various journal-related and corporate promotional activities, including newsletters, conferences, seminars, author training, journal awards, content creation, digital marketing, and social media.
I was pleased by the ambition and curiosity of our marketing colleagues. They showed a strong desire to collaborate and acquire knowledge and tactics to effectively market and promote MDPI-journal-related activities. I presented some of the principles and objectives that we apply in the Corporate Marketing and Communications department, and used the opportunity to strengthen our collaborative communications across offices.
Stefan Tochev (CEO, MDPI) with the Wuhan Marketing team.
Coming Together for Science
Collaborations, Scholarships and Meetings
MDPI maintains partnerships with nearly 190 learned societies and over 800 institutions and consortia, helping to facilitate the transition to OA publishing. Our commitment to working with institutions is evident in China, where we have successfully established over 35 Institutional Open Access Programs (IOAP) with esteemed institutions such as the Tsinghua University, Huazhong University of Science and Technology, and Shanghai Jiao Tong University.
Our institutional partnerships, waiver programs, and article processing cost discounts create diverse pathways to OA publishing for researchers worldwide.
Scholarships in China
Since 2021, several MDPI journals (Sensors, Photonics, Coatings, Materials, Energies, and Journal of Fungi) have funded full scholarships for four Master’s and five Ph.D. projects in China. These scholarships align with Tianjin University, Wuhan University of Technology, Central South University, the Chinese Academy of Sciences, and the China University of Petroleum (Beijing).
Meeting with the Society of Chinese University Journals (CUJS)
Prof. Tieming Zhang (President of CUJS, centre) and MDPI colleagues at CUJS office.
I am pleased to have participated in some highly productive meetings during my visit to China, including one with the Society of Chinese University Journals (CUJS). The meeting involved Prof. Tieming Zhang (President of CUJS), Assoc. Prof. Xin Zhang (Vice President and Secretary General), and Dr. Fei Gao (Executive Member of CUJS). Alongside my colleagues Dr. Guoshi Liu, Dr. Giulia Stefenelli, and Anita Sun, I represented MDPI and held an open discussion to address any questions regarding OA and MDPI.
We discussed several methods for collaboration, including a workshop on the future of peer review, MDPI sponsoring a funding grant for early-career researchers, and transitioning journals from diamond to gold OA. I am thankful for the opportunity to have met our colleagues at CUJS in person and feel very confident about our future collaborations in support of OA publishing in China.
MDPI hosts free academic seminars, author training sessions, and academic conferences as part of its commitment to enrich and support the scholarly community. CUJS often stages academic events (e.g., conferences, editor training, and editor competitions), and I believe there are great opportunities for CUJS and MDPI to collaborate accordingly.
Meeting with National Science Library, Chinese Academy of Sciences (NSLC)
Stefan Tochev (CEO, MDPI), Dr. Giulia Stefenelli (Chair of Scientific Officers, MDPI), Anita Sun (PR Manager, MDPI) and Dr. Guoshi Liu (Managing Director, MDPI) at the National Science Library, Chinese Academy of Sciences.
We also visited the NSLC Director, Xiwen Liu, and colleagues Ying Jin, Zhesi Shen, and Sichao Tong. Following our introductions, we gave a presentation on the history and editorial process at MDPI, discussing specific details related to MDPI’s business and data. We highlighted the status of our IOAP collaborations in China and the makeup of our author base, specifically in China, and drew attention to the fact that MDPI has published research by authors from every country in the world. We then discussed the design indicators, calculation methods and implementation purposes of the ‘Early Warning Journal List’ and how we can have open communication to provide any data regarding MDPI journals. I am pleased to report that we reached a consensus on future communications, and am grateful to NSLC for hosting us in their offices.
In-person meetings with stakeholders provide an invaluable opportunity to communicate what MDPI is about and the various ways in which we serve the scholarly community. While digital marketing and online communication are essential, they are no replacement for the understanding and trust that come about through in-person interactions.
The Numbers
As at September 2023, China holds the largest position in MDPI’s global market, ranking as the largest contributor to the total number of papers published by MDPI.
At this point in time, there were more than 847,000 China mainland scholars who have published with MDPI, 51 of whom are Section-Editors-in-Chief (SEiC) of MDPI journals, with seven serving as Editors-in-Chief (EiCs) for journals such as Air, Big Data and Cognitive Computing, Blockchains, Future, Nanoenergy Advances, and Targets.
Our growth and presence in China are a true testament to the service we provide to the scholarly community, and to the relationships we foster through collaborative activities. We look forward to continuing to support the growth of the scholarly community in China, providing a valuable and trusted experience with MDPI.
Closing Thoughts
Final Reflections on our MDPI Offices in Beijing and Wuhan
Stefan Tochev (CEO, MDPI), Dr. Constanze Schelhorn (Indexing Manager, MDPI), Jiale Shang (Admin, Tongzhou, MDPI) at Beijing Capital International Airport, Beijing.
I spent approximately two weeks visiting some of our offices in China, and the first word that comes to mind when describing my experience is ‘hospitality.’ My colleagues and I were met with enthusiasm and delight at the airport by the Tongzhou Admin team (thank you, Jiale Shang, and thank you, Eric Wang, for keeping us organized on this trip!) and were taken care of with great attention. From hotels to transportation, dinners, and meetings, our stay was catered for perfectly.
Perhaps this is where MDPI’s focus on customers and service originates. At our core, we are a service company that provides a publishing platform for its authors. It’s therefore no surprise that authors consistently rate their experience with MDPI very highly.
95% of submitting authors rate their overall experience with the MDPI publication process as Excellent or Good (Springer Nature report 90%).
91% of submitting authors rate their overall experience with the MDPI peer review process as Excellent or Good.
Speed/Efficiency and Editorial Relationship are two key reasons underlying this high satisfaction score. ‘Editorial Relationship’ can be further explored, but in the past month, the most commonly noted aspects were the professionalism, kindness, availability, communicativeness, and personalized assistance provided by our editorial staff throughout the process. These attributes are at the core of our work across all our offices and continents.
Hospitality and Service
Just as our Chinese colleagues strove to keep us engaged by showing us the city sights (thank you, Thea Pan, and Jason Wu from the Wuhan Marketing team!) and sharing a variety of wonderful meals, our editorial staff are committed to serving our authors throughout their publishing journey. Our aim is to place the author at the centre of everything we do, eager to welcome our ‘guests’ and provide them with a pleasant publishing experience.
I asked my colleague Francis Wu (Senior Publisher, Wuhan office) where this hospitality originates. He responded that it is part of Chinese culture. I reflected long and deep on this answer. China is a vast country, and when visitors arrive, hosts want to ensure they feel welcomed and taken care of in order to maximize their time and visit. I can’t think of a better analogy for how I would want our authors to feel when they visit MDPI for their publishing needs. A company culture that prioritizes service, something that goes beyond products and productivity, and focuses on the overall experience. Over 6,000 people, across all MDPI offices, are ready, willing and able to go the extra mile for their colleagues and their customers. This is something I am truly proud of.
Chief Executive Officer
MDPI AG
19 September 2023
Meet Us at the 13th Member Congress of the Chinese Society of Biochemistry and Molecular Biology and 2023 National Academic Congress, 19–22 October 2023, Hefei, China
MDPI will attend the 13th Member Congress of the Chinese Society of Biochemistry and Molecular Biology and 2023 National Academic Congress. This event will be held from 19 to 22 October 2023 in Hefei, China, and is hosted by the Chinese Society of Biochemistry and Molecular Biology.
This event includes invited reports of the conference, branch (special topic) reports, and posters. The theme of this conference is gene expression and regulation; RNA function and regulation; protein modification and function; metabolic homeostasis and networks; frontier technology and application, etc.
The following MDPI journals will be represented:
- Biomolecules (leading);
- Genes (leading);
- IJMS (leading);
- Cancers;
- Cells;
- Pharmaceutics;
- CIMB;
- Biology;
- Symmetry.
If you plan on attending this conference, please feel free to stop by our booth (#C07) and chat with us. Our delegates look forward to meeting you in person and answering any questions that you may have. For more information about the conference, please visit https://www.csbmb.org.cn/2023/.
6 September 2023
Recap of Awards Granted to Scholars in 2022
MDPI is committed to supporting the academic community, nurturing talent and advancing science. Awards are an important part of the research landscape and play a vital role in helping academics gain recognition, especially young researchers as they embark on new research avenues.
In 2022, our journals presented a total number of 394 Awards, including Travel Awards, Young Investigator Awards, Best PhD Thesis Awards, Best Paper Awards, and Outstanding Reviewer Awards, with several winners announced for some of the awards. The total prize sum amounted to just under 580,000 Swiss francs (CHF), or approximately 650,000 US dollars. Overall, more than 720 scholars were awarded.
The majority of the awards were dedicated to young researchers in relatively early stages of their careers. This encompassed 66 of the afore-mentioned Travel Awards, 60 Young Investigator Awards, supporting research projects and conference attendance, as well as 51 Best PhD Thesis Awards. Additionally, 113 Best Paper Awards were given by our journals. The selection committees were entrusted with identifying the most impactful and novel research and review articles published in their journal within a given year.
MDPI will continue its support and recognition for the academic community moving forward, sponsoring new awards across disciplines. To learn more about all the awardees and their research projects in your field of study, please visit the following pages:
To explore more MDPI awards, please click here.
5 September 2023
Meet Us at the 16th China Pharmaceutical Preparations Conference, 15–17 September 2023, Changsha, China
The upcoming conference is the 16th so far, and it has become an important conference in the field of pharmaceutical research in China. The theme of this formulation conference is "New Technologies, New Opportunities, and New Challenges" which will be held in Changsha, China. Experts from various fields and directions in pharmacy at home and abroad will be invited to conduct exchanges and discussions on theoretical research, technology applications, policies, and regulations on pharmaceutical formulations. In addition to the main venue, the conference also has a basic pharmacy forum (targeted drug delivery strategy, controlled release strategy), industrial pharmacy forum, International Controlled Release Association China Branch Forum, external preparations forum, improved new drugs and clinical research forum, medicinal excipients and pharmaceutical packaging materials forum, preparation R&D services and equipment forum, young pharmaceutical workers forum, graduate student forum, and other sub-venues.
Pharmaceutics (ISSN: 1999-4923) is a peer-reviewed, open access journal on the science and technology of pharmaceutics and biopharmaceutics, and it is published monthly online by MDPI. Pharmaceutics will participate in this event as an exhibitor together with seven other MDPI journals.
The following MDPI journals will be represented:
- Pharmaceutics (leading);
- Biomedicines;
- Medicina;
- Hematology Reports;
- Polymers;
- Future Pharmacology;
- Pharmacy;
- Bioengineering.
If you are attending this conference, please feel free to start a conversation with us at our booth #A39. Our delegates look forward to meeting you in person and answering any questions that you may have.
For more information, please feel free to contact the Pharmaceutics Editorial Office at [email protected].
30 August 2023
MDPI Insights: The CEO's Letter #3 - Sustainability and Co-opetition
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
Our Commitment to Sustainability
As a pioneer in academic open access publishing since 1996, MDPI has always been dedicated to facilitating scientific exchange across all disciplines. Our approach to open science is guided by principles such as Open Access (OA), Timeliness and Efficiency, Simplicity, High-Quality Service, Flexibility, and a commitment to Sustainability. This commitment involves preserving published papers for the long term and supporting the future of science through partnerships, sponsorships, and awards.
In this edition of the CEO Letter, I will delve into MDPI’s various sustainability initiatives. As a leader in OA publishing, we are able to provide the public with a significant amount of environment-related content at no cost.
MDPI and the Sustainable Development Goals (SDGs)
In 2020, the SDG Publishers Compact was launched to accelerate implementation of the SDGs by promoting content that informs, develops, and inspires action. MDPI joined this initiative in 2021 and subsequently launched the MDPI SDG Hub in 2022, offering free access to recent research within the scope of each of the 17 SDGs. We also support authors from underrepresented communities by waiving publication charges for selected SDG-related papers. Detailed sustainability practices and supported publications are available in the report under each Goal page.
“More than 80% of MDPI articles and reviews published in 2022 relate to the Sustainable Development Goals.” [source: InCites, Accessed on 21.08.2023]
As at August 2023, MDPI boasts 14 journals dedicated to sustainability-related topics. Our first journal in this area, Sustainability, has published over 29,000 articles on the SDGs, accumulating over 240,000 citations (source: InCites, as at 1 January 2023). These journals serve as vital platforms for researchers to share insights and address environmental challenges. In addition:
MDPI journals specializing in sustainability-related topics:
- 2009: Sustainability
- 2012: Resources
- 2013: Climate
- 2014: Environments
- 2016: Recycling
- 2019: Clean Technologies
- 2020: Sustainable Chemistry
- 2021: Wind, Biomass, Conservation, Pollutants, Solar
- 2022: Waste, Microplastics
Read more:
Impactful Research
Highly Cited Articles in Sustainability
In 2022, content published in Sustainability and indexed in Journal Citation Reports (JCR) received nearly 190,000 citations. This highlights the fact that Sustainability publishes highly cited research articles related to environmental sciences and SDG-related topics such as climate action.
We are pleased to share that Sustainability received a 2022 CiteScore of 5.8, marking a 16% increase from the 2021 metric. Specifically, the CiteScore positions Sustainability as follows: Q1 (27 out of 163) in the “Environmental Science (miscellaneous)” category, and Q1 (101 out of 779) in the “Geography Planning and Development” category. For additional journal statistics, please visit here.
“Sustainability received a 2022 CiteScore of 5.8”
While MDPI journals such as Climate and Atmosphere have a distinct focus on atmosphere pollution and its impact on climate processes, journals like Sustainability, Environments, Water, Remote Sensing, and IJERPH publish content related to climate change. These journals have published over 32,300 articles related to SDG 13: Climate Action.
Highly Cited Papers in Sustainability
Below are several highly cited papers published in Sustainability over the past three years. Citation metrics are current as at 15 August 2023.
1. “A Global Assessment: Can Renewable Energy Replace Fossil Fuels by 2050?”Authors: Jerry L. Holechek, Hatim M. E. Geli, Mohammed N. Sawalhah, and Raul Valdez
Sustainability 2022, 14(8), 4792; https://doi.org/10.3390/su14084792
Citations: Crossref (97), Scopus (91), Web of Science (82), Google Scholar (125)
This paper addresses one of the most significant challenges of climate change – achieving Net Zero Carbon by 2050. The meta-analysis suggests that while difficult, this transition is possible through the concerted application of pathways, lifestyle changes, and global cooperation.
2. “Anxiety and the Ecological Crisis: An Analysis of Eco-Anxiety and Climate Anxiety”Author: Panu Pihkala
Sustainability 2020, 12(19), 7836; https://doi.org/10.3390/su12197836
Citations: Crossref (144), Scopus (121), Web of Science (159), Google Scholar (382)
This paper has received substantial media attention, including coverage by The Guardian, BBC, Vice, and CNBC. An interview with Dr. Panu Pihkala, a leading interdisciplinary researcher on the topic, can be found on MDPI’s podcast: Insight Faster, Episode 1.
3. “Impact of Climate Change on Agriculture and Its Mitigation Strategies: A Review”Authors: Gurdeep Singh Malhi, Manpreet Kaur, and Prashant Kaushik
Sustainability 2021, 13(3), 1318; https://doi.org/10.3390/su13031318
Citations: Crossref (207), Scopus (221), Web of Science (186), Google Scholar (355)
This paper reviews literature on climate change, addressing its causes, future projections, impact on agriculture, including plant physiology, growth, productivity, pest infestation, and the economic implications of mitigation strategies.
4. “Impacts of Plastic Pollution on Ecosystem Services, Sustainable Development Goals, and Need to Focus on Circular Economy and Policy Interventions”Authors: Rakesh Kumar, Anurag Verma, Arkajyoti Shome, Rama Sinha, Srishti Sinha, Prakash Kumar Jha, Ritesh Kumar, Pawan Kumar, Shubham, Shreyas Das, Prabhakar Sharma, and P. V. Vara Prasad
Sustainability 2021, 13(17), 9963; https://doi.org/10.3390/su13179963
Citations: Crossref (134), Scopus (136), Web of Science (113), Google Scholar (184)
This review aims to assess the adverse effects of plastic pollution on ecosystems, link the management of plastic with the SDGs, and propose policy measures using transdisciplinary approaches. Empowering communities to reduce plastic use is crucial. Addressing global plastic pollution is a priority.
Sustainability is an international, cross-disciplinary, open access journal that explores environmental, cultural, economic, and social sustainability of human beings. It provides a forward-looking platform for research on sustainability and sustainable development, and is published semi-monthly online by MDPI. Sustainability is affiliated with The Canadian Urban Transit Research & Innovation Consortium (CUTRIC) and The International Council for Research and Innovation in Building and Construction (CIB).
Read more:
- Testimonials: See what our editors and authors say about Sustainability.
Inside MDPI
President of Ireland Authors Editorial in MDPI Journal Sustainability
It’s a very special occasion when the president of a country takes the initiative to write an editorial for a journal. Michael D. Higgins, President of the Republic of Ireland, has contributed his insights to a forthcoming Special Issue in Sustainability:
This Special Issue, focusing on “making sustainable development happen” at grassroots levels, allows for perspectives from, and on, the major world faiths, exploring how challenges have been conceptualised and addressed, in addition to case studies of faith-based sustainability initiatives in practice.
The experience of faith institutions and communities in translating theological and moral commitments to sustainable development into action is now a topic we must examine with urgency; one on which I am so glad this Special Issue focuses.
As President of Ireland, I very much support this Special Issue of Sustainability. It is my great hope that the contents of the papers contained herein will assist in making sustainable development happen at grassroots levels across the world so that we can cooperate together, people of faith and of none, to ensure a just, inclusive and sustainable future for all on our fragile planet.
Read the completed editorial here:
Special Issue “Faith and Sustainable Development: Exploring Practice, Progress and Challenges among Faith Communities and Institutions”: Foreword by the President of Ireland
Author: Michael D. Higgins
Sustainability 2023, 15(12), 9683; https://doi.org/10.3390/su15129683
Coming Together for Science
The World Sustainability Forum 2023
The World Sustainability Forum (WSF) is a biennial MDPI event focused on sustainability. WSF 2023 marks the tenth anniversary of the conference series, taking place on 14 September. For the first time, the event will be hosted as a 24-hour conference across three locations – Singapore, Basel in Switzerland, and Toronto in Canada – alongside virtual streaming.
This unique format allows us to span three time zones, providing live coverage of critical sustainability-related topics throughout the day:
- The Singapore Hub, chaired by Professor Horn Mun Cheah and Associate Professor Renee Tan, will explore “Sustainability for Social and Community Impact”.
- The Basel Hub, chaired by Prof. Dr. Anet Režek Jambrak and Dr. Lela Mélon, will delve into “Sustainability in the industry, and at university and corporate settings”.
- The Toronto Hub, led by Dr. Umberto Berardi, will discuss “The Sustainable Built Environment”.
MDPI Sustainability Foundation: Recognizing Excellence in Sustainability Research
The MDPI Sustainability Foundation supports researchers through two sustainability-focused awards:
- The World Sustainability Award, amounting to USD 100,000, is given to senior researchers.
- The Emerging Sustainability Leader Award, valued at USD 20,000, sponsored by the journal Sustainability, is presented to early-career researchers.
The winners of the Sustainability Foundation will be formally awarded during the WSF2023 on 14 September. Interviews with the award winners and finalists are available below.
2023 World Sustainability Award Winners
Interviews with 2023 Emerging Sustainability Leader Award Finalists
- Dr. Bahareh Kamranzad
- Dr. Youjin Kim
- Dr. Julia Lohmann
As a hybrid event, WSF23 provides scholars with the option to attend in person at one of the conference sites or, for a more sustainable approach, virtually. All sessions will be recorded and archived for future access. Registration is open until 3 September 2023, with in-person and virtual tickets available here.
Read more:
Closing Thoughts
“Co-opetition”: Collaboration Plus Healthy Competition – A Visit to Elsevier
I firmly believe in fostering collaboration and at the same time promoting healthy competition within the academic publishing industry. The market offers ample room for publishers and related companies to provide valuable services and products that enrich the academic community. While MDPI is recognized for its efficient and streamlined processes –thanks to our over 6,000 colleagues, in-house tools, and initiatives that support the author journey – our ethos has always involved learning from and collaborating with other organizations.
MDPI’s Interaction with Elsevier
In January 2023, I had a brief conversation with Judy Verses, President of Global Academic and Government Markets at Elsevier, following her participation in a panel discussion at the Academic Publishers Europe event in Berlin. One of the highlights for me was Judy’s insight into the impact of research, particularly her emphasis on the role of collaboration, including policy and showing the impact of research to influence on funding decisions.
“Such collaborations drive forward-looking strategies to elevate our support for the scholarly community”
Judy and I resumed our discussion in August, when I visited Elsevier's office to review current projects, such as our recent agreement with Science Direct and the continued indexing of MDPI journals in Scopus (indexing database owned by Elsevier). We also explored possible opportunities for the future, including a potential collaboration to expand MDPI’s Scilit data infrastructure. This endeavour aims to aggregate and provide access to scholarly metadata encompassing journal articles, conference papers, books, preprints, and more. While these discussions are ongoing, the underlying principle remains that such collaborations drive forward-looking strategies to elevate our services and support for the scholarly community.
It was great that Judy and I acknowledged the merits of 'co-opetition,' a concept based of the belief that fostering cooperation alongside healthy competition can lead to shared advancements for both individual companies and the industry at large.
‘Fully OA’ Organizations Dedicated to Open Access
MDPI proudly aligns with the ‘Fully OA’ group, a collaborative initiative comprising nine organizations dedicated to Open Access. Our monthly meetings, including an OASPA representative, serve as platforms to share non-confidential information, resources, and projects. These gatherings also facilitate discussions on topics relevant to fully OA organizations. Occasionally, joint actions spring from these interactions, such as collaborative blog posts on pertinent subjects and joint statements, such as a recent response to the House Appropriations Committee.
This display of cooperation among competing entities forms a strategic alliance focused on nurturing the best interests of the OA publishing model.
As I wrap up this third edition of the CEO Letter, I encourage you to seize opportunities for collaboration and contribute to advancing our shared academic culture. As the African proverb has it, “If you want to go fast, go alone; if you want to go far, go together.”
Chief Executive Officer
MDPI AG
18 August 2023
Meet Us at the 2023 China Biomaterials Conference, 12–15 October 2023, Chongqing, China
Conference: 2023 China Biomaterials Conference (CSBM2023)
Date: 12–15 October 2023
Booth: #B4
MDPI journals will be attending the 2023 China Biomaterials Conference (CSBM2023) as an exhibitor. This meeting will be held in Chongqing, China, from 12 to 15 October 2023.
The theme of the conference is “Innovative Biomaterials to Protect People's Health”, focusing on the frontiers of biomaterials science, technological innovation, achievement transformation, regulatory science, etc., to discuss and share the latest developments in the current field of biomaterials.
The following MDPI journals will be represented:
- IJMS;
- JFB;
- Bioengineering;
- Biomimetics;
- Marine Drugs;
- Polymers;
- Nanomaterials;
- Biomedicines;
- Micromachines;
- Pharmaceutics;
- Electrochem.
If you plan on attending this conference, please feel free to stop by our booth (#B4) and speak with us. Our delegates look forward to meeting you in person and answering any questions that you may have.
For more information about the conference, please visit http://2023.csbm.org.cn/index.php/index/index/index.html.
18 August 2023
MDPI’s 2022 Young Investigator Awards in Medicine and Pharmacology—Winners Announced
MDPI’s Young Investigator Awards recognize promising young researchers, acknowledge their contributions, and enhance communication among scientists. We are proud to present the winners for the year 2022 in medicine and pharmacology. The winners were selected by the journals’ Award Evaluation Committee.
We would like to warmly congratulate the awarded young investigators for their outstanding contributions. MDPI will continue to provide support and recognition to the academic community.
- Yuyan Jiang, Stanford University, USA
- Billy Wai-Lung Ng, Chinese University of Hong Kong, China
- Ashleigh Poh, The Olivia Newton-John Cancer Research Institute, Australia
- Miranda Fidler-Benaoudia, University of Calgary, Canada
- Bishal Gyawali, Queen’s University, Canada
- Shahnawaz Anwer, Hong Kong Polytechnic University, Hong Kong
- Jan Bednarsch, Universitätsmedizin Berlin, Germany
- Anda Mihaela Naciu, Fondazione Policlinico Universitario Campus Bio-Medico, Italy
- Jerome Lechien, University of Mons, Belgium
- Daniele Bertoglio, University of Antwerp, Belgium
- Gregor Fuhrmann, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany
- Haley Adcox, Virginia Commonwealth University, USA
About MDPI Awards:
In order to support the academic community, especially young researchers, and enhance communication among scientists, MDPI journals regularly offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and a form of recognition, help to promote the influence of talented individuals who have made outstanding achievements and are making significant contributions to the advancement of their fields.
For more MDPI awards, please click here.
18 August 2023
MDPI’s 2022 Travel Awards in Medicine and Pharmacology—Winners Announced
We are proud to recognize the winners of MDPI’s 2022 Travel Awards in medicine and pharmacology category for their outstanding presentations.
MDPI journals regularly offer Travel Awards to encourage talented junior scientists to present their research at academic conferences in specific fields, which helps to enhance their influence.
The winners mentioned below were carefully selected by the journal editors based on an outline of their research and the work to be presented at an academic conference.
We would like to congratulate the winners of the 2022 Travel Awards and wish them success with their future research endeavors. MDPI will continue to enhance communication among scientists.
- Filip Jansåker, Lund University, Lund, Sweden
- Vanessa Silva, University of Trás-os-Montes and Alto Douro, Portugal
- Diego de Miguel Perez, Icahn School of Medicine at Mount Sinai, USA
- Luigi Russo, Italian Institute of Technology (IIT), Italy
- Sneha Sethi, University of Adelaide, Australia
- Xiyin Wang, Indiana University School of Medicine, USA
- Sonia Nath, University of Adelaide, Australia
- Konstantina Kritikou, Carol Davila University of Medicine and Pharmacy, Romania
- Adrien Holzgreve, The University Hospital of Munich, Germany
- Antonella Padella, Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l., Italy
- Susanna Cooper, St. George’s University of London, UK
- Renée Tillie, Maastricht University Medical Center, the Netherlands
- Max Lennart Eckstein, University of Bayreuth, Germany
- Lorenzo Bertani, University of Pisa, Italy
- Yuxue Cao, University of Queensland, Australia
- Flávia Sousa, Italian Institute of Technology, Italy
About MDPI Awards:
In order to support the academic community, especially young researchers, and enhance communication among scientists, MDPI journals regularly offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and form ot recognition, help to promote the influence of talented individuals who have made outstanding achievements and are making significant contributions to their fields.
See more MDPI awards, please click here.
18 August 2023
MDPI’s 2022 Outstanding Reviewer Awards in Medicine and Pharmacology—Winners Announced
In order to acknowledge our reviewers, who so generously dedicate their time to reviewing papers and demonstrate diligence, professionalism, and timeliness when reviewing manuscripts, MDPI journals regularly offer outstanding reviewer awards to scholars who participate in the peer-review process.
We are proud to recognize the winners for the year 2022 in medicine and pharmacology for their outstanding contributions among the extensive competition by presenting them with an Outstanding Reviewer Award.
We would like to take this opportunity to congratulate all of the winners on their achievements. MDPI will continue to provide support and recognition to the academic community.
- Maxime Pichon, Centre Hospitalier Universitaire de Poitiers, France
- Violeta Popovici, Ovidius University of Constanta, Romania
- Yosra A. Helmy, University of Kentucky, USA
- Antonio G. Solimando, Aldo Moro University of Bari, Italy
- Linlin Guo, The Ohio State University Medical Center, USA
- Ravindra Deshpande, Wake Forest School of Medicine, USA
- Songli Zhu, Fred Hutchinson Cancer Research Center, USA
- Antonella Argentiero, IRCCS Istituto Tumori “Giovanni Paolo II” of Bari, Italy
- Camelia Coada, Alma Mater Studiorum-University of Bologna, Italy
- Chenghui Li, University of Arkansas for Medical Sciences, USA
- Laurentiu Pop, University of Texas Southwestern Medical Center, USA
- Muhammad Fazal Ijaz, Dongguk University, Republic of Korea
- Rafał Watrowski, University of Freiburg, Germany
- Ruben C. Petreaca, The Ohio State University, USA
- Ruchi Roy, Rush University Medical Center, USA
- Salvatore Cocuzza, University of Catania, Italy
- Santosh Kumar Singh, Morehouse School of Medicine, USA
- Sergei Boichuk, Kazan State Medical University, Russia
- Simon John Christoph Soerensen, Stanford University, USA
- Takuya Koie, Gifu University, Japan
- Teresa Rubio-Tomás, Foundation for Research and Technology Hellas, Greece
- Teruki Nii, Kyushu University, Japan
- Tomasz Marjanski, Medical University of Gdansk, Poland
- Kristen Haase, The University of British Columbia, Canada
- Ravi Ramjeesingh, Nova Scotia Cancer Centre and Dalhousie University, Canada
- Makoto Endo, Kyushu University, Japan
- Tefera Tadesse, Addis Ababa University, Ethiopia
- Ravi Ramjeesingh, Nova Scotia Cancer Centre and Dalhousie University, Canada
- Ryuichi Ohta, Unnan City Hospital, Japan
- Henry Sutanto, Cardiovascular Research Institute Maastricht, the Netherlands
- José-María Sánchez-González, University of Seville, Spain
- Emmanouil Kapetanakis, General Hospital of Piraeus “Tzaneio”, Greece
- Eleonora Topino, Libera Università Maria Santissima Assunta (LUMSA), Italy
- Rodolfo Reda, Sapienza University of Rome, Italy
- Giulio Francesco Romiti, Sapienza University of Rome, Italy
- Maria Gabriella Melchiorre, IRCCS INRCA—National Institute of Health and Science on Ageing, Italy
- James Walter, 1Hines VA Hospital, USA; 2 Loyola Medical Center, USA
- Vasiliki Tsigkou, Sotiria Hospital, Greece
- Flavia Zacconi, Pontificia Universidad Católica de Chile, Chile
- Bhupendra Prajapati, Ganpat University, India
- Van-An Duong, Gachon University, Republic of Korea
- Ashish Agrawal, Indian Institute of Technology (BHU), India
- Aydin Eresen, University of California Irvine, USA
About MDPI Awards:
In order to support the academic community, especially young researchers, and enhance communication among scientists, MDPI journals regularly offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and form of recognition, help to promote the influence of talented individuals who have made outstanding achievements and are making significant contributions to their fields.
See more MDPI awards, please click here.
18 August 2023
MDPI’s 2022 Best PhD Thesis Awards in Medicine and Pharmacology—Winners Announced
MDPI’s Best PhD Thesis Awards aim to recognize young scholars who are deemed to have produced the most outstanding PhD thesis in their fields of research and to encourage them to continue their outstanding work and further contributions to their field.
We would like to congratulate the winners of the 2022 Best PhD Thesis Awards in medicine and pharmacology and wish them success with their future research endeavors. MDPI will continue to enhance communication among scientists.
- “Uncovering Novel Prognostic and Predictive Epigenetic Biomarkers in Malignant Testicular Germ Cell Tumors”
by João Pedro da Silva Machado Lobo, University of Porto, Portugal
- “Metastatic Recurrence in Colorectal Cancer Arises from Residual EMP1+ Cells”
by Adrià Cañellas Socias, University of Barcelona, Spain
- “Investigating Novel Aspects of the Blood–Brain Barrier Using High-Resolution Electron Microscopy”
by Shireen Mentor, University of Cape Town, South Africa
- “An Epidemiological Approach to Study The Interplay between Genome, Epigenome and Exposome in Women”
by Roberta Magnano San Lio, University of Catania, Italy
- “Intravitreal Liposomes as Ocular Drug Delivery Systems: Vitreal Interactions, Retinal Permeation and Drug Release Characteristics”
by Shirin Tavakoli, University of Helsinki, Finland
- “Microbiome-Mediated Colonization Resistance: Defense against Enteropathogens and Multi-Drug Resistant Organisms”
by Quinten Ducarmon, Leiden University Medical Center, the Netherlands
About MDPI Awards:
In order to support the academic community, especially young researchers, and enhance communication among scientists, MDPI journals offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and form of recognition, help to promote the influence of talented individuals who have made outstanding achievements and are making significant contributions to their fields.
For more MDPI awards, please click here.
18 August 2023
MDPI’s Best Paper Awards in Medicine and Pharmacology—Winners Announced in 2022
The purpose of our Best Paper Awards is to promote and recognize the most impactful contributions published within MDPI journals.
The editors of each journal carefully selected review and research papers through a rigorous evaluative process based on criteria such as the scientific merit, overall impact, and quality of presentation of the papers published in the journal.
We are honored to present the winners for the year 2022 in medicine and pharmacology, who were selected amongst extensive competition, and congratulate the authors for their outstanding scientific publications. MDPI will continue to provide support and recognition to the academic community.
- “Development and Challenges of Antimicrobial Peptides for Therapeutic Applications”
by Charles H. Chen and Timothy K. Lu
Antibiotics 2020, 9(1), 24; https://doi.org/10.3390/antibiotics9010024
- “Antimicrobial Usage and Resistance in Companion Animals: A Cross-Sectional Study in Three European Countries”
by Philip Joosten, Daniela Ceccarelli, Evelien Odent, Steven Sarrazin, Haitske Graveland, Liese Van Gompel, Antonio Battisti, Andrea Caprioli, Alessia Franco, Jaap A. Wagenaar et al.
Antibiotics 2020, 9(2), 87; https://doi.org/10.3390/antibiotics9020087
- “Management of Peri-Implantitis Lesions without the Use of Systemic Antibiotics: A Systematic Review”
by Ahsen Khan, Ankit Goyal, Scott D. Currell and Dileep Sharma
Dent. J. 2020, 8(3), 106; https://doi.org/10.3390/dj8030106
- “Associations among Primary Stability, Histomorphometric Findings, and Bone Density: A Prospective Randomized Study after Alveolar Ridge Preservation with a Collagen Cone”
by Sigmar Schnutenhaus, Werner Götz, Jens Dreyhaupt, Heike Rudolph, Ralph G. Luthardt and Cornelia Edelmann
Dent. J. 2020, 8(4), 112; https://doi.org/10.3390/dj8040112
- “Novel Prefrontal Synthesis Intervention Improves Language in Children with Autism”
by Andrey Vyshedskiy, Edward Khokhlovich, Rita Dunn, Alexander Faisman, Jonah Elgart, Lisa Lokshina, Yuriy Gankin, Simone Ostrovsky, Lauren deTorres, Stephen M. Edelson et al.
Healthcare 2020, 8(4), 566; https://doi.org/10.3390/healthcare8040566
- “The Effects of Long-Term 40-Hz Physioacoustic Vibrations on Motor Impairments in Parkinson’s Disease: A Double-Blinded Randomized Control Trial”
by Abdullah Mosabbir, Quincy J. Almeida and Heidi Ahonen
Healthcare 2020, 8(2), 113; https://doi.org/10.3390/healthcare8020113
- “Racial Disparities-Associated COVID-19 Mortality among Minority Populations in the US”
by Donald J. Alcendor
J. Clin. Med. 2020, 9(8), 2442; https://doi.org/10.3390/jcm9082442
- “Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence”
by Celestino Sardu, Jessica Gambardella, Marco Bruno Morelli, Xujun Wang, Raffaele Marfella and Gaetano Santulli
J. Clin. Med. 2020, 9(5), 1417; https://doi.org/10.3390/jcm9051417
- “Estimation of the Transmission Risk of the 2019-nCoy and Its Implication for Public Health Interventions”
by Biao Tang, Xia Wang, Qian Li, Nicola Luigi Bragazzi, Sanyi Tang, Yanni Xiao and Jianhong Wu
J. Clin. Med. 2020, 9(2), 462; https://doi.org/10.3390/jcm9020462
- “Molecular and Cellular Mechanisms Affected in ALS”
by Laura Le Gall, Ekene Anakor, Owen Connolly, Udaya G. Vijayakumar, William J. Duddy and Stephanie Duguez
J. Pers. Med. 2020, 10(3), 101; https://doi.org/10.3390/jpm10030101
- “Postulated Adjuvant Therapeutic Strategies for COVID-19”
by Anderson O. Ferreira, Hudson C. Polonini and Eli C. F. Dijkers
J. Pers. Med. 2020, 10(3), 80; https://doi.org/10.3390/jpm10030080
- “Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models”
by Vincenzo Quagliariello, Margherita Passariello, Domenica Rea, Antonio Barbieri, Martina Iovine, Annamaria Bonelli, Antonietta Caronna, Gerardo Botti, Claudia De Lorenzo and Nicola Maurea
J. Pers. Med. 2020, 10(4), 179; https://doi.org/10.3390/jpm10040179
- "Manufacturing Considerations for the Development of Lipid Nanoparticles Using Microfluidics”
by Carla B. Roces, Gustavo Lou, Nikita Jain, Suraj Abraham, Anitha Thomas, Gavin W. Halbert and Yvonne Perrie
Pharmaceutics 2020, 12(11), 1095; https://doi.org/10.3390/pharmaceutics12111095
- “Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing”
by Sawittree Sahakijpijarn, Chaeho Moon, John J. Koleng, Dale J. Christensen and Robert O. Williams III
Pharmaceutics 2020, 12(11), 1002; https://doi.org/10.3390/pharmaceutics12111002
- “Skin Wound Healing Process and New Emerging Technologies for Skin Wound Care and Regeneration”
by Erika Maria Tottoli, Rossella Dorati, Ida Genta, Enrica Chiesa, Silvia Pisani and Bice Conti
Pharmaceutics 2020, 12(8), 735; https://doi.org/10.3390/pharmaceutics12080735
- “The Role of Hospital and Community Pharmacists in the Management of COVID-19: Towards an Expanded Definition of the Roles, Responsibilities, and Duties of the Pharmacist”
by Nicola Luigi Bragazzi, Muhammad Mansour, Alessandro Bonsignore and Rosagemma Ciliberti
Pharmacy 2020, 8(3), 140; https://doi.org/10.3390/pharmacy8030140
- “Association of a Novel Medication Risk Score with Adverse Drug Events and Other Pertinent Outcomes Among Participants of the Programs of All-Inclusive Care for the Elderly”
by David L. Bankes, Hubert Jin, Stephanie Finnel, Veronique Michaud, Calvin H. Knowlton, Jacques Turgeon and Alan Stein
Pharmacy 2020, 8(2), 87; doi.org/10.3390/pharmacy8020087
About MDPI Awards:
In order to support the academic community, especially young researchers, and enhance communication among scientists, MDPI journals regularly offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and form of recognition, help to promote the influence of talented individuals who have made outstanding achievements and are making significant contributions to their fields.
See more MDPI awards, please click here.
8 August 2023
Pharmaceutics | Selected Special Issue Reprints in 2021–2022
We are pleased to invite you to read the selected Special Issue reprints in 2021 and 2022 in Pharmaceutics (ISSN: 1999-4923). The reprints are listed as follows:
1. “Preclinical Evaluation of Lipid-Based Nanosystems”
Guest Editors: Dr. Ana Catarina Silva and Prof. Dr. José Manuel Sousa Lobo
Published: July 2021, Pages: 352, ISBN 978-3-0365-1550-2 (hardback); ISBN 978-3-0365-1549-6 (PDF), https://doi.org/10.3390/books978-3-0365-1549-6
Available online: https://www.mdpi.com/books/book/4039
2. “Advanced Blood-Brain Barrier Drug Delivery”
Guest Editor: Prof. Dr. William M. Pardridge
Published: January 2023, Pages: 496, ISBN 978-3-0365-6417-3 (hardback); ISBN 978-3-0365-6416-6 (PDF), https://doi.org/10.3390/books978-3-0365-6416-6
Available online: https://www.mdpi.com/books/book/6675
3. “Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside”
Guest Editor: Dr. Oya Tagit
Published: June 2022, Pages: 296, ISBN 978-3-0365-4490-8 (hardback); ISBN 978-3-0365-4489-2 (PDF), https://doi.org/10.3390/books978-3-0365-4489-2
Available online: https://www.mdpi.com/books/book/5741
4. “Delivery of Molecules Using Nanoscale Systems for Cancer Treatment and/or Diagnosis”
Guest Editors: Dr. Marina Santiago Franco and Prof. Dr. Yu Seok Youn
Published: August 2022, Pages: 302, ISBN 978-3-0365-4961-3 (hardback); ISBN 978-3-0365-4962-0 (PDF), https://doi.org/10.3390/books978-3-0365-4962-0
Available online: https://www.mdpi.com/books/book/5975
5. “Drug Absorption Studies: In Situ, In Vitro and In Silico Models”
Guest Editor: Prof. Dr. Im-Sook Song
Published: December 2021, Pages: 189, ISBN 978-3-0365-2461-0 (hardback); ISBN 978-3-0365-2460-3 (PDF), https://doi.org/10.3390/books978-3-0365-2460-3
Available online: https://www.mdpi.com/books/book/4689
6. “Solid Dispersions for Drug Delivery: Applications and Preparation Methods”
Guest Editors: Prof. Dr. Vitaliy Khutoryanskiy and Dr. Hisham Al-Obaidi
Published: January 2022, Pages: 244, ISBN 978-3-0365-2639-3 (hardback); ISBN 978-3-0365-2638-6 (PDF), https://doi.org/10.3390/books978-3-0365-2638-6
Available online: https://www.mdpi.com/books/book/4817
7. “Novel Anticancer Strategies (Volume II)”
Guest Editor: Dr. Hassan Bousbaa
Published: March 2023, Pages: 700, ISBN 978-3-0365-7033-4 (hardback); ISBN 978-3-0365-7032-7 (PDF), https://doi.org/10.3390/books978-3-0365-7032-7
Available online: https://www.mdpi.com/books/book/6986
8. “Special Issue in Honor of Dr. Michael Weber's 70th Birthday: Photodynamic Therapy: Rising Star in Pharmaceutical Applications”
Guest Editors: Prof. Dr. Udo Bakowsky, Dr. Matthias Wojcik, Dr. Eduard Preis and Prof. Dr. Gerhard Litscher
Published: November 2022, Pages: 528, ISBN 978-3-0365-5960-5 (hardback); ISBN 978-3-0365-5959-9 (PDF), https://doi.org/10.3390/books978-3-0365-5959-9
Available online: https://www.mdpi.com/books/book/6387
9. “Model-Informed Precision Dosing”
Guest Editors: Dr. Jonás Samuel Pérez-Blanco and Prof. Dr. José Martínez Lanao
Published: March 2023, Pages: 320, ISBN 978-3-0365-6896-6 (hardback); ISBN 978-3-0365-6897-3 (PDF), https://doi.org/10.3390/books978-3-0365-6897-3
Available online: https://www.mdpi.com/books/book/7075
10. “In Silico Strategies for Prospective Drug Repositionings”
Guest Editors: Dr. Lucreția Udrescu, Prof. Dr. Ludovic Kurunczi, Prof. Dr. Paul Bogdan and Prof. Dr. Mihai Udrescu
Published: January 2023, Pages: 288, ISBN 978-3-0365-6134-9 (hardback); ISBN 978-3-0365-6133-2 (PDF), https://doi.org/10.3390/books978-3-0365-6133-2
Available online: https://www.mdpi.com/books/book/6556
27 July 2023
MDPI Insights: The CEO's Letter #2 - Open Peer-Review and IJERPH
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
Open Peer Review Reports
Continuing the topic of openness from my inaugural monthly CEO letter, in these Opening Thoughts, I highlight the growth and importance of open peer-review reports at MDPI. Open peer reports align with the principles of open science, making the publishing process more transparent and facilitating rigorous peer review.
MDPI journals operate an open peer-review option by default, allowing authors to publish review reports and author responses (often referred to as open reports) together with the published paper. Publishing the reviewer reports and author responses together with the article provides greater transparency and trust for readers, as this allows them to track the editorial decision-making process. Open peer-review also encourages reviewers and editors to provide high-quality comments, as these will be made public if the article is accepted for publication.
Start and Growth of Open Peer Review at MDPI
The MDPI journal Life was a pioneer in offering this opportunity to its authors in 2014. The first MDPI article with peer-review reports openly published was a review by the Nobel Laureate Werner Arber, in which the review reports were published as supplementary material. By 2018, open peer-review was available across all MDPI journals. As such, MDPI authors have embraced the open peer-review model, providing a steady increase in the number of MDPI articles. As of 2023, approximately one-third (34.0%) of MDPI articles were published with open review reports.
As at July 2023, the percentage of MDPI articles published with open peer review has increased to 36.2% of the total papers published in 2023 so far, indicating ongoing growth in adoption.
Open peer review continues to play a critical role in the assessment of the peer-review process in Life. For further insights, please see the recent editorial by Dr. Pabulo Henrique Rampelotto, the former Editor-in-Chief of Life, who spearheaded the implementation of the open peer-review process.
Benefits of Open Peer Review
The benefits of open peer review include increased transparency, trust and constructive feedback. To promote open communication further and increase the robustness of the peer-review process, we encourage reviewers to sign their reports so that their name appears on the review report (this process is referred to as open identity). The default option is for reviewers to remain anonymous; however, by signing the reports, reviewers receive direct credit for their contribution to the peer-review process and show their commitment towards open science.
As the leading open access publisher, MDPI remains committed to promoting open peer-review and encourages authors to choose this approach. Our goal is to provide a rigorous and transparent peer-review process that benefits the scientific community, and we believe that open peer-review is a vital step in fostering openness and collaboration in scientific communication.
Impactful Research
MDPI Papers Cited in the News – IJERPH edition
Every month, our corporate marketing team compiles data from Altmetrics to create a list of MDPI papers that have been cited in the news. This list continues to grow as renowned news outlets regularly reference research published by MDPI in their articles.
During 2022, a total of 111,965 MDPI research papers were mentioned in prominent news outlets such as National Geographic, The Washington Post, Forbes, The Guardian, the BBC, CNN, Time, and Harvard Business Review.
Highly Cited Journal Publications
IJERPH, known for publishing impactful research, received the most news mentions among all MDPI journals in 2022, based on Altmetrics data:
- International Journal of Environmental Research and Public Health: 3509 mentions
- Nutrients: 2698 mentions
- International Journal of Molecular Sciences: 1701 mentions
- Journal of Clinical Medicine: 1131 mentions
- Viruses: 1111 mentions
These numbers show the recognition and impact of the articles published in IJERPH. For a more detailed view of the journal’s most cited and viewed papers, you can visit here. In total, IJERPH has garnered over 28,000 mentions in prominent news outlets, and as at July 2023, an impressive count of over 17,000 papers cited 10 times or more. These figures highlight the impactful contribution of IJERPH publications to the scientific community.
Example of Recent Mentions
During May and June 2023, a noteworthy selection of articles from IJERPH was cited in news articles, including:
The Washington Post: “Bringing nature inside can improve your health. Here’s how to do it.”
IJERPH paper: “Physiological Benefits of Viewing Nature: A Systematic Review of Indoor Experiments”
Harvard Business Review: “How to Take Better Breaks at Work, According to Research”
IJERPH paper: “Canine-Assisted Therapy Improves Well-Being in Nurses”
National Geographic: “Lyme disease is spreading fast—but a vaccine may be on the way”
IJERPH paper: “Range Expansion of Tick Disease Vectors in North America: Implications for Spread of Tick-Borne Disease”
Inside MDPI
MDPI Develops an Artificial Intelligence Tool to Enhance the Peer-Review Process
At MDPI, we believe that rigorous peer-review is the corner-stone of high-quality academic publishing. We are grateful to the scholars who generously dedicate their time to peer-review articles submitted to MDPI journals. Their contributions are invaluable to the advancement of science.
Peer-review is a critical part of the publication process, ensuring that MDPI upholds the highest quality standards for the papers we publish. Every manuscript submitted to our journals undergoes a comprehensive peer-review process conducted by subject-matter experts.
To further enhance our peer-review process, our Data Analytics team has developed an Artificial Intelligence (AI) tool designed to support the selection of reviewers. This proprietary tool utilizes Natural Language Processing (NLP), a specially designed AI language model, to extract information from the title and abstract of submitted papers. It then searches our database for similar manuscripts and suggests potential reviewers based on this analysis. Integrated with MDPI's submission system (SuSy), the AI tool cross-references the suggested candidates with our reviewer database to verify their invitation status and availability.
The goal of this tool is to provide better targeted peer-review invitations, reducing the number of emails sent for each paper and increasing the efficiency of our editorial staff.
In the near future, our Data Analytics team plans to deploy similar AI projects to improve other critical aspects of our services, offering an enhanced experience to our authors and readers.
Click here to learn about MDPI’s review process, including procedures, responsibilities, and benefits.
Read more:
Coming Together for Science
The Future of IJERPH
On 5 July 2023, Prof. Dr. Paul B. Tchounwou, the founding Editor-in-Chief of IJERPH, along with five Section Editors in Chief (Prof. Dr. Germán Vicente-Rodríguez, Prof. Dr. Karl Goodkin, Prof. Dr. William A. Toscano, Prof. Dr. Jimmy T. Efird, and Prof. Dr. William Douglas Evans), gathered in Basel to discuss the future of the journal. The meeting provided an opportunity to address the recent decision by The Web of Science to delist IJERPH due to the journal failing the Content Relevance criterion, and propose best strategies that will ensure high scientific rigor as well as a clear scope and aim of IJERPH, going forward.
While the delisting is disappointing for IJERPH, as well as for our authors, academic editors, and the entire scientific community supporting our journal, we see it as an opportunity to reflect and prepare for the future direction of the journal.
Since its launch in 2004, IJERPH’s vision and mission have evolved to be more complete and comprehensive in engaging scientific communities. In light of this, we will refresh the journal’s aims and scope, ensuring they align with the organic expansion of IJERPH. Additionally, we will restructure the journal sections into broader categories, encouraging collaborative research and transdisciplinary approaches for authors. This is designed to foster collaboration and knowledge exchange among diverse fields, contributing to a holistic understanding of health promotion and disease prevention. We are confident that these next steps will enhance the scientific strength and societal impact of our journal.
Journal Achievements
In addition to the productive discussions, we took the time to celebrate some of the remarkable achievements of IJERPH, which I highlight below:
- Founded by Prof. Dr. Paul B. Tchounwou in 2004
- Indexed in PubMed in 2008
- Received its first Impact Factor in 2012
- Published its 5000th paper in 2017
- Over 60,000 papers published as at June 30, 2023
- 131,628,173 paper views in 2018–2022
- Over 28,000 mentions in prominent news outlets
- 17,000 papers cited 10 times or more as at June 30, 2023
- No.1 journal in the 2022 Google Scholar Metrics in the category of Public Health
- Awarded several editions of Young Investigator Awards, Travel Awards, and Outstanding Reviewer Awards since 2018.
These achievements showcase the journal’s significant contributions to the field and its impact on global health. We are proud of the exceptional work accomplished by the IJERPH team and look forward to building upon this success in the years to come.
Closing Thoughts
MDPI’s Impact in Spain
During the past month, I had the opportunity to visit our new office building in Barcelona, where I met with our local colleagues to discuss the ways we serve the scholarly community, particularly in Spain. The multi-functional office plays a vital role in supporting various business needs, including editorial, design, conference management, data analytics, journal relationship management, publishing partnerships, and collaborations with societies.
Spain holds a significant position in MDPI’s global market, ranking as the fourth-largest contributor to the total number of papers published by MDPI as at July 2023, ranking next to Italy, the USA, and China, with Germany completing the top five.
The Numbers
Out of the 1,680,000 total MDPI articles published as at 25 July, almost 80,000 articles are contributed by Spanish authors, representing nearly 40,000 unique authors affiliated with Spanish institutions. Remarkably, over 6,300 of these authors hold editorial board member (EBM) positions within MDPI journals, with 30 of them serving as Editors-in-Chief (EiCs).
Our commitment to working with institutions is very evident in Spain, where we have successfully established over 40 Institutional Open Access Programs (IOAP) with esteemed institutions such as the University of Barcelona, the Autonomous University of Barcelona, Pompeu Fabra University, the University of Navarre, and Complutense University of Madrid.
Over the past five years, we have successfully organized eight in-person conferences in Barcelona, attracting over 1,150 registrations, with two forthcoming events scheduled for 2024. Barcelona's excellent connectivity to international airports makes it easily accessible to participants from around the world. Its welcoming atmosphere provides us with the perfect environment for knowledge-sharing, networking, and contributing to the local economy.
Our growth and presence in Spain are a true testament to the incredible service we provide to the scholarly community and the relationships we foster through responsive and collaborative communication. We look forward to continuing to support Spanish scholars, providing them a valuable and trusted experience with MDPI, the leader in open access publishing.
Testimonials
I close this letter as I did in the first edition, by sharing testimonials from our stakeholders. Here are a few IJERPH testimonials from a Spanish guest editor and an author:
Guest Editor
“I want to thank the kindness, attention and professionalism of the MDPI team throughout the editorial process of the Special Issue. I believe that it is a very professional and quality editorial process.”
- Professor Víctor Arufe-Giráldez, University of A Coruña
Special Issue in International Journal of Environmental Research and Public Health: Physical Activity in Childhood and Adolescence
Special Issue in International Journal of Environmental Research and Public Health: Physical Education: Present and Future
__
Author
“I want to thank the rigor of the revisions made to the manuscripts to improve their quality, the support to the authors for the editor assignment system they have and the follow-up they carry out, for the speed in answering and in carrying out the entire process of the revision, and for doing all this at an affordable price.”
- Dr. María Paz García-Caro, University of Granada
Article in International Journal of Environmental Research and Public Health: Factors Associated with Suicide Attempts and Suicides in the General Population of Andalusia (Spain)
Chief Executive Officer
MDPI AG
27 July 2023
Pharmaceutics | Highly Cited Papers in 2021–2022
We are pleased to invite you to read the highly cited papers in 2021 and 2022 in Pharmaceutics (ISSN: 1999-4923). The paper list is as follows:
1. “Photodynamic Therapy Review: Principles, Photosensitizers, Applications, and Future Directions”
by José H. Correia, José A. Rodrigues, Sara Pimenta, Tao Dong and Zhaochu Yang
Pharmaceutics 2021, 13(9), 1332; https://doi.org/10.3390/pharmaceutics13091332
Available online: https://www.mdpi.com/1999-4923/13/9/1332
2. “Unlocking the Power of Exosomes for Crossing Biological Barriers in Drug Delivery”
by Rebekah Omarkhail Elliott and Mei He
Pharmaceutics 2021, 13(1), 122; https://doi.org/10.3390/pharmaceutics13010122
Available online: https://www.mdpi.com/1999-4923/13/1/122
3. “Biodegradable Alginate Films with ZnO Nanoparticles and Citronella Essential Oil—A Novel Antimicrobial Structure”
by Ludmila Motelica, Denisa Ficai, Ovidiu Oprea, Anton Ficai, Roxana-Doina Trusca, Ecaterina Andronescu and Alina Maria Holban
Pharmaceutics 2021, 13(7), 1020; https://doi.org/10.3390/pharmaceutics13071020
Available online: https://www.mdpi.com/1999-4923/13/7/1020
4. “Electrospinning Proteins for Wound Healing Purposes: Opportunities and Challenges”
by Alma Akhmetova and Andrea Heinz
Pharmaceutics 2021, 13(1), 4; https://doi.org/10.3390/pharmaceutics13010004
Available online: https://www.mdpi.com/1999-4923/13/1/4
5. “Clinical Efficacy and Nephrotoxicity of the Loading Dose Colistin for the Treatment of Carbapenem-Resistant Acinetobacter baumannii in Critically Ill Patients”
by Wasan Katip, Suriyon Uitrakul and Peninnah Oberdorfer
Pharmaceutics 2022, 14(1), 31; https://doi.org/10.3390/pharmaceutics14010031
Available online: https://www.mdpi.com/1999-4923/14/1/31
6. “Multifunctional Biomimetic Nanofibrous Scaffold Loaded with Asiaticoside for Rapid Diabetic Wound Healing”
by Sneha Anand, Paruvathanahalli Siddalingam Rajinikanth, Dilip Kumar Arya, Prashant Pandey, Ravi K. Gupta, Ruchi Sankhwar and Kumarappan Chidambaram
Pharmaceutics 2022, 14(2), 273; https://doi.org/10.3390/pharmaceutics14020273
Available online: https://www.mdpi.com/1999-4923/14/2/273
7. “EGFR-Targeted Photodynamic Therapy”
by Luca Ulfo, Paolo Emidio Costantini, Matteo Di Giosia, Alberto Danielli and Matteo Calvaresi
Pharmaceutics 2022, 14(2), 241; https://doi.org/10.3390/pharmaceutics14020241
Available online: https://www.mdpi.com/1999-4923/14/2/241
8. “Review on the Scale-Up Methods for the Preparation of Solid Lipid Nanoparticles”
by Sakshi V. Khairnar, Pritha Pagare, Aditya Thakre, Aswathy Rajeevan Nambiar, Vijayabhaskarreddy Junnuthula, Manju Cheripelil Abraham, Praveen Kolimi, Dinesh Nyavanandi and Sathish Dyawanapelly
Pharmaceutics 2022, 14(9), 1886; https://doi.org/10.3390/pharmaceutics14091886
Available online: https://www.mdpi.com/1999-4923/14/9/1886
9. “Recent Developments in Metallic Nanomaterials for Cancer Therapy, Diagnosing and Imaging Applications”
by Dan Nicolae Păduraru, Daniel Ion, Adelina-Gabriela Niculescu, Florentina Mușat, Octavian Andronic, Alexandru Mihai Grumezescu and Alexandra Bolocan
Pharmaceutics 2022, 14(2), 435; https://doi.org/10.3390/pharmaceutics14020435
Available online: https://www.mdpi.com/1999-4923/14/2/435
10. “Imination of Microporous Chitosan Fibers—A Route to Biomaterials with “On Demand” Antimicrobial Activity and Biodegradation for Wound Dressings”
by Alexandru Anisiei, Irina Rosca, Andreea-Isabela Sandu, Adrian Bele, Xinjian Cheng and Luminita Marin
Pharmaceutics 2022, 14(1), 117; https://doi.org/10.3390/pharmaceutics14010117
Available online: https://www.mdpi.com/1999-4923/14/1/117
You can check all highly cited publications at the following link: https://www.mdpi.com/journal/pharmaceutics/most_cited.
21 July 2023
Pharmaceutics | Selected Papers in 2022 in the Section “Nanomedicine and Nanotechnology”
We are pleased to invite you to read the selected papers in Pharmaceutics (ISSN: 1999-4923) in the Section “Nanomedicine and Nanotechnology”. The paper list is as follows:
1. “Methods of Liposomes Preparation: Formation and Control Factors of Versatile Nanocarriers for Biomedical and Nanomedicine Application”
by Domenico Lombardo and Mikhail A. Kiselev
Pharmaceutics 2022, 14(3), 543; https://doi.org/10.3390/pharmaceutics14030543
Available online: https://www.mdpi.com/1999-4923/14/3/543
2. “An Overview of Nanotechnologies for Drug Delivery to the Brain”
by Ahsan Ayub and Shawn Wettig
Pharmaceutics 2022, 14(2), 224; https://doi.org/10.3390/pharmaceutics14020224
Available online: https://www.mdpi.com/1999-4923/14/2/224
3. “Transferrin Receptor-Targeted Nanocarriers: Overcoming Barriers to Treat Glioblastoma”
by Maria João Ramalho, Joana Angélica Loureiro, Manuel A. N. Coelho and Maria Carmo Pereira
Pharmaceutics 2022, 14(2), 279; https://doi.org/10.3390/pharmaceutics14020279
Available online: https://www.mdpi.com/1999-4923/14/2/279
4. “Emerging Albumin-Binding Anticancer Drugs for Tumor-Targeted Drug Delivery: Current Understandings and Clinical Translation”
by Hanhee Cho, Seong Ik Jeon, Cheol-Hee Ahn, Man Kyu Shim and Kwangmeyung Kim
Pharmaceutics 2022, 14(4), 728; https://doi.org/10.3390/pharmaceutics14040728
Available online: https://www.mdpi.com/1999-4923/14/4/728
5. “Silica-Based Stimuli-Responsive Systems for Antitumor Drug Delivery and Controlled Release”
by Avelino Corma, Pablo Botella and Eva Rivero-Buceta
Pharmaceutics 2022, 14(1), 110; https://doi.org/10.3390/pharmaceutics14010110
Available online: https://www.mdpi.com/1999-4923/14/1/110
6. “Glioblastoma-Derived Exosomes as Nanopharmaceutics for Improved Glioma Treatment”
by Hyeji Lee, Kanghye Bae, Ah-Rum Baek, Eun-Bin Kwon, Yeoun-Hee Kim, Sung-Wook Nam, Gang Ho Lee and Yongmin Chang
Pharmaceutics 2022, 14(5), 1002; https://doi.org/10.3390/pharmaceutics14051002
Available online: https://www.mdpi.com/1999-4923/14/5/1002
7. “Superparamagnetic Iron Oxide Nanoparticles Decorated Mesoporous Silica Nanosystem for Combined Antibiofilm Therapy”
by Elena Álvarez, Manuel Estévez, Alvaro Gallo-Cordova, Blanca González, Rafael R. Castillo, María del Puerto Morales, Montserrat Colilla, Isabel Izquierdo-Barba and María Vallet-Regí
Pharmaceutics 2022, 14(1), 163; https://doi.org/10.3390/pharmaceutics14010163
Available online: https://www.mdpi.com/1999-4923/14/1/163
8. “mRNA-Loaded Lipid Nanoparticles Targeting Dendritic Cells for Cancer Immunotherapy”
by Kosuke Sasaki, Yusuke Sato, Kento Okuda, Kazuki Iwakawa and Hideyoshi Harashima
Pharmaceutics 2022, 14(8), 1572; https://doi.org/10.3390/pharmaceutics14081572
Available online: https://www.mdpi.com/1999-4923/14/8/1572
9. “Cu-Doped Hollow Bioactive Glass Nanoparticles for Bone Infection Treatment”
by Javier Jiménez-Holguín, Sandra Sánchez-Salcedo, Mónica Cicuéndez, María Vallet-Regí and Antonio J. Salinas
Pharmaceutics 2022, 14(4), 845; https://doi.org/10.3390/pharmaceutics14040845
Available online: https://www.mdpi.com/1999-4923/14/4/845
10. “A Unique Core—Shell Structured, Glycol Chitosan-Based Nanoparticle Achieves Cancer-Selective Gene Delivery with Reduced Off-Target Effects”
by Bei Cheng, Hye-Hyun Ahn, Hwanhee Nam, Zirui Jiang, Feng J. Gao, Il Minn and Martin G. Pomper
Pharmaceutics 2022, 14(2), 373; https://doi.org/10.3390/pharmaceutics14020373
Available online: https://www.mdpi.com/1999-4923/14/2/373
You can check all publications in the Section “Nanomedicine and Nanotechnology” at the following link: https://www.mdpi.com/search?journal=pharmaceutics§ion=1027.
21 July 2023
Pharmaceutics | Selected Papers in 2022 in the Section “Gene and Cell Therapy”
We are pleased to invite you to read the selected papers in Pharmaceutics (ISSN: 1999-4923) in the Section “Gene and Cell Therapy”. The paper list is as follows:
1. “Peptides vs. Polymers: Searching for the Most Efficient Delivery System for Mitochondrial Gene Therapy“
by Rúben Faria, Milan Paul, Swati Biswas, Eric Vivès, Prisca Boisguérin, Ângela Sousa and Diana Costa
Pharmaceutics 2022, 14(4), 757; https://doi.org/10.3390/pharmaceutics14040757
Available online: https://www.mdpi.com/1999-4923/14/4/757
2. “IFN-α/β Signaling Is Required for CDG-Mediated CTL Generation and B Lymphocyte Activation”
by Ahmed E. I. Hamouda, Kai Schulze, Thomas Ebensen, Carlos Alberto Guzmán and Darío Lirussi
Pharmaceutics 2022, 14(12), 2821; https://doi.org/10.3390/pharmaceutics14122821
Available online: https://www.mdpi.com/1999-4923/14/12/2821
3. “Effervescent Atomizer as Novel Cell Spray Technology to Decrease the Gas-to-Liquid Ratio”
by Anja Lena Thiebes, Sarah Klein, Jonas Zingsheim, Georg H. Möller, Stefanie Gürzing, Manuel A. Reddemann, Mehdi Behbahani, Stefan Jockenhoevel and Christian G. Cornelissen
Pharmaceutics 2022, 14(11), 2421; https://doi.org/10.3390/pharmaceutics14112421
Available online: https://www.mdpi.com/1999-4923/14/11/2421
4. “Development of a Combined Lipid-Based Nanoparticle Formulation for Enhanced siRNA Delivery to Vascular Endothelial Cells”
by Yutong He, Dongdong Bi, Josée A. Plantinga, Grietje Molema, Jeroen Bussmann and Jan A. A. M. Kamps
Pharmaceutics 2022, 14(10), 2086; https://doi.org/10.3390/pharmaceutics14102086
Available online: https://www.mdpi.com/1999-4923/14/10/2086
5. “Development of WRAP5 Peptide Complexes for Targeted Drug/Gene Co-Delivery toward Glioblastoma Therapy“
by Ana Raquel Neves, Tânia Albuquerque, Rúben Faria, Ana M. Gonçalves, Cecília Santos, Eric Vivès, Prisca Boisguérin, Luís A. Passarinha, Ângela Sousa and Diana Costa
Pharmaceutics 2022, 14(10), 2213; https://doi.org/10.3390/pharmaceutics14102213
Available online: https://www.mdpi.com/1999-4923/14/10/2213
6. “Non-Viral Delivery of CRISPR/Cas Cargo to the Retina Using Nanoparticles: Current Possibilities, Challenges, and Limitations”
by Ahmed Salman, Ariel Kantor, Michelle E. McClements, Gemma Marfany, Sonia Trigueros and Robert E. MacLaren
Pharmaceutics 2022, 14(9), 1842; https://doi.org/10.3390/pharmaceutics14091842
Available online: https://www.mdpi.com/1999-4923/14/9/1842
7. “The Potential of Nanomedicine to Unlock the Limitless Applications of mRNA”
by Laura Taina-González and María de la Fuente
Pharmaceutics 2022, 14(2), 460; https://doi.org/10.3390/pharmaceutics14020460
Available online: https://www.mdpi.com/1999-4923/14/2/460
8. “A Narrative Review of Cell-Based Approaches for Cranial Bone Regeneration”
by Maria I. Falguera Uceda, Silvia Sánchez-Casanova, Clara Escudero-Duch and Nuria Vilaboa
Pharmaceutics 2022, 14(1), 132; https://doi.org/10.3390/pharmaceutics14010132
Available online: https://www.mdpi.com/1999-4923/14/1/132
You can check all publications in the Section “Gene and Cell Therapy” at the following link: https://www.mdpi.com/search?journal=pharmaceutics§ion=1033.
21 July 2023
Pharmaceutics | Selected Papers in 2022 in the Section “Physical Pharmacy and Formulation”
We are pleased to invite you to read the selected papers in Pharmaceutics (ISSN: 1999-4923) in the Section “Physical Pharmacy and Formulation”. The paper list is as follows:
1. "Polysaccharide 3D Printing for Drug Delivery Applications"
by Alexandra Zamboulis, Georgia Michailidou, Ioanna Koumentakou and Dimitrios N. Bikiaris
Pharmaceutics 2022, 14(1), 145; https://doi.org/10.3390/pharmaceutics14010145
Available online: https://www.mdpi.com/1999-4923/14/1/145
2. "Engineering the Surface of Ti3C2 MXene Nanosheets for High Stability and Multimodal Anticancer Therapy"
by Chiranjeevi Korupalli, Kai-Long You, Girum Getachew, Akash S. Rasal, Worku Batu Dirersa, Mochamad Zakki Fahmi and Jia-Yaw Chang
Pharmaceutics 2022, 14(2), 304; https://doi.org/10.3390/pharmaceutics14020304
Available online: https://www.mdpi.com/1999-4923/14/2/304
3. "Chemical Composition and Effect against Skin Alterations of Bioactive Extracts Obtained by the Hydrodistillation of Eucalyptus globulus Leaves"
by Patrícia Moreira, Fábio Jesus Sousa, Patrícia Matos, Gonçalo Sousa Brites, Maria José Gonçalves, Carlos Cavaleiro, Artur Figueirinha, Lígia Salgueiro, Maria Teresa Batista, Pedro Costa Branco et al.
Pharmaceutics 2022, 14(3), 561; https://doi.org/10.3390/pharmaceutics14030561
Available online: https://www.mdpi.com/1999-4923/14/3/561
4. "3D Printing of Pediatric Medication: The End of Bad Tasting Oral Liquids?—A Scoping Review"
by Iris Lafeber, Elisabeth J. Ruijgrok, Henk-Jan Guchelaar and Kirsten J. M. Schimmel
Pharmaceutics 2022, 14(2), 416; https://doi.org/10.3390/pharmaceutics14020416
Available online: https://www.mdpi.com/1999-4923/14/2/416
5. "Polymeric Nanocapsules Containing Fennel Essential Oil: Their Preparation, Physicochemical Characterization, Stability over Time and in Simulated Gastrointestinal Conditions"
by Giuseppe Granata, Carla Riccobene, Edoardo Napoli and Corrada Geraci
Pharmaceutics 2022, 14(4), 873; https://doi.org/10.3390/pharmaceutics14040873
Available online: https://www.mdpi.com/1999-4923/14/4/873
6. "Biodegradable and Bioactive Carriers Based on Poly(betulin disuccinate-co-sebacic Acid) for Rifampicin Delivery"
by Daria Niewolik, Barbara Bednarczyk-Cwynar, Piotr Ruszkowski, Alicja Kazek-Kęsik, Grzegorz Dzido and Katarzyna Jaszcz
Pharmaceutics 2022, 14(3), 579; https://doi.org/10.3390/pharmaceutics14030579
Available online: https://www.mdpi.com/1999-4923/14/3/579
7. "Drug Stability: ICH versus Accelerated Predictive Stability Studies"
by Olga González-González, Irving O. Ramirez, Bianca I. Ramirez, Peter O’Connell, Maria Paloma Ballesteros, Juan José Torrado and Dolores R. Serrano
Pharmaceutics 2022, 14(11), 2324; https://doi.org/10.3390/pharmaceutics14112324
Available online: https://www.mdpi.com/1999-4923/14/11/2324
8. "Moxifloxacin Liposomes: Effect of Liposome Preparation Method on Physicochemical Properties and Antimicrobial Activity against Staphylococcus epidermidis"
by Evangelos Natsaridis, Foteini Gkartziou, Spyridon Mourtas, Marc C. A. Stuart, Fevronia Kolonitsiou, Pavlos Klepetsanis, Iris Spiliopoulou and Sophia G. Antimisiaris
Pharmaceutics 2022, 14(2), 370; https://doi.org/10.3390/pharmaceutics14020370
Available online: https://www.mdpi.com/1999-4923/14/2/370
9. "Skin Regenerative Potential of Cupuaçu Seed Extract (Theobroma grandiflorum), a Native Fruit from the Amazon: Development of a Topical Formulation Based on Chitosan-Coated Nanocapsules"
by Geisa Nascimento Barbalho, Breno Noronha Matos, Gabriel Ferreira da Silva Brito, Thamires da Cunha Miranda, Thuany Alencar-Silva, Fernando Fabriz Sodré, Guilherme Martins Gelfuso, Marcilio Cunha-Filho, Juliana Lott Carvalho, Joyce Kelly do Rosário da Silva et al.
Pharmaceutics 2022, 14(1), 207; https://doi.org/10.3390/pharmaceutics14010207
Available online: https://www.mdpi.com/1999-4923/14/1/207
10. "Glycosylated Ang-(1-7) MasR Agonist Peptide Poly Lactic-co-Glycolic Acid (PLGA) Nanoparticles and Microparticles in Cognitive Impairment: Design, Particle Preparation, Physicochemical Characterization, and In Vitro Release"
by David Encinas-Basurto, John P. Konhilas, Robin Polt, Meredith Hay and Heidi M. Mansour
Pharmaceutics 2022, 14(3), 587; https://doi.org/10.3390/pharmaceutics14030587
Available online: https://www.mdpi.com/1999-4923/14/3/587
You can check all publications in the Section “Physical Pharmacy and Formulation” at the following link: https://www.mdpi.com/search?journal=pharmaceutics§ion=1029.
21 July 2023
Pharmaceutics | Selected Papers in 2022 in the Section “Pharmacokinetics and Pharmacodynamics”
We are pleased to invite you to read the selected papers in Pharmaceutics (ISSN: 1999-4923) in the Section “Pharmacokinetics and Pharmacodynamics”. The paper list is as follows:
1. “Toxicokinetics of β-Amanitin in Mice and In Vitro Drug–Drug Interaction Potential”
by Young Yoon Bang, Im-Sook Song, Min Seo Lee, Chang Ho Lim, Yong-Yeon Cho, Joo Young Lee, Han Chang Kang and Hye Suk Lee
Pharmaceutics 2022, 14(4), 774; https://doi.org/10.3390/pharmaceutics14040774
Available online: https://www.mdpi.com/1999-4923/14/4/774
2. “Physiologically Based Pharmacokinetic (PBPK) Model of Gold Nanoparticle-Based Drug Delivery System for Stavudine Biodistribution”
by Hinojal Zazo, Clara I. Colino, Carmen Gutiérrez-Millán, Andres A. Cordero, Matthias Bartneck and José M. Lanao
Pharmaceutics 2022, 14(2), 406; https://doi.org/10.3390/pharmaceutics14020406
Available online: https://www.mdpi.com/1999-4923/14/2/406
3. “Adoption of Machine Learning in Pharmacometrics: An Overview of Recent Implementations and Their Considerations”
by Alexander Janssen, Frank C. B